



Impact of Injectable Hormonal Contraceptives on 
Innate Immune Environment in the Genital Tract in 




Submitted in fulfilment of the academic requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
School of Laboratory Medicine & Medical Sciences 
Faculty of Health Science 
 
UNIVERSITY OF KWAZULU-NATAL 
September 2015
 ii 
Table of Contents 
Preface ................................................................................................................................................. v 
Declaration ....................................................................................................................................... vi 
Ethics Approval .............................................................................................................................. vii 
Presentations and Publications .............................................................................................. viii 
Dedication ......................................................................................................................................... ix 
Acknowledgements ......................................................................................................................... x 
List of Figures ................................................................................................................................. xii 
List of Tables .................................................................................................................................. xiv 
Abbreviations ................................................................................................................................. xv 
Abstract ........................................................................................................................................ xviii 
CHAPTER 1: Introduction ............................................................................................................. 2 
1.3  Study Aims and Objectives ............................................................................................. 10 
CHAPTER 2: Literature Review ................................................................................................ 17 
2.1 Progestin-only injectable contraceptives .................................................................. 17 
2.1.1 DMPA ................................................................................................................................... 19 
2.1.2 Norethisterone Enanthate (NET-EN) ................................................................................... 21 
2.2 Link between injectable HCs and risk for HIV-1 acquisition............................... 22 
2.3 Mechanisms for increased HIV-1 risk in women using injectable HCs ............ 24 
2.3.1 Influence of injectable HCs on genital epithelial thickness and cell proliferation ............... 24 
2.3.2 Influence of injectable HC use on mucosal immunity .......................................................... 27 
2.3.3 Influence of injectable HC use on innate and soluble factors in the genital tract ................. 28 
2.3.4 Susceptibility to bacterial vaginosis (BV) and stability of the vaginal microbiome following 
injectable HC use .............................................................................................................................. 32 
2.3.5 Injectable HCs and susceptibility to sexually transmitted infections (STIs) ................. 34 
2.4 Injectable HCs and HIV-1 shedding from HIV-1 infected women ...................... 39 
2.5 Injectable HCs and rate of disease progression in HIV-1 infected women ..... 41 
2.6 Injectable HC and anti-retroviral therapy during HIV infection ........................ 42 
2.7 Conclusions ........................................................................................................................... 42 
CHAPTER 3: Lower concentrations of chemotactic cytokines and soluble innate 
factors in the lower female genital tract associated with use of injectable 
hormonal contraceptives ........................................................................................................... 45 
3.1 Abstract .................................................................................................................................. 45 
3.2 Introduction ......................................................................................................................... 47 
 iii 
3.3 Materials and Methods ..................................................................................................... 49 
3.3.1 Study design, participants and sample collection ................................................................. 49 
3.3.2 Laboratory testing for STIs and BV ..................................................................................... 50 
3.3.3 Measurement of cytokines and soluble factors in CVL ........................................................ 50 
3.3.4 Statistical analyses ................................................................................................................ 51 
3.4 Results .................................................................................................................................... 52 
3.4.1 Prevalence of BV and STIs in injectable HC versus non-HC users ..................................... 54 
3.4.2 Impact of injectable HCs on innate factors in the female genital tract ................................. 54 
3.4.3 Impact of BV and STIs on cytokines in injectable HC versus non-HC users ...................... 58 
3.5 Discussion ............................................................................................................................. 67 
CHAPTER 4: Influence of semen on inflammatory and innate cytokine responses 
in the female genital tract .......................................................................................................... 72 
4.1 Abstract .................................................................................................................................. 72 
4.2 Introduction ......................................................................................................................... 74 
4.3 Materials and Methods ..................................................................................................... 77 
4.3.1 Study design, participants and sample collection ................................................................. 77 
4.3.2 Measurement of cytokine, MMP and TIMP concentrations ................................................. 78 
4.3.3 ELISA to detect PSA ............................................................................................................ 79 
4.3.4 Detection of Y-chromosome................................................................................................. 79 
4.3.5 Statistical analyses ................................................................................................................ 80 
4.4 Results .................................................................................................................................... 81 
4.4.1 Presence of semen altered cytokine profiles in CVLs .......................................................... 85 
4.5 Discussion ............................................................................................................................. 91 
CHAPTER 5: In vivo and in vitro effects of injectable hormonal contraceptives on 
innate immune cell activation and cytokine responses .................................................. 95 
5.1 Abstract .................................................................................................................................. 95 
5.2 Introduction ......................................................................................................................... 97 
5.3 Materials and Methods ..................................................................................................... 99 
5.3.1 Study design, samples size and inclusion criteria ................................................................. 99 
5.3.2 Ex vivo characterization of PBMCs from women using injectable HCs ............................ 101 
5.3.3 Measurement of plasma cytokines ...................................................................................... 102 
5.3.4 Measurement mDC and pDC function and activation ........................................................ 102 
5.3.4.1 Flow cytometry of DC subsets for intracellular cytokine production............................... 103 
5.3.5 Statistical analysis ............................................................................................................... 105 
5.4 Results ................................................................................................................................. 106 
5.4.1 Effects of injectable HC use on monocyte and DC subsets ................................................ 106 
5.4.2 Impact of injectable HCs on innate immune factors in the female genital tract ................. 110 
5.4.3 Effect of exogenous hormones on mDC lineage activation................................................ 111 
5.4.4 Impact of exogenous HCs on mDC function ...................................................................... 117 
5.5 Discussion .......................................................................................................................... 120 
 iv 
CHAPTER 6: Influence of injectable HCs on vaginal epithelial thickness, mucosal 
cytokines, HIV-1 target cell density and depth in the female genital tract during 
acute HIV-1 infection ................................................................................................................ 125 
6.1 Abstract ............................................................................................................................... 125 
6.2 Introduction ...................................................................................................................... 127 
6.3 Materials and Methods .................................................................................................. 130 
6.3.1 Study participants and sample collection............................................................................ 130 
6.3.2 Processing of vaginal biopsies ............................................................................................ 131 
6.3.3 Measurement of cytokine concentrations in CVLs ............................................................. 134 
6.3.4 Statistical analyses .............................................................................................................. 135 
6.4 Results ................................................................................................................................. 137 
6.4.1 Influence of measurement method on vaginal epithelial thickness .................................... 139 
6.4.2 Relationship between injectable HC use and vaginal epithelial thickness in HIV-1 infected 
women 141 
6.4.3 Relationship between injectable HCs and vaginal target cell density and depth in HIV-1 
infected women ............................................................................................................................... 142 
6.4.4 Impact of injectable HCs on genital tract cytokines concentrations ................................... 148 
6.4.5 Relationship between genital cytokine concentrations and target cell densities ................ 151 
6.4.6 Genital cytokine concentrations and the depth of target cells ............................................ 153 
6.4.7 Factors associated with recruitment of HIV-1 target cells in vaginal biopsies ................... 154 
6.4.8 Influence of injectable HC use on rate of HIV-1 disease progression ................................ 157 
6.4.9 Influence of vaginal target cell density on rate of HIV-1 disease progression ................... 158 
6.5 Discussion .......................................................................................................................... 159 
CHAPTER 7 .................................................................................................................................... 165 
Discussion ..................................................................................................................................... 165 
7.1 Injectable HCs modulate soluble genital immune mediators ................................................ 167 
7.2 Influence of semen on cytokine responses in the lower reproductive tract ........................... 170 
7.3 Impact of injectable HCs on innate cell activation and function ........................................... 173 
7.4 Effect of injectable HC use on HIV-1 disease progression ................................................... 174 
7.5 Injectable HC use and vaginal squamous epithelial thickness............................................... 175 
7.5 Injectable HC use and vaginal HIV-1 target cell density and depth ...................................... 176 
7.6 Conclusion ............................................................................................................................. 180 
7.7 Recommendations for future research ................................................................................... 181 
REFERENCES ................................................................................................................................. 183 







I Sinaye Ngcapu declare that: 
(i) The research reported in this thesis, except where otherwise indicated, is my original 
work. 
(ii) This thesis has not been submitted for any degree or examination at any other university. 
(iii) This thesis does not contain other persons’ data, pictures, graphs or other information, 
unless specifically acknowledged as being sourced from other persons. 
(iv) This thesis does not contain other persons’ writing, unless specifically acknowledged as 
being sourced from other researchers. Where other written sources have been quoted, then: 
a) Their words have been re-written but the general information attributed to them has 
been referenced; 
b) Where their exact words have been used, their writing has been placed inside 
quotation marks, and referenced. 
(v) Where I have reproduced a publication of which I am an author, co-author or editor, I 
have indicated in detail which part of the publication was actually written by myself alone 
and have fully referenced such publications. 
(vi) This thesis does not contain text, graphics or tables copied and pasted from the internet, 
unless specifically acknowledged, and the source being detailed in the thesis and in the 
References sections. 
Signed:____ ____ ____ Date: 28 February 2016________ 
          Sinaye Ngcapu 
 vii 
Ethics Approval 
Full ethics approval, from the Biomedical Research Ethics Committee of the Nelson R. 
Mandela School of Medicine, University of KwaZulu-Natal (Ref: E111/06 and E013/04) was 
obtained for this study.  
 viii 
Presentations and Publications 
1. Sinaye Ngcapu, Tracy Meiring, Lindi Masson, Lise Werner, Lenine Liebenberg, 
Nigel Garrett, Koleka Mlisana, Carolyn Williamson, Quarraisha Abdool Karim, Salim 
Abdool Karim, Jo-Ann Passmore. Presence of Male Partner Semen Influences the 
Inflammatory and Innate Cytokine Environment in the Female Genital Tract. HIV 
Research for Prevention (HIV R4P) Conference 2014, Cape Town, South Africa. 
(Poster presentation). 
 
2. Sinaye Ngcapu, Lindi Masson, Sengeziwe Sibeko, Muki Shey, Natasha Samsunder, 
Salim Abdool Karim, Quarraisha Abdool Karim, Jo-Ann Passmore. Hormonal 
contraception use and HIV-1 risk in the context of prevention research: DMPA and 
NET-EN dampen immunity in the female genital tract. AIDS Vaccine Conference. 
2013, 7-10 October in Barcelona, Spain. (Poster presentation). 
 
3. Ngcapu S, Masson L, Sibeko S, Werner L, McKinnon LR, Mlisana K, Shey M, 
Samsunder N, Abdool Karim SS, Abdool Karim Q, Passmore J-AS. Lower 
concentrations of chemotactic cytokines and soluble innate factors in the lower 
female genital tract associated with the use of injectable hormonal contraceptive. 












I dedicate this thesis to Miss Noludumo “Tsili” Eunice Ngcapu, my 
mother and the wind beneath my wings; for her bravery, strength and 
faith, and to Jesus, I could not have done this without you.   
 x 
Acknowledgements 
First and foremost, I would like to thank Dr. JoAnn Passmore for her guidance, support and 
encouragement over the last three years. It was always reassuring to know that she had faith 
in my abilities, and patience with my progress when frustration would get the better of me. I 
am particularly grateful for the freedom and opportunity to pursue a project that was different 
from the norm and allowed me to explore the many facets of my interests in mucosal 
immunology. Under her watch, the boundaries of my abilities were tested and expanded as I 
developed further confidence in myself and matured into a well-rounded independent 
scientist. Thank you for being the person you are: kind, sensitive and thoughtful. You are 
unselfish always, putting others before yourself, making us feel special and important.  
 
Special thanks as well to Prof Quarraisha Abdool Karim for believing in me and for the 
endless opportunities that you have provided me during my PhD studies. I am blessed to be 
part of the CAPRISA team and it’s really a great opportunity to be working with you.  
 
I also owe a great deal of thanks to my colleagues in the lab and stats (particularly, Mrs Lise 
Jamieson) departments, both past and present that helped me in various ways. They provided 
a great deal of unparalleled scientific insight and valuable suggestions on my research. Both 
were instrumental in teaching or exposing me to skills and techniques that would help me 
along the way, and I greatly thank them for their friendship and support.  
 
 
I’d also like to thank the following individuals for their contributions to this dissertations: 
Professor Salim Abdool Karim, Dr Sengeziwe Sibeko (for trusting me with your grant and 
project, hope I made you proud), Dr Lindi Masson, Dr Cheryl Baxter, Dr Koleka Mlisana, Dr 
Lenine J. Liebenberg, Dr Ann Carias, Dr Gianguido C. Cianci, Dr Nigel J. Garrett, Mrs Jean-
 xi 
Mari Kriek, Dr Lyle R. McKinnon, Professor Thomas J. Hope, Dr Muki Shey, Dr Desery 
Archary, Dr Aida Sivro, Dr Kerry Leask, Dr Tracy Meiring, Mr Michael McRaven, Mrs 
Nonhlanhla Yende-Zuma, Miss Karyn Pretorius, Miss Kewreshini Naidoo and the CAPRISA 
002 Acute Infection Team for designing and managing the CAPRISA 002 and 004 cohorts, 
for sharing their clinical data and/or for contributing to the preparation of manuscripts 
encompassing these findings. 
 
I would like to thank my family and friends, for their unwavering support and confidence in 
me. Lastly, I would like to thank my best friend, my love (Ntombikhona F. Maphumulo) and 
my angel (Sinesihle Ambesa Maphumulo) for their sacrifices and unconditional loving 
support they made in helping me to achieve my goal. Just knowing that they supported me 
and were always available to listen were all that I needed to keep persevering and to see this 
through to fruition.  
 
This work was supported by the Poliomyelitis Research Fund (PRF, grant number 11/22) and 
Columbia University-Southern African Fogarty AIDS International Training and Research 
Programme (AITRP, grant number D43TW00231) for funding my training in Chicago, 
U.S.A. Research infrastructure was made possible by Centre for the AIDS Programme of 
Research in South Africa (CAPRISA), which was created through the US National Institutes 
for Health’s Comprehensive International Program of Research on AIDS (CIPRA, grant 
number AI 51794).   
 xii 
List of Figures 
Figure 1.1 Global prevalence of HIV-1 in 2013 according to geographic region. The 
darker colors indicate regions with higher prevalence.  
Figure 2.1 The chemical structures of (a) progesterone, (b) cortisol, (c) depot 
medroxyprogesterone acetate (DMPA) and (d) norethisterone enanthate (NET-
EN).  
Figure 2.2 Analysis of study-specific risk for HIV-1 infection in women using injectable 
HCs, including the 18 studies analysed by Morrison et al., (2015).  
Figure 2.3 Biological mechanisms by which injectable HCs might contribute to an 
increased risk of HIV-1 acquisition and transmission 
Figure 3.1 Cytokine concentrations in cervicovaginal lavages (CVLs) from women using 
injectable  HCs (DMPA or NET-EN) compared to those not using HCs, 
stratified according to presence of discharge causing STIs (C. trachomatis, N. 
gonnorhoea, M. genitalium; GCM).   
Figure 5.1 Summary of study design for ex vivo study. PBMCs from 98 HIV-1 uninfected 
women (40 DMPA users, 40 NET-EN users and 18 non-HC users as controls) 
from the CAPRISA 004 were stratified by age.  
Figure 5.2 Impact of DPMA (blue dots) or NET-EN (red dots) use on frequencies of 
monocytes in blood from DMPA (n=40) and NET-EN (n=40) users compared 
to non-HC users (n=18).  
Figure 5.3 Cytokine concentrations in plasma samples from women using either DMPA 
or NET-EN compared to those not using HCs.  
Figure 5.4 Gating strategy used to identify DC subsets and cytokine production of TNF-α 
and IL-6 that were either unstimulated (control), stimulated with LPS/CpG or 
a combination of LPS/CpG and hormone (DMPA, cortisol and progesterone).  
Figure 5.5 Gating strategy for analysis of DC subset activation (CD86 and CD40).  
Figure 5.6 Effect of DMPA, cortisol and progesterone on CD40 production by DCs 
stimulated with LPS (top panels) or CpG (bottom panels).  
Figure 5.7 Effect of DMPA, cortisol and progesterone on CD86 production by DCs 
stimulated with LPS (top panels) or CpG (bottom panels).  
Figure 5.8 Effect of DMPA, cortisol and progesterone on TNF-α production by mDCs 
stimulated with LPS (top panels) or CpG (bottom panels).  
Figure 5.9 Effect of DMPA, cortisol and progesterone on IL-6 production by mDCs 
stimulated with LPS (top panels) or CpG (bottom panels).  
 xiii 
Figure 6.1 Vaginal epithilial thickness measurements in biopsy tissues collected from 
acutely HIV-1 infected women, who were either using injectable HCs or not.  
Figure 6.2 Comparison of epithelial thickness from three different experts. Assessor 1 
and 2 used the manual counting method while assessor 3 used an automated 
method in IDL.  
Figure 6.3 CD4+ Tcells in vaginal biopsies of acutely HIV-1 infected women.  
Figure 6.4 CD68+ macrophages in vaginal biopsies of acutely HIV-1 infected women.  
Figure 6.5 Relationship between HIV-1 target cells in vaginal biopsies during acute HIV-
1 infection and genital cytokine concentrations. 
Figure 6.6 Relationship between HIV-1 target cell depth in vaginal biopsies during acute 
HIV-1 infection and genital cytokine concentrations. 
   
 xiv 
List of Tables 
Table 2.1 Summary of published studies describing the relationship between injectable 
HC use and risk for acquiring STIs 
Table 2.2 Studies investigating the relationship between injectable HC use by 
chronically HIV-1 infected women and the risk of them transmitting HIV-1 to 
their male partners 
Table 3.1 Baseline demographic and clinical characteristics  
Table 3.2 Influence of injectable hormonal contraceptive use on cytokine, MMP and 
TIMP concentrations in genital secretions 
Table 3.3 Relationship between injectable HC use and cytokine responses to BV 
Table 3.4 Relationship between injectable HC use and cytokine responses to T. vaginalis 
Table 3.5 Relationship between injectable HC use and cytokine responses to sexually 
transmitted infections (C. trachomatis, N. gonnorhoea, and M. genitalium) 
Table 4.1 Cohort characteristics according to presence of PSA or Y-chromosome in 
genital secretions 
Table 4.2 Relationship between cytokine concentrations and recent semen exposure (≤48 
hrs post-sex) in the female genital tract 
Table 4.3 Relationship between cytokine concentrations and semen exposure (>48 hrs 
post-sex) in the female genital tract 
Table 5.1 Demographics of women included in the ex vivo study  
Table 5.2        Comparison of full blood counts of injectable HC users and non-HC users 
Table 6.1 Demographic and clinical characteristics of participants, stratified by 
injectable HCs use 
Table 6.2 Vaginal epithelial thickness in women using injectable HCs 
Table 6.3 Impact of HC use on HIV-1 target cell density within vaginal biopsies 
Table 6.4  Target cell depth in vaginal biopsies of women using injectable HCs versus 
non-injectable users. 
Table 6.5 Influence of injectable hormonal contraceptive use on cytokine concentrations 
in matching genital secretions  
Table 6.6         Factors associated with CD4 and CD68 cell density in vaginal biopsies 
















x g G force 
AIDS 
 










C-C chemokine receptor 
CD 
 




COC  Combined oral contraceptive 
CpG  Cytosine-guanine 
CTACK 
 





















Epidermal growth factor 
ELISA 
 
Enzyme-linked immunosorbent assay 
FGF 
 
Fibroblast growth factor 
FGT 
 
Female genital tract 
FLT3 
 
FMS-like tyrosine kinase 3 
FSH 
 
Follicle stimulating hormone 
G-CSF 
 






Granulocyte macrophage-colony stimulating factor 
GRO 
 







H&E  Hematoxylin and eosin 
HGF 
 
Hepatocyte growth factor 
HIV-1 
 
Human immunodeficiency virus 
HLA-DR 
 

































Leukemia inhibitory factor 
LPS  Lipopolysaccharide 
MCP 
 




mDC  Myeloid dendritic cells 
MIF 
 
Macrophage migration inhibitory factor 
MIG 
 
Monokine induced by gamma-Interferon 
MIP 
 
Macrophage inflammatory protein 
mm2 
 












Nerve growth factor 
NHLS 
 
National Health Laboratory Service 
nM  Nano Molar 
OCP 
 
Oral contraceptive pill 
OCT 
 
Optimum cutting temperature 
OR  Odds ratio 
PBMC  Peripheral blood mononuclear cell 
PBS 
 
Phosphate buffered saline 
PCR 
 
Polymerase chain reaction 
pDC  Plasmacytoid dendritic cells 
PDGF 
 
Platelet-derived growth factor 






Prostate specific antigen 
qPCR 
 
Real time PCR 
RH  Risk hazard  
SAS 
 
Statistical Analysis System 
sCD40L 
 
soluble cluster of differentiation 
SCF 
 
Stem cell factor 
SCGF 
 
Stem cell growth factor 
SDF 
 




SLP  Secretory leukocyte protease 
SIV 
 






Sexually transmitted infections 
TGF 
 
Transforming growth factor 
TIMP 
 
Tissue inhibitors of metalloproteinases 
TLR  Toll-like receptor 
TNF 
 
Tumour necrosis factor 
TRAIL 
 




Testis-specific protein Y-encoded 
VEGF 
 
Vascular endothelial growth factor 
WHO 
 




Background: The impact of injectable hormonal contraceptives (HCs) on HIV-1 acquisition 
risk in HIV-1 negative women represents an important public health issue, as is the risk of 
transmission from HIV-infected women to their HIV discordant partners. Women using the 
long-acting injectable depot medroxyprogesterone acetate (DMPA) are reportedly at 2-fold 
increased risk for HIV-1 infection from epidemiology studies, and at an increased risk of 
transmitting HIV to their sexual partners should they become infected. The aims of this PhD 
dissertation were to investigate possible biological mechanisms influencing HIV risk, by 
evaluating (i) the effects of injectable HC use on soluble immune mediators in the lower 
reproductive tract of HIV-1 negative women at high risk for HIV-1 acquisition, particularly 
in response to common sexually transmitted infections (STIs) (Chapter 3); (ii) the impact of 
recent sexual intercourse [measured by presence of Y-chromosome DNA or prostate specific 
antigen (PSA)] on these soluble mucosal factors (Chapter 4); and (iii) the in vivo and in vitro 
influence of DMPA use on activation status and functional characteristics of circulating 
dendritic cells (Chapter 5). Following HIV-1 infection, this dissertation investigated the 
impact of injectable HC use on (iv) vaginal epithelial barrier thickness and HIV-1 target cell 
density in vaginal biopsies taken from acutely HIV-1 infected women; (v) genital viral loads 
contributing to risk of HIV-1 transmission to sexual partners during acute infection and (vi) 
rate of HIV-1 disease progression (Chapter 6).  
 
Methods: For studies involving HIV-1 negative women at risk for HIV-1 infection, Chapters 
3 to 5 included 64 HIV-1 uninfected women using injectable HCs (DMPA or NET-EN) and 
64 women not using any form of HCs, enrolled into the prospective CAPRISA 002 
observational cohort study.  The concentrations of 48 cytokines, 5 matrix metalloproteases 
 xix 
(MMPs), and 4 tissue inhibitors of matrix metalloproteases (TIMPs) were measured in 
cervicovaginal lavage (CVL) using Luminex and ELISA. CVLs were assessed for the 
presence of semen, measured by presence of Y-chromosome DNA by real-time PCR  and 
prostate specific antigen (PSA) by ELISA, to confirm semen exposure as a surrogate for 
recent sexual intercourse (Chapter 4). Finally, for studies involving HIV-1 infected women, 
49 acutely HIV-1 infected women who became infected during the CAPRISA 004 1% 
tenofovir microbicide trial were included (36 DMPA users, 5 NET-EN users and 8 controls 
not using injectable HCs) (Chapter 6). Immunohistochemical staining was used to assess 
epithelial thickness and target cell densities biopsy specimens. Blood CD4 T cell counts, and 
viral loads were measured in both CVL and plasma samples during acute infection and in 
plasma during the first year of infection (as a measure of disease progression). The 
concentrations of 48 cytokines were measured in CVL from acutely HIV-1 infected women 
using Luminex. 
 
Results: In Chapter 3, HIV-1 negative women using injectable HCs were found to have 
significantly lower concentrations of several chemokines (eotaxin, MCP-1, MDC), the 
adaptive cytokine IL-15, the growth factor PDGF-AA, and the tissue inhibitor of 
metalloproteinases TIMP-2 (responsible for tissue remodelling) in genital secretions (CVLs) 
than women not using injectable HCs (controls), after adjusting for condom use, sex work 
status, marital status, BV and STIs. In Chapter 4, CVLs collected from these women who 
were positive for PSA (indicating exposure to semen within 72 hours) were shown to have 
significantly lower concentrations of IL-12p70, sIL-2Rα and IL-2, indicating that certain 
innate responses in the genital tract were suppressed by exposure to semen. In contrast, 
concentrations of TIMP-1 and MMP-9, both associated with tissue remodelling in the female 
 xx 
reproductive tract, were higher in CVLs from PSA positive women, after adjusting for 
confounders. 
 
In vitro and in vivo experiments focusing on monocytes and dendritic cells (DCs) in Chapter 
5 showed that exogenous addition of DMPA was associated with decreased capacity of 
circulating myeloid DCs to produce TNF-α and IL-6 in response to Toll-like receptor (TLR)-
4 (CpG) and -9 (LPS) agonists. Finally, focusing on acutely HIV-1 infected women, Chapter 
6 showed that injectable HC use did not influence vaginal epithelial thickness notably, with 
women using injectable HCs  having a median thickness of 356.9 µm/cc (IQR 302.0-414.2) 
compared to women using no or non-injectable HC users (361.4; 271.0-409.4). However, the 
frequencies of target CD4+ T cells in the squamous epithelium from injectable HC users 
were significantly higher than non-injectable HC users (median of 33 cells/mm2, IQR 23-74 
versus 23 cells/mm2, IQR 17-43, p=0.028]. Other HIV-1 target cells, like CD68+ 
macrophages were closer to the surface of the vaginal lumen in HIV-1 acutely infected 
women using injectable HC compared to non-injectable HC users (median 158 µm, IQR 
131.8 – 163.8 versus 97 µm, 81.3 – 117.1; p=0.021), although CD68+ target cell density did 
not differ between groups. Injectable HC use was not associated with higher genital HIV-1 
viral loads or influence the rate of disease progression, measured by CD4 T cell counts at 12 
months post-infection or plasma viral load set-point.  
 
Conclusion: Overall, the findings from this dissertation suggest that injectable HC use may 
have immunosuppressive effects in lower reproductive tract of women, altering the innate 
immune profile through the suppression of dendritic cell activation and function. The 
presence of semen should be taken into consideration when investigating biological markers 
 xxi 
in the female genital tract, since semen has the capacity to modulate host responses. Although 
injectable HC use was not found to influence vaginal epithelial thickness in this study, 
evidence of immune cell regulation for intraepithelial and mucosally-associated CD4+ and 
CD68+ target cells was found. Together, these findings suggest that more mechanistic studies 
are urgently needed on DMPA and other HCs (such as NET-EN), using ex vivo and in vivo 
models, in order to inform their use at public health level particularly in those settings with  















1.1 Young women: vulnerability to HIV-1 infection and the epidemic 
Almost seventy percent of the 35.3 million people globally infected with HIV-1 
reside in sub-Saharan Africa, with women accounting for about 60% of these 
infections (UNAIDS, 2013). Heterosexual transmission of HIV-1 across the genital 
mucosa in women is the most common mode of infection (Abdool Karim et al., 
2010b; Shattock and Moore, 2003; UNAIDS, 2013). In particular, young women (15–
24 years) are much more likely to acquire HIV-1 than older women (Stirling et al., 
2008). Young women acquire HIV-1 infection 5-7 years before men and they are 
eight times more likely to be infected than their male counterparts (Abdool Karim et 
al., 1992; UNAIDS, 2012). 
 
Figure 1.1     Global prevalence of HIV-1 in 2013 according to geographic region. 
The darker colors indicate regions with higher prevalence. Approximately, 70% of 
the 35.3 million people infected with HIV-1 worldwide were concentrated in sub-




The unique vulnerability of young women to HIV infection stems from various 
behavioural and biological factors. While risk for HIV-1 infection may vary from 
person to person, behavioural factors including unprotected sex, douching after 
intercourse, sexual relationships with older partners, and a history of sexual abuse or 
violence are well documented risk factors for HIV-1 infection in young women 
(Abdool Karim et al., 2014; Chersich and Rees, 2008; Dunkle et al., 2004; Stirling et 
al., 2008). In addition, fewer years of schooling and lack of food security have also 
been documented as risk factors driving HIV-1 acquistion in young women who 
engage in transactional relationships with older men (Abdool Karim et al., 2014; 
Greif, 2012). Studies in resource-limited settings have demonstrated that sexual 
relationships with older men can expose young women to an increased risk of HIV-1 
infection as they are less likely to be able to negotiate condom use (Gregson et al., 
2002; Pettifor et al., 2004).  
 
It is thought that young women become infected with HIV-1 after fewer acts of 
unprotected sex (Glynn et al., 2001; Pettifor et al., 2005), and several biological risk 
factors that may predispose women to become infected with HIV-1 have been 
proposed (Chersich and Rees, 2008). The surface area of the lower reproductive tract 
exposed during sexual intercourse in women is greater than the reproductive tissue of 
men, which may increase surface area exposed, time in contact with infectious fluids 
post-coitus, and exposure of intraepithelial HIV-1 target cells to pathogens (Yi et al., 
2013). Microabrasions in the genital tract, in the comparatively more fragile and less 
keratinized epithelial barrier, may be more common in women than men and provide 
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a portal for pathogen entry (Stanley, 2009). Cervical ectopy (particularly to younger 
women) may facilitate increased exposure of HIV-1 target cells to pathogens in the 
lower reproductive tract during sex (Critchlow et al., 1995). Finally, the presence of 
co-factors such as sexually transmitted infections (STIs), often asymptomatic and 
therefore untreated in women, also increase the risk of HIV-1 infection (Cohen, 2004; 
McKinnon et al., 2011).  
 
1.2 Hormone contraceptives (HCs) and HIV risk in women 
Unprotected heterosexual intercourse is the predominant mode of HIV acquisition 
which also puts young women at risk of unplanned pregnancies (Bearinger et al., 
2007; UNAIDS, 2013). HIV-1 is linked to general reproductive health issues in 
women because many new HIV-1 infections occur during sex (Bearinger et al., 
2007). Pregnant women generally have higher HIV-1 prevalence rates than non-
pregnant women (39% HIV-1 prevelence in 15-24 year old pregnant women from 
sub-Saharan Africa compared to 20% in similarly aged non-pregnant women) (Berer, 
2004; Department of Health, 2013; Kharsany et al., 2015). Access to safe, effective 
methods of hormonal contraception (HC) is an essential strategy in women for 
reducing unwanted pregnancies, and vertical transmission of HIV-1 from infected 
mothers to their newborn infants, especially in areas of high HIV-1 seroprevalence 
such as sub-Saharan Africa (Baru, 1993; Berer, 2004). 
 
A number of HC methods are available to prevent unplanned pregnancies, and it is 
estimated that >150 million women use HC globally, with two thirds of women on 
combine oral contraceptives (COCs) and a third on long-acting injectable progestin 
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HCs (Population, 2008; United Nations, 2003). The most commonly used HC in sub-
Saharan Africa is depot medroxyprogesterone acetate (DMPA), although use of more 
modern version of the injectable progestin called norethisterone enanthate (NET-EN) 
is increasing, especially among young women in South Africa (Department of Health 
et al., 2007; Sibeko et al., 2011). DMPA use is popular in sub-Saharan Africa because 
it is cheap, safe, provides contraception that is long acting and highly effective, and 
does not require a woman to remember to take birth control daily (Department of 
Health, 2001; Margulies and Miller, 2001). Although the use of injectable HCs has 
explicit gains in terms of maternal-infant health (WHO, 2015), long acting high-dose 
progestin formulations (such as DMPA) have also been associated with an increased 
risk for HIV-1 infection (Baeten et al., 2007b; Heffron et al., 2012; Martin et al., 
1998; Morrison et al., 2010). A recent systemic review summarizing findings from 
several good quality studies (Ralph et al., 2015) and an individual participant data 
meta-analysis (Morrison et al., 2015) have reported increased HIV-1 risk in women 
using DMPA and NET-EN compared those not using hormonal contraception. 
Although the meta-analysis showed increased HIV-1 risk, several individual studies 
reported no increased risk in women using DMPA compared to non-DMPA using 
counterparts (Kiddugavu et al., 2003; Kleinschmidt et al., 2007; Myer et al., 2007; 
Reid et al., 2010; Stringer et al., 2009). Most studies found no evidence that NET-EN 
use increases women’s risk of HIV risk (McCoy et al., 2013; Myer et al., 2007). 
 
1.2.1 Biologic mechanisms by which HCs increase HIV-1 acquisition risk 
The mechanism by which injectable HCs may increase risk to HIV-1 infection is not 
clearly understood. Some studies have found that injectable HCs reduce the integrity 
and thickness of the genital mucosal barrier in women and the density of intracellular 
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junction proteins in the stratefied epithelial layer (Chandra et al., 2013; Ildgruben et 
al., 2003; Miller et al., 2000; Wieser et al., 2001; Wira et al., 2011b). Reduced genital 
barrier function might facilitate more efficient contact between HIV-1 target cells 
within the cervicovaginal mucosa and HIV-1 particles entering the vaginal lumen. In 
non-human primates, high-dose DMPA is commonly used in the simian 
immunodeficiency virus (SIV) vaginal challenge model, specifically because it thins 
the vaginal epithelium and significantly increases the efficiency of vaginal 
transmission (Abel et al., 2004; Marx et al., 1996; Trunova et al., 2006; Wieser et al., 
2001). The role of DMPA in increasing risk of HIV-1 infection in women is less 
clear. Little consensus exists about mucosal epithelial thickness with some reports 
claiming women who use DMPA have detectably thinner genital epithelial barriers 
compared to non-DMPA users (Kiddugavu et al., 2003; Myer et al., 2007), while 
other have found no association between HC use and genital epithelial barrier 
integrity (Chandra et al., 2013; Mitchell et al., 2014).  
 
DMPA has been reported to alter cervicovaginal mucosal immune responses that 
could affect mucosal susceptibility to HIV-1 transmission, through increased 
recruitment of mucosal immune cells of the female genital mucosa (Chandra et al., 
2013, Wira et al., 2011; (Ildgruben et al., 2003; Miller et al., 2000; Wieser et al., 
2001; Wira et al., 2011b; Wira and Veronese, 2011). Chandra et al. (2013) showed 
that women using DMPA had significantly higher numbers of activated T cells and 
macrophages expressing CCR5 compared to their non-DMPA counterparts. In 
contrast, Mitchell et al. (2014) found no difference in density or numbers of T cells or 
CCR5+ HIV-1 target cells in the lower reproductive tract. In vitro experiments 
showed that peripheral blood mononuclear cells (PBMCs) from women using DMPA 
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had higher rates of HIV-1 replication than PBMCs from women not using DMPA, 
and had higher concentrations of HIV-1 co-receptors CXCR4 and CCR5 on activated 
T cells (Huijbregts et al., 2013). 
 
DMPA use suppresses both innate and adaptive immune responses and thereby 
potentially reduces host resistance to the infection with HIV-1 and other pathogens 
(Huijbregts et al., 2013; Kleynhans et al., 2013). DMPA treatment of PBMCs in vitro 
reduced production of several inflammatory and adaptive cytokines [including 
interleukin (IL)-6, IL-1β, IL-12p40, IL-12p70, tumor necrosis factor (TNF)-α, TNF-β, 
granulocyte macrophage colony-stimulating factor (GM-CSF), macrophage 
inflammatory protein (MIP)-1α, interferon (IFN)-γ, IL-2, IL-4, IL-13, IL-17 
(Huijbregts et al., 2013)] (Huijbregts et al., 2014). DMPA also reduced the production 
of IFN-α and TNF-α by plasmacytoid dendritic cells (pDCs) in response to activation 
by ligands of Toll-like receptors (TLRs)-7, -8 and -9 (Huijbregts et al., 2014). PBMCs 
from DMPA users stimulated with a common antigen such as BCG (vaccine against 
tuberculosis) produced significantly lower concentrations of IL-1α, IL-12p40, IL-10, 
IL-13 and G-CSF compared to non-DMPA users (Kleynhans et al., 2011). Similarly, 
mice treated with DMPA produced less IFN-γ, IL-6, IL-17, GM-CSF, monocyte 
chemotactic protein 1 (MCP-1), granulocyte colony-stimulating factor (G-CSF), 
TNF-α, IL-10, and IL-6 (Kleynhans et al., 2013). Although the in vivo and in vitro 
biological effects of DMPA have been investigated, comparatively fewer mechanistic 
studies have been conducted using NET-EN. 
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A potential mechanism by which DMPA may decrease expression of cytokines is 
through its ability to bind to the glucocorticoid receptor complex, as some cytokine 
genes are regulated by the glucocorticoid receptor. Although some studies have 
shown a comparatively lower binding affinity of NET to the glucocorticoid receptor 
compared to DMPA (Koubovec et al., 2005; Schoonen et al., 2000), both are capable 
of binding with high affinity (Kontula et al., 1983; Koubovec et al., 2005). Ex vivo 
studies also demonstrated that DMPA acts as full to partial agonist of the 
glucocorticoid receptor, more potent and effective on gene promoter-mediating 
immune functions than progesterone . 
 
Injectable HCs may also modulate the host environment by altering the vaginal 
microbiome or susceptibility to bacterial vaginosis (BV) and sexually transmitted 
infections (STIs), including HPV, Chlamydia trachomatis, Nessiria gonnorhoeae 
(Huijbregts et al., 2013; Kleynhans et al., 2011). The healthy vaginal microbiome is 
generally dominated by Lactobacillus species, which metabolise carbohydrates in the 
lower reproductive tract to lactic acid, lowering vaginal pH which is inhospitable to 
pathogens (Ma et al., 2012). When Lactobacillus colonization in the reproductive 
tract declines, the vaginal pH neutralizes, and the risk of HIV-1 infection increases 
(Cook et al., 1992; Ma et al., 2012). Decreased abundance of Lactobacillus spp. may 
alternatively create an environment that favors the growth of BV-associated 
organisms (Cook et al., 1992). BV is a highly prevalent dysbiosis in the vagina, 
characterized by a thin homogeneous white discharge, a vaginal pH >4.5, a positive 
amine test, and the presence of clue cells microscopically (Amsel et al., 1983; Cook et 
al., 1992). BV increases risk of HIV-1 infection (Atashili et al., 2008), herpes simplex 
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virus (HSV) shedding (Cherpes et al., 2005), preterm delivery, and pelvic 
inflammatory disease (Ness et al., 2005). Microscopy and culture-based studies have 
suggested that hormonal fluctuations over the course of the menstrual cycle 
contributes to fluctuation in the vaginal microbiome (Eschenbach et al., 2000). Higher 
estrogen levels are associated with a lactobacilli-dominated vaginal microbiome, 
thought to be protective against HIV-1 (van de Wijgert et al., 2013; reviewed by 
Murphy et al., 2014). The impact of progesterone and its synthetic derivatives DMPA 
and NET-EN on the vaginal microbiome is less clear.  
 
DMPA use has been associated with increased risk for gonorrhea and chlamydia in 
US women (Morrison et al., 2004). Conversely, DMPA use was found to reduce risk 
of BV and Trichomonas vaginalis amongst Kenyan sex workers (Baeten et al., 2001). 
DMPA treatment increased susceptibility to HSV-2 infection 100-fold in the mouse 
model (Kaushic et al., 2003). Mechanisms that have been suggested to explain this 
include inhibition of local innate immune responses to HSV-2, increased expression 
of the HSV-2 entry receptor nectin-1 in a progesterone-dominant environment, or 
progesterone-associated thinning of the vaginal stratefied epithelium following 
progesterone treatment (Kaushic et al., 2003). However, a similar relationship 
between NET-EN and risk for STI infections has not been established.  
 
The mechanisms by which synthetic progesterone-based injectable HCs might 
increase susceptibility to HIV-1 acquisition are important to investigate, especially in 
regions where injectable HCs commonly are used and HIV-1 prevelence rates are 
high, such as sub-Saharan Africa. Because access to effective methods of HC have 
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substantially reduced maternal and infant mortality rates, through giving women more 
control over when to have children, negative public perceptions about adverse health 
risks surrounding a widely used HC could be detrimental to the gains made in 
improved maternal and child health. Strong, unequivocal  evidence needs to be 
provided and biological mechanisms demonstrated, to definitively inform policy to 
avoid these unintended negative consequences. The following literature review 
describes biological mechanisms proposed by which injectable hormonal 
contraceptive use could influence susceptibility to HIV-1. 
 
1.3  Study Aims and Objectives 
The overall aims of this dissertation were to investigate: (i) the biological effect of 
injectable HCs use on the innate environment in the genital tract of HIV-1 negative 
women at high risk of HIV-1 infection; and (ii) the impact of injectable HC use on the 
genital immune environment and epithelial barrier function of HIV-1 infected women 
and the consequence of these immune changes to their infectiousness to their sexual 
partners during acute HIV-1 infection. 
 
Rationale 
Several HC methods are widely used by South African women to prevent unplanned 
or mistimed pregnancies, with over 57% of women (aged 15 - 49 years) using long-
acting injectable progestin HCs, particularly DMPA (South African Department of 
Health, 2003). Although the use of DMPA to prevent unplanned pregnancies has 
explicit gains (WHO, 2010), it has also be associated with an increased risk of HIV-1 
infection (Baeten et al. 2007; Martin et al. 1998; Morrison et al. 2010, 2011 and 
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2012). The precise mechanism by which DMPA may increase risk to HIV-1 infection 
has not been conclusively demonstrated yet although several studies have suggested 
that DMPA may reduce integrity and thickness of vaginal and epithelial lining, 
increase recruitment of HIV-1 target cells to the genital mucosa, and change the 
vaginal microbiota which may influence HIV-1 risk (Chandra et al. 2013; Ildgruben et 
al. 2003; Miller et al. 2000; Wieser et al. 2001; Wira et al. 2011). This dissertation 
focuses on the influence of injectable HC use (DMPA and NET-EN) on risk for HIV-
1 infection in the context of a heterosexual epidemic in South Africa; and the 
potentially confounding effect of injectable HC use in HIV-1 prevention research. If 
biological plausibility is demonstrable, more informed policy measures could be 
implemented timeously to avoid these negative consequences.  
 
Specific Objectives 1 
To compare concentrations of genital tract soluble immune mediators [including 
cytokines, chemokines, growth factors, matrix metalloproteinases (MMPs) and tissue-
inhibitors of metalloproteinases (TIMPs)] between women using long-acting 
injectable HCs and women not using HCs, while accounting for BV and common 
STIs (Chapter 3).  
 
Rationale.  
DMPA might increase HIV-1 aquisition risk by changing the inflammatory or 
chemotactic environment of the genital mucosa so as to influence the recruitment of 
HIV-1 susceptible immune cells to the mucosa (Ildgruben et al., 2003; Miller et al., 
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2000; Wieser et al., 2001; Wira et al., 2011b; Wira and Veronese, 2011). However, in 
vitro treatment of PBMCs with injectable HC was shown to cause reduced production 
of several inflammatory and adaptive cytokines (Huijbregts et al., 2013). Defining the 
impact of injectable HCs on female genital tract innate immunity in relation to 
susceptibility to STIs or BV will provide important insights into biological co-factors 
influencing HIV-1 risk in women. 
 
Hypothesis.  
Injectable HC use is associated with reduced cytokine and soluble factor 
concentrations in genital secretions compared to non-HC users.  
 
Specific Objective 2 
To investigate whether detection of semen in cervicovaginal lavages (CVLs) from 
high-risk HIV-1 negative women, by assessment of Y-chromosome by PCR and 
prostate specific antigen (PSA) by ELISA, influenced the cytokine milieu and soluble 
factors of cervicovaginal secretions (Chapter 4). 
 
Rationale.  
The vaginal mucosa immune environment plays a potentially important role in 
regulating the transmission of STIs, including HIV-1 (Chormont et al., 2001). Genital 
specimens, including CVLs, vaginal and/or cervical swabs, from women have been 
used to study vaginal mucosa immunity in a number of studies (Bebell et al., 2008; 
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Belec et al., 1995; Roberts et al., 2012). However, immunological characterization of 
factors in these genital fluids from sexually active women may be biased by the 
presence of semen (Silverman et al., 1980). Semen contains high concentrations of 
both inflammatory and anti-inflammatory cytokines and prostaglandins, which may 
moderate the cytokine environment in the female genital tract (Olivier et al., 2014). 
Detection of PSA and the Y-chromosome are semen markers that have been used as 
surrogate indicators for the presence of semen in female genital fluids (Chormont et 
al., 2001). Detecting the presence of semen in genital fluids using these biomarkers 
provides a tool to objectively assess recent exposure to semen, allowing for objective 
assessment of unprotected sexual intercourse in HIV-1 prevention trials. In addition, 
detecting semen also allows evaluation of the confounding effects of semen exposure 
on the immunological environment in the female genital tract. 
 
Hypothesis. 
Presence of semen in cervico-vaginal specimens from sexually active women will 
influence cytokine concentrations in cervicovaginal fluids. 
 
Specific Objectives 3 
To compare the impact of DMPA on innate cell function in vitro, to natural 





In vitro study has shown that addition of exogenous progesterone-derivates such as 
DMPA decreased TLR-9-induced IFN-α production by plasmacytoid dendritic cells 
(Hughes et al., 2008). Studies elucidating the basic mechanism/s by which injectable 
HCs might increase HIV-1 infection could aid the WHO consultants to reach a 
definitive conclusion on guideline for Medical eligebility criteria for contraceptive 
use, particuraly DMPA. 
 
Hypothesis.  
In vitro exogenous addition of HCs to PBMCs from women not using injectable HCs 
will influence the activation phenotype and suppress cytokine production by 
monocytes and dendritic cells following TLR stimulation. 
 
Specific Objectives 4 
To investigate the influence of DMPA on vaginal epithelial thinning and density of 
HIV-1 target cells in vaginal biopsies from HIV-1 infected women during acute 
infection; and implications to their infectiousness to their sexual partners (Chapter 
6). 
Rationale. 
DMPA use has been suggested to increase the likelihood of an HIV-1 infected woman 
infecting her sex partner. The mechanism/s accounting for increased HIV-1 
transmission risk in HIV-1 infected women using DMPA remain poorly 
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characterized. HIV-1 target cell density in the genital mucosa and inflammatory 
cytokines present in genital secretions has been suggested to influence HIV-1 risk (Li 
et al., 2009; Masson et al., 2015).  HIV-uninfected women with genital inflammation 
were at 2.9-fold increased risk for HIV-1 infection (Masson et al., 2015). In addition, 
women who seroconverted had similar levels of genital tract inflammation before they 
became infected as they had during acute HIV-1 infection (Roberts et al., 2012). 
Better understanding of the influence of DMPA on recruitment of HIV-1 target cells 
to the female genital tract, properties of the epithelial barrier that could influence 
HIV-1 penetration, altered genital cytokine profiles and HIV-1 shedding in vaginal 
secretions could lead to interventions to disrupt HIV-1 transmission.  
 
Hypothesis. 
DMPA use will reduce the thickness of the vaginal epithelial barrier in women, 
reduce the distance between HIV-1 target cell numbers and the vaginal lumen, reduce 
pro-inflammatory cytokine concentrations in CVLs, and increase HIV-1 viral loads at 
the mucosa. Furthermore, DMPA-induced alterations in genital HIV-1 target cell 
numbers in the epithelium during acute HIV-1 infection will be associated with faster 
HIV-1 disease progression (as measured by CD4 decline to 350 cells/ml and viral 












                                                       CHAPTER 2 
Literature Review 
 
2.1 Progestin-only injectable contraceptives 
Progestin-only injectable HCs are a highly effective, long-acting and reversible 
method of contraception. They are exogenous hormones administered by injection, 
which contain a synthetic progestin hormone, similar to natural progesterone found in 
women. Currently, there are three types of injectable progestin-only HCs in wide use 
(Figure 2.1): DMPA (150mg dose in 1 ml injection, Figure 2.1c), depo-subQ provera 
104™ (subcutaneous formulation of DMPA, 104mg dose in 0.65ml) and NET-EN 
(200mg dose in 1 ml; Figure 2.1d) (Bhathena, 2001; Elder, 1984; Fraser and 




Figure 2.1 The chemical structures of (a) progesterone, (b) cortisol, (c) depot medroxyprogesterone acetate (DMPA) and (d) norethisterone 
enanthate (NET-EN). The structure of progesterone has 21-carbon precursor (C21H30O2) that are directly altered by enzymes within tissues 
resulting into different major classes of steroids (Wiebe et al., 2006). For example, the enzyme actions lead indirectly to the corticosteroids 
(cortisol, C21H28O5). DMPA (24-carbon precursor, C24H34O4) is a synthetic 17-hydroxyprogesterone derivative of progesterone (Fraser and 
Weisberg, 1981) while NET-EN is a 17C-alpha-ethinyl-17beta-heptanoyloxy-4esterene-3-one synthetic progesterone derivative (Zanartu and 
Navarro, 1968). Figure drawn by Sinaye Ngcapu. 
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DMPA and NET-EN differ in cost and frequency of administration, which has implications 
on budgeting in the health system and patient uptake, respectively. In South Africa and 
internationally, DMPA is substantially cheaper than NET-EN which is an important 
consideration from a public health perspective.  According to the South African Department 
of Health Medicine Prices database from the 12th March 2015, a single dose of DMPA 
(150mg in a 1 ml injection) cost the government R25 (including value added tax) while NET-
EN cost more than twice that at R58 per dose (200mg in 1 ml) 
(http://www.health.gov.za/index.php/single-exit-price-documents). In South Africa, both of 
these options are available free of charge at national primary health care facilities and are 
listed in the South African Essential Drugs List (Smit et al., 2001). Internationally, they are 
also extensively used in reproductive health programs, forming a large proportion of health 
system expenditure on contraception, especially in resource limited regions (Kaunitz, 1994; 
Margulies and Miller, 2001). Both of these injectable HC formulations are given by 
intramuscular injection, and the progestin is then slowly released into bloodstream from the 
injection site over the course of months.  
 
2.1.1 DMPA 
DMPA is a synthetic 17-hydroxyprogesterone derivative of progesterone (Figure 2.1c), 
administered by intramuscular depot injection as an aqueous microcrystalline suspension 
(150mg/ml) every three months. It was developed by the UpJohn Company in the late 1950s 
and was approved as a contraceptive method in many countries in the late 1960s (Babcock et 
al., 1958; Fraser and Weisberg, 1981). DMPA binds with high affinity to the progesterone 
receptor expressed by epithelial cells, fibroblast and smooth muscle in the upper female 
reproductive tract, where it induces secretory transformation of the oestrogen-primed 
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endometrium, which is then shed (Hatcher et al., 2011).  
 
DMPA gained popularity because of its prolonged 3-month duration of action, achieved by 
the progestin being slowly released (due to the low solubility of the microcrystals) into the 
bloodstream from the gluteal or deltoid muscles where it is injected (Mishell, 1996). DMPA 
can be detected in the bloodstream within 30 minutes after intramuscular injection and 
increases steadily to effective plasma levels >0.2ng/ml within 24 hours (Ortiz et al., 1977). 
Plasma DMPA concentrations plateau between 1.0 to 1.5ng/ml for the 3 month duration of 
the contraceptive treatment but these plasma concentrations then gradually decline to 
~0.2ng/ml during the fourth month (Ortiz et al., 1977). The active plasma concentrations of 
DMPA achieved vary between women, with some women having detectable plasma levels 
>0.2ng/ml for more than 9 months after a single dose of 150mg/ml (Fraser and Weisberg, 
1981; Mishell, 1996). DMPA is highly effective as a form of contraception, with an 
accidental pregnancy rate of 0.4 per 100 women, with lower efficacy generally only being 
seen because of inconsistent or incorrect use (Chinnatamby, 1971; Dodds, 1975; Powell and 
Seymour, 1971).  
 
DMPA primarily provides contraceptive protection by suppressing levels of the follicle 
stimulating hormone and luteinizing hormone, which lead to inhibition of gonadotropin 
secretion, thereby inhibiting follicular maturation and ovulation (Hatcher et al., 2011; 
Mishell, 1996; Mishell et al., 1968; Speroff and Darney, 2010). This action also results in a 
hypoestrogenic state (Mishell, 1996). DMPA also induces atrophy of the endometrium, by 
decreasing glycogen content needed to provide energy for the development of the blastocyst 
after the morula has entered the uterine cavity (Hatcher et al., 2011; Mishell, 1996; Mishell et 
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al., 1968; Speroff and Darney, 2010). Furthermore, DMPA causes thickening of cervical 
mucus, making it unfavourable for spermatozoa to migrate to the oviduct to fertilize the egg 
(Hatcher et al., 2011; Mishell, 1996; Mishell et al., 1968; Speroff and Darney, 2010).  
 
DMPA is a reversible, coitally-independent method of contraception, which takes an average 
of 4 months for women to return to fertility after DMPA is discontinued (Pardthaisong, 
1984). Studies have shown that the use of DMPA during pregnancy or breastfeeding does not 
adversely affect the duration of lactation, quantity or quality of breast milk or the health and 
development of nursing infants (Pardthaisong, 1984; Pardthaisong et al., 1992). 
 
2.1.2 Norethisterone Enanthate (NET-EN) 
NET-EN is a 17C-alpha-ethinyl-17beta-heptanoyloxy-4esterene-3-one synthetic progesterone 
derivative (Figure 2.1d), similar to DMPA, developed in 1966 (Zanartu and Navarro, 1968), 
and now commonly used for contraception. It is expensive compared to DMPA, resulting in 
more limited roll-out in limited-resourced countries (Smit et al., 2001). NET-EN is a long 
chain ester of norethisterone prepared in an oily solution that is effective for two months as a 
contraception (Fotherby et al., 1978; Goebelsmann et al., 1979). The usual dose administered 
contains 200mg/ml of NET-EN, with the plasma concentrations reaching a peak of 5.5 to 
11ng/ml in about 10 days that gradually decreases to 0.8ng/ml at 8 weeks after intramuscular 
injection (Goebelsmann et al., 1979). NET-EN inhibits ovulation, coinciding with high levels 
of plasma progesterone (Fraser and Weisberg, 1981; Zanartu and Navarro, 1968). This is 
followed by premature luteolysis, the structural and functional degradation of the corpus 
luteum, together with peripheral fertility-inhibiting effect when ovulation-inhibiting effect 
wears off. The progestogenic effect also cause changes in cervical mucus, tubal function and 
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endometrium thereby reducing fertility (Fraser and Weisberg, 1981; Zanartu and Navarro, 
1968). Like DMPA, the overall pregnancy rate for NET-EN is low, ranging from 0.01–1.49 
per 100 women years (Kesseru-Koos et al., 1973). Like DMPA, NET-EN is a reversible 
method of contraception, but women take an average of 8 months to return to fertility after 
use (Banerjee et al., 1986). NET-EN use does not adversely affect lactating women but its 
administration is not advised in the first and early second trimesters of pregnancy (Fine et al., 
1963; Karim et al., 1971).  
2.2 Link between injectable HCs and risk for HIV-1 acquisition 
The potential impact of progesterone-containing injectable HCs (including both DMPA and 
NET-EN) on HIV-1 acquisition and transmission is an important public health concern, 
especially in sub-Saharan Africa, where these injectable HCs are popular and HIV-1 
prevalence is high. There has been considerable debate about the role of injectable HCs in 
influencing risk for HIV-1 infection in women. A recent individual participant data meta-
analysis of 18 large studies (including 9 cohort studies and 9 randomized controlled trials) 
concluded an increased risk for HIV-1 infection in women using DMPA [hazard ratio (HR): 
1·50, 95% CI 1·24–1·83] although no significant evidence was found for increased HIV-1 
risk in women using NET-EN (HR: 1·24, 95% CI 0·84 –1·82), after adjusting for region, 
marital status, age, number of sex partners, and condom use (Figure 2.2) (Morrison et al., 
2015). Similarly, in a recent systematic review, HRs for HIV-1 infection were higher for 
DMPA (1·40, 95% CI 1·16–1·69) than for NET-EN (1·10, 0·88–1·37) when either method 




Figure 2.2 Analysis of study-specific risk for HIV-1 infection in women using injectable 
HCs, including the 18 studies analysed by Morrison et al., (2015). A summary of clinical 
studies assessing the effects of injectable HCs on HIV-1 acquisition in women compared to 
non-HC users. Studies that used both Cox proportional hazards (Cox) and marginal structural 
model (MSM) analyses are also shown. Studies listed above the x-axis show results 
suggesting that injectable HCs increase risk of HIV-1 infection. Studies listed below the x-
axis show results suggesting that injectable HCs decrease risk of HIV-1 infection. HR=hazard 
ratio. CI = confidence interval. DMPA=depot medroxyprogesterone acetate. NET-EN = 
norethisterone enanthate. Forest plots were compiled from the following references: (Abdool 
Karim et al., 2010a; Baeten et al., 2007a; Delany-Moretlwe and Rees, 2010; Heffron et al., 
2012; Kapiga et al., 1998; Kaul et al., 2004; Kleinschmidt et al., 2007; Kumwenda et al., 
2008; McCormack et al., 2010; McGrath et al., 2014; Morrison et al., 2007; Noguchi et al., 
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2015; Padian et al., 2007; Skoler-Karpoff et al., 2008; Vallely et al., 2007; Van Damme et al., 
2012; Vandepitte et al., 2011; Watson-Jones et al., 2009). Figure drawn by Sinaye Ngcapu. 
 
Despite epidemiological evidence for increased HIV-1 risk in women using DMPA, many 
public health officials would argue that the maternal and infant benefits (such as preventing 
unintended pregnancies with all its harmful biological and social sequelae) for using these 
HC formulations outweigh these potential moderate although significant risks (WHO, 2012). 
It is therefore critical to focus research efforts on understanding the biological mechanisms 
that could contribute to unravelling the epidemiological association  between injectable HCs 
and HIV-1 acquisition. Such basic research into the mechanisms will promote informed 
policy decisions and could facilitate the promotion of safer alternative modern methods 
choice of contraception, including intrauterine devices or contraceptives that have  a lower 
impact on the immune system (Huijbregts et al., 2013). 
 
2.3 Mechanisms for increased HIV-1 risk in women using injectable HCs 
 
2.3.1 Influence of injectable HCs on genital epithelial thickness and cell proliferation 
It has been suggested that progestin-containing injectable HCs may increase risk to HIV-1 
infection by reducing the thickness of the lower genital tract epithelial barrier (Figure 2.3, 
number 1) (Mauck et al., 1999; Miller et al., 2000). However, the impact of injectable HC use 
on genital epithelial thickness is contentious, since some have found no change (Bahamondes 
et al., 2000; Bahamondes et al., 2014; Chandra et al., 2013; Mitchell et al., 2014), while 
others have reported an increase in epithelial thickness (Ildgruben et al., 2003) or even a 
slight decrease in squamous epithelial thickness (Mauck et al., 1999; Miller et al., 2000). It is 
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important to note that some of the measurements reported in these studies were performed on 
genital tract tissues from women following only short-term (≤ 6 months) (Mauck et al., 1999, 
Miller et al., 2000) DMPA use, while others were performed on tissues taken from women on 
long-term use (≥ 3years) (Bahamondes et al., 2000). Chandra and colleagues (2013) reported 
thinner vaginal squamous epithelium during the late luteal phase and DMPA use as compared 
to both the follicular and mid-menstrual cycle stages of the menstrual cycle. They also 
demonstrated that the method used to measure epithelial thickness could introduce >30% 
intra-observer variation in measurements, and that multiple factors should be considered 
when determining epithelial thickness: including (1) timing of the biopsy in the menstrual 
cycle, (2) location of the biopsy (upper versus lower reproductive tract), (3) the ability 
distinguish non-viable stratum corneum from the viable stratum malighii, and (4) that 
sophisticated algorithms need to be developed to measure the distance between the basal 
layer to the lumen epithelial (Chandra et al., 2013; Mauck et al., 1999).  
 
In addition to their potential impact on epithelial thickness, injectable HCs might decrease the 
integrity of the epithelial barrier by effecting intraepithelial junctions, thereby facilitating 
closer contact between HIV-1 and mucosal target cells (Figure 2.3, number 2). DMPA has 
also been reported to alter epithelial cell proliferation, increasing the expression of Ki-67 
proliferation marker after 12 weeks of DMPA-treatment (Chandra et al., 2013). Increased 
proliferation had no effect on cellular proteins involved in protection against microbial 
invasion, however, and the epithelial structure and integrity was similar in women in the 





Figure 2.3 Mechanisms by which injectable HCs might contribute to an increased risk of 
HIV-1 acquisition and transmission include: (1) thinning of the epithelial barrier (including 
the stratum corneum and granulosa); (2) disruption of tight intercellular junctions, adherens 
junctions and desmosomes between epithelial cells; (3) changing the inflammatory milieu of 
the vaginal mucosa; (4) decreased hydrogen peroxide (H2O2) producing lactobacilli; (5) 
modulating recruitment of immune cells [intraepithelial target cells including DC-SIGN+ 
dendritic cells (DCs), CD4+ T cells and macrophages]; (6) micro-abrasions in the stratified 
squamous epithelium barrier; and increased acquisition of other STIs (Figure drawn by 




2.3.2 Influence of injectable HC use on mucosal immunity 
DMPA may alter cervicovaginal immune responses that could influence susceptibility to 
HIV-1 infection, through modulating the innate environment of the genital tract and 
recruitment of immune cells to the mucosa (Figure 2.3, number 5) (Chandra et al., 2013; 
Mitchell et al., 2014; Wira and Veronese, 2011). From vaginal biopsy tissue, a recent study 
reported that women using DMPA had increased numbers of CD3+, CD8+, HLA-DR+, 
CCR5+, CD45+ leukocytes and CD68+ macrophages in the squamous epithelium compared to 
women not using DMPA (Chandra et al., 2013). In contrast, Brunelli and colleagues (1996) 
reported women using DMPA had decreased natural killer (NK) cells in blood and CD8+ 
CD11b+ T-lymphocytes function than women not using DMPA (Brunelli et al., 1996). 
Similar infiltrations of immune cells were also noted in women not using HCs during a 
normal menstrual cycle phases during the late luteal phase, with endogenous progesterone 
inducing the migration of macrophages, increasing immunoglobulin content and cytokine 
expression within the endometrium (Starkey et al., 1991). In other studies, an increase in the 
density of cervicovaginal lymphocytes expressing CCR5 was observed in response to 
increasing progesterone levels (Sheffield et al., 2009), although no difference in HLA-DR+ 
and CCR5+ target cells was found in vaginal biopsies after 12 months of DMPA use 
(Mitchell et al., 2014).  
 
DMPA has also been shown to increase expression of the HIV-1 co-receptors CXCR4 and 
CCR5 on activated T cells, resulting in increased proliferation of CCR5 and CXCR4-tropic 
viruses (Huijbregts et al., 2013).  An in vitro study showed that immune cells treated with 
progesterone had 10-fold increased expression of CCR5 on CD14+ monocytes/macrophages 
(Patterson et al., 1998). DMPA also reduced the ability of pDCs to respond to stimulation via 
TLR-7/8 and TLR-9 (Huijbregts et al., 2013) (Hughes et al., 2008). Progesterone has also 
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been shown to significantly inhibit proliferation of blood CD8+ T cells and cytokine 
production by both CD4+ and CD8+ T cells (Vassiliadou et al., 1999). Several studies have 
shown that the number of antibody-secreting plasma cells at the mucosa, trans-epithelial 
mucosal transport of immunoglobulins (Igs), and concentrations of mucosal IgG and IgA 
were down-regulated by progesterone and DMPA in women and non-human primates treated 
with DMPA (Kutteh et al., 1996; Lu et al., 2002; Lu et al., 2003; Patton et al., 2000). In 
contrast, higher concentrations of total and antigen-specific IgG secreting cells have been 
detected in blood after DMPA administration although no differences in plasma IgA and IgM 
concentrations were observed (Lali et al., 1996).  
 
In macaques vaginal-challenged with SIV, treatment with DMPA enhanced risk for mucosal 
SIV infection >7-fold (Marx et al., 1996; Trunova et al., 2006; Veazey et al., 2003). In 
addition to influencing the thickness of the epithelial barrier of macaques, DMPA 
administration also increased SIV replication, and downregulated cellular immune responses. 
The dramatic impact of DMPA on SIV acquisition in non-human primates may be 
exaggerated by the higher doses of DMPA typically used in primates, the way in which 
viruses are administered (high-dose SIV-culture medium in primates), and the rate of 
metabolism and circulation of DMPA in these non-human primates after the 3 monthly 
injection (Hel et al., 2010).  
 
2.3.3 Influence of injectable HC use on innate and soluble factors in the genital tract 
HIV-1 infection has been shown to result in productions of inflammatory cytokines that play 
a central role in determining viral kinetics, influence recruitment of HIV-1 target cells to the 
mucosa, and development of anti-viral immunity following infection (Stacey et al., 2009; 
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Roberts et al., 2010; Roberts et al., 2012; Bebell et al., 2008). In addition, pre-existing 
inflammatory responses, both in the genital mucosa and systemically, are also thought to 
influence risk of HIV-1 infection in women before they become infected (Masson et al., 
2015; Naranbhai et al., 2014).  
 
Several different, partially overlapping, functional classes of cytokines have been described 
(Abbas and Lichtman, 2007; Charo and Ransohoff, 2006; Connolly et al., 2005).  Pro-
inflammatory cytokines, such as TNF-β, L-12p40, IL-12p70, IL1α, IL-6, TNF-α, and IL-1β, 
are involved in recruitment of immune cells from blood into tissue, stimulating their 
differentiation and activation. Anti-inflammatory cytokines, including IL-1Ra and IL-10, 
regulate excessive inflammatory reactions, and are produced to counteract the actions of 
inflammatory cytokines. Chemokines are chemotactic cytokines, including eotaxin, monocyte 
chemoattractant protein (MCP)-1, macrophage-derived chemokine (MDC), Fractalkine, 
macrophage inflammatory protein (MIP)-1α, MCP-3, interferon-γ-induced protein (IP)-10, 
growth related oncogene (GRO), MIP-1β, IL-8, and RANTES, are responsible for 
recruitment of immune cells to inflammatory sites and damaged tissue. Growth factors, such 
as interferon (IFN)-α, transforming growth factor (TGF)-α, vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF)-AB/BB, and 
fibroblast growth factors (FGF)-2, are involved in cell growth and proliferation. 
Hematopoietic cytokines, such as IL-9, FMS-like tyrosine kinase-3 (Flt3L), granulocyte 
colony-stimulating factor (G-CSF), granulocyte-macrophage (GM)-CSF, IL-7, and IL-3, are 
involved in hematopoesis of immune cells from stem cell progenitors. Adaptive cytokines, 
such as IL-15, IL-5, IL-17, soluble CD40 ligand (sCD40L), IFN-γ, IL-2, IL-4, IL-13, sIL-
2Rα, and IFN-α, stimulate growth, differentiation, activation and survival of immune cells.  
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Changes in hormones during the menstrual cycle, including changes induced by HC use, has 
been suggested to alter cytokine production in both the upper and lower female reproductive 
tract (Huijbregts et al., 2013). Use of DMPA has been shown to reduce resistance to 
microbial invasion by modulating soluble innate mucosal defenses (Figure 2.3, number 3). 
DMPA was found to inhibit secretion of IFN-γ, IL-2, IL-4, IL-6, IL-12, TNF-α and MIP-1α 
by activated PBMCs in vitro (Huijbregts et al., 2013). DMPA has also been shown to have 
glucocorticoid receptor (GR) agonistic activity that inhibits the expression of GR-regulated 
genes (Bamberger et al., 1999; Koubovec et al., 2005; Koubovec et al., 2004). For example, 
DMPA represses the gene encoding IL-2 in normal human lymphocytes via the GR, which 
suggests that the GR might mediate the immunosuppressive effects of DMPA in vivo 
(Bamberger et al., 1999; Koubovec et al., 2005; Koubovec et al., 2004). Cervical cell lines 
stimulated with both DMPA and TNF-α produced lower levels of RANTES and increased 
levels in IL-8, while NET-EN stimulation had no effect (Africander et al., 2011). Govender et 
al. (2014) showed that endocervical cells treated with DMPA showed decreased 
inflammatory responses, marked by lower expression of IL-6, IL-8 and RANTES mRNA, 
while NET-EN did not (Govender et al., 2014).  
 
In contrast to these studies showing dampening of inflammatory responses, others have 
suggested that DMPA use may increase expression of RANTES, although decreasing levels 
of other protective innate factors like the secretory leukocyte protease inhibitor (SLPI) and 
biodefensin-2 (BD-2) in genital secretions (Morrison et al., 2014). Importantly, this increase 
in genital RANTES and decreased concentrations of SPLI was also associated with increased 
risk of HIV-1 acquisition (Morrison et al., 2014).  
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Others have suggested that DMPA use may dampen immune responses to other common 
infectious diseases in women, such as tuberculosis. PBMCs from women with tuberculosis 
who were using DMPA produced lower amounts of IL-1α, IL-12p40, IL-10, IL-13 and G-
CSF following stimulation with the mycobacterial antigen BCG compared to non-HC users 
(Kleynhans et al., 2011). In addition, DMPA using women also had decreased frequencies of 
circulating monocytes, a key correlate of protection against tuberculosis, compared to non-
HC users (Kleynhans et al., 2011). In mice infected with tuberculosis, treatment with DMPA 
also resulted in down-regulated plasma cytokine levels of TNF-α, IFN-γ, G-CSF, IL-6, IL-10, 
IL-17 and MCP-1 and increased secretion of IP-10 compared to control mice (Kleynhans et 
al., 2013).  
 
Matrix metalloproteases (MMPs) are a family of zinc dependent proteases that are required 
during normal reproductive processes for degradation of specific components of the extra 
cellular matrix and tissue remodeling in the endometrial compartment of the female genital 
tract during normal menstruation (Birkedal-Hansen, 1995; Cawston, 1995; Lockwood and 
Schatz, 1996; Rodgers et al., 1994; Rodgers et al., 1993). MMPs comprise collagenases 
(enzymes that break down peptide bonds in collagen that includes MMP-1), gelatinases 
(proteolytic enzymes that hydrolyze gelatin that include MMP-2 and MMP-9), stromelysins 
(enzymes involved in breakdown of the extracellular matrix that include MMP-3 and MMP-
10) and matrilysins (uterine metalloproteinases that are also involved in extracellular matrix 
degradation that include MMP-7). MMPs are regulated by multiple ways, being activated by 
other proteases, at the level of gene transcription and by hormones (Vincent et al., 2000). 
MMPs are inhibited by specific endogenous tissue inhibitors of metalloproteinases (TIMPs) 
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(Fernandez-Catalan et al., 1998; Gomis-Ruth et al., 1997). Regulation of TIMP expression 
occurs during tissue development and remodelling (Fernandez-Catalan et al., 1998; Gomis-
Ruth et al., 1997). Injectable HCs have been shown to suppress production of epithelial cell-
specific MMP-7 and stromal-epithelial specific MMP-3 (Bruner et al., 1995; Osteen et al., 
1994; Schatz et al., 1997; Singer et al., 1997). Women using injectable HCs were also found 
to have decreased TIMP concentrations in their upper reproductive tracts (Vincent et al., 
2002). Although not fully understood, changes in the local ratio of MMPs:TIMPs may 
influence tissue remodeling processes in the reproductive tract, and degradation of 
extracellular matrix components such as collagen, elastin, fibronectin and laminin by MMP-
1, MMP-2 and MMP-9 thus affecting epithelial barrier function upon HIV-1 exposure (Li et 
al., 2007; Osteen et al., 1994; Vincent et al., 2000, 2002; Zhang et al., 1998; Zhang, 1998). 
 
2.3.4 Susceptibility to bacterial vaginosis (BV) and stability of the vaginal microbiome 
following injectable HC use 
Injectable HCs have been suggested to influence the vaginal microbiome in a way that may 
increase risk for HIV-1 acquisition (Figure 2.3, number 4) (Atashili et al., 2008; Martin et al., 
1999; Miller et al., 2000). H2O2-producing lactobacilli species, including Lactobacillus 
crispatus, L. jensenii and L. gasseri, are thought to predominate in the healthy vaginal 
environment and contribute to host defense via metabolism of glycogen to lactic acid, 
biosurfactants and hydrogen peroxide to maintain the vagina at an acidic pH <5, (Aroutcheva 
et al., 2001; Boris and Barbes, 2000; Witkin et al., 2007). Low vaginal pH is thought to 
inhibit CD4 T-cell activation and proliferation and decrease the number of HIV-1 target cells 
available for infection in the vaginal mucosa (Hill and Anderson, 1992). However, the 
menstrual cycle affects the vaginal microbial environment. Fluctuations in endogenous 
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estrogen and progesterone levels around ovulation and menses affect attachment and growth 
of Lactobacilli species to the mucosal epithelium, in addition to influencing cervical mucus 
secretion, vaginal pH and epithelial cell glycogen content (Miller et al., 2000). Use of DMPA 
results in a hypo-estrogenic state, which has been associated with reduced H2O2-producing 
lactobacilli colonization, possibly weakening the vaginal epithelial barrier and allowing 
microbial invasion (Miller et al., 2000). Mitchell et al. (2014) reported that women using 
DMPA for ~12 months had lower proprotions of H2O2-producing Lactobacilli species 
compared to before they started using DMPA (Mitchell et al., 2014). Both Miller et al. (2000) 
and Mitchell et al. (2014) reported an overall decrease in glycogen content, required for 
lactobacilli to sustain growth, as well as lactate metabolism in epithelial cells from women 
using DMPA (Miller et al., 2000; Mitchell et al., 2014).  
 
Decreased glycogen content has also been associated with reduced water content in vaginal 
epithelial cells, leading to cytoplasmic dehydration and changes in the vaginal microbiota that 
favour less acid-tolerant bacteria colonization (Miller et al., 2000). BV is a prevalent 
microbial dysbiosis, characterized by reduced concentrations of commensal Lactobacilli 
species and concomitant overgrowth of anaerobic bacterial species, including Gardnerella 
spp, Prevotella spp, and Mobiluncus spp (Hiller et al., 2008). BV is typically diagnosed using 
a clinical algorithm including signs and symptoms such as odorous but clear vaginal 
discharge, a vaginal pH >4.5, a positive amine test, and the presence of clue cells (vaginal 
epithelial cells with a distinctive stippled appearance as a result of being covered with 
bacteria in a biofilm) (Amsel et al., 1983; Cook et al., 1992). In addition, BV is also 
evaluated using Nugent scoring whereby bacterial morphotypes are scored using Gram 
staining from smears of lateral vaginal wall swabs (Nugent et al., 1991).  
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While BV has been implicated in moderate increased risk for HIV-1 infection, several studies 
reported that women using DMPA have reduced risk of prevalent and recurrent BV 
(Eschenbach et al., 2000; Hayes et al., 2010; Low et al., 2011; Riggs et al., 2007; 
Shoubnikova et al., 1997; van de Wijgert et al., 2013). Reduced prevelence of BV in women 
using DMPA could be because these women often do not menstruate and the presence of 
haemoglobin in the genital tract has been associated with development of BV (Eschenbach et 
al., 2000; Pettifor et al., 2009; van de Wijgert et al., 2013). Further studies are needed to 
understand the mechanism by which DMPA use reduce the risk of BV (Jarosik et al., 1998). 
 
2.3.5 Injectable HCs and susceptibility to sexually transmitted infections (STIs) 
Studies have suggested that injectable HC users may be at increased risk of infection with 
other common STIs (including C. trachmatis and HSV-2) but not others (including N. 
gonnorhoea, human papillomavirus (HPV), T. vaginalis, and syphilis) (Figure 2.3, number 
7). Increased cervical ectopy following injectable HC use and the resultant hypo-oestrogenic 
state that exists in women using high dose progesterone HCs result in thinning of the mucosal 
epithelium that result in increased risk for bacterial and viral sexually-transmitted infections 
that favour infection at the cervix, as well as HIV-1 (Baeten et al., 2001; Critchlow et al., 
1995; Harrison et al., 1985; Lavreys et al., 2004; Mohllajee et al., 2006; Morrison et al., 
2004; Plourde et al., 1994; van de Wijgert et al., 2013). Table 2.1 summarizes the recent 
studies that have investigated the relationship between injectable HCs use and risk of STIs. 
Several of these studies found that use of injectable HCs was associated with a significant 
increased risk of infection with Chlamydia (Baeten et al., 2001; Lavreys et al., 2004; 
Morrison et al., 2004), while others did not (Jacobson et al., 2000; Noguchi et al., 2014; 
 35 
Overton et al., 2008; Pettifor et al., 2009). Similar controversy exists for HSV-2 infection risk 
in women using injectable HCs, with (Noguchi et al., 2014) reporting enhanced risk for HSV-
2, while (Lavreys et al., 2004) did not. For other common STIs, including syphilis, 
gonorrhea, and HPV, no association with DMPA use was found (Baeten et al., 2001; 
Guiuliano et al., 2001; Harris et al., 2009; Marks et al., 2011; Moscicki et al., 2001). In 
contrast to the increased susceptibility noted for infections like chlamydia and HSV-2, albeit 
controversial, DMPA use was reported to decrease risk for Trichomonas infection 
(Brahmbhatt et al., 2014; Pettifor et al., 2009), although several other groups did not find the 
same effect (Baeten et al., 2001; Overton et al., 2008; Torok et al., 2009). 
 
It is difficult to assess whether the observed results may reflect systematic behavioural or 
other differences in exposure to STIs among women using injectable HCs compared to those 
not selecting this option.  This is compounded by the fact that most studies were performed in 
cross-sectional studies that could not differentiate whether STIs occurred before DMPA use. 
In addition, other potential confounding factors and heterogeneity in study designs also make 
it difficult to directly assess the link between injectable HC use and risk for STIs, in the 
absence of more detailed mechanistic studies.  
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Table 2.1 Summary of recent studies exploring the relationship between injectable HC use and risk for acquiring STIs 
STI Study n, population Adjusted for DMPA Risk 
C. trachmatis (Baeten et al., 2001) 948, Kenyan sex workers Age, education, years of sex work, parity, place of work, 
number of sex partners per week, number of sex acts per 
week, condom use 
HR 1·6, 95% CI 1·1–2·4, comparing 
DMPA users with women who were 
sterilized or non-HC users 
Increased 
 (Lavreys et al., 2004) 242, HIV-1 positive Kenyan sex 
workers 
 
Age, education, duration of sex work, parity, number of sex 
partners per week, condom use 
HR 3·1, 95% CI 1·0–9·4, comparing 
DMPA users with women who were 
sterilized or non-HC users 
Increased 
 (Morrison et al., 2004) 819, American patients seeking 
reproductive health care 
Age, race, site, sexual and reproductive health 
characteristics 
HR 4·3, 95% CI 1·7–11·1, comparing 
DMPA users with non-HC users 
Increased 
 (Jacobson et al., 2000) 97, HIV-1 negative Baltimore 
adolescent females 
Age, lifetime number of partner OR 5·44, 95% CI 1·25 – 23·6 
comparing DMPA users with non-HC 
users 
No risk 
 (Pettifor et al., 2009) 567 HIV-1 negative women Age, education, and condom use consistency in the past 3 
months 
IRR 1·2, 95% CI 0·8–1·9, comparing 
DMPA users with non-HC users 
No risk 
 (Noguchi et al., 2014) 3,163 women were enrolled in 
The MTN-003 (VOICE) trial was 
a Phase 2B, multi-site, 
randomized, placebo controlled 
trial 
Age, married, cohabiting, education, BL HSV-2, time-
varying partners, partner has other partners, and 
unprotected sex, stratified by site, with censoring at 
pregnancy 
HR 1·09, 95% CI 0·92-1·29, comparing 
DMPA users with NET-EN users 
No risk 
 (Overton et al., 2008) 304 HIV-1 negative women No adjustment HR 1·19, 95% CI 0·7-1·9, comparing 
DMPA users with no-DMPA users  
No risk 
N. gonnorhoea (Baeten et al., 2001) 948, Kenyan sex workers Age, education, years of sex work, parity, place of work, 
number of sex partners per week, number of sex acts per 
week, condom use 
HR 1·1, 95% CI 0·8–1·6, comparing 
DMPA users with women who were 
sterilized or non-HC users 
No risk 
 (Lavreys et al., 2004) 242, HIV-1 positive Kenyan sex 
workers 
 
Age, education, duration of sex work, parity, number of sex 
partners per week, condom use 
HR 1·0, 95% CI 0·6–1·7, comparing 
DMPA users with women who were 
sterilized or non-HC users 
No risk 
 37 
 (Morrison et al., 2004) 819, American patients seeking 
reproductive health care 
Age, race, site, sexual and reproductive health 
characteristics 
Insufficient cases to evaluate risk of 
gonorrhoea alone; HR for either 
chlamydia or gonorrhoea 3·6, 95% CI 
1·6–8·5, comparing DMPA users with 
non-HC users 
No risk 
 (Pettifor et al., 2009) 567 HIV-1 negative women Age, education, and condom use consistency in the past 3 
months 
IRR 1·3, 95% CI 0·6–3·0, comparing 
DMPA users with non-HC users 
No risk 
 (Noguchi et al., 2014) 3,163 women were enrolled in 
The MTN-003 (VOICE) trial was 
a Phase 2B, multi-site, 
randomized, placebo controlled 
trial 
Age, married, cohabiting, education, BL HSV-2, time-
varying partners, partner has other partners, and 
unprotected sex, stratified by site, with censoring at 
pregnancy 
HR 0·92, 95% CI 0·64 –1·3, comparing 
DMPA users with NET-EN users 
No risk 
 (Overton et al., 2008) 304 HIV-1 negative women No adjustment HR 1·04, 95% CI 0·6-1·8, comparing 




(Marks et al., 2011) 1000 HIV-1 negative women  Age, lifetime number of partners, number of partners L6M, 
smoking and ever GC/CT/SYP infection. 
Risk hazard (RH) 1·24, 95% CI 0·8-
1·91 comparing DMPA users with non-
HC users 
No risk 
 (Moscicki et al., 2001) 897 women in HPV and LSIL 
incidence cohort 
No adjustment HR 0·79, 95% CI 0·2-3·25 comparing 
DMPA users with non-HC users 
No risk 
 (Harris et al., 2009) 284 HPV DNA positive women Age, lifetime number of male partners and parity OR 4·7, 95% CI, 1·4-15·8 comparing 
DMPA users with non-HC users 
No risk 
 (Guiuliano et al., 
2001) 
2319 women marital status, employment status,age, number of male 
partners 
OR 2·3, 95% CI, 1·5 – 3·53 comparing 
injectable HC users with non-HC users 
No risk 
HSV-2 (Noguchi et al., 2014) 3,163 women were enrolled in 
The MTN-003 (VOICE) trial was 
a Phase 2B, multi-site, 
randomized, placebo controlled 
trial 
Age, married, cohabiting, education, BL HSV-2, time-
varying partners, partner has other partners, and 
unprotected sex, stratified by site, with censoring at 
pregnancy 
HR 2·06 95% CI 1·12 –3·79, 
comparing DMPA users with NET-EN 
users 
Increased 
 (Lavreys et al., 2004) 242, HIV-1 positive Kenyan sex 
workers 
 
Age, education, duration of sex work, parity, number of sex 
partners per week, condom use 
HR 0·6, 95% CI 0·4–1·0, comparing 
DMPA users with women who were 
sterilized or non-HC users 
No risk 
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T. vaginalis (Baeten et al., 2001) 948, Kenyan sex workers Age, education, years of sex work, parity, place of work, 
number of sex partners per week, number of sex acts per 
week, condom use 
HR 0·6, 95% CI 0·4–1·0, comparing 
DMPA users with women who were 
sterilized or non-HC users 
No risk 
 (Torok et al., 2009)   OR 1·4, 95% CI, 0·6 – 3·4 comparing 
injectable HC users with non-HC users 
No risk 
 (Pettifor et al., 2009) 567 HIV-1 negative women Age, education, and condom use consistency in the past 3 
months 
IRR 0·4, 95% CI 0·1–1·0, comparing 





(Brahmbhatt et al., 
2014) 
2374 HIV-1 negative women sociodemographic, behavioral risk factors, syphilis 
infection, and BV status 
IRR 2·8, 95% CI 1·0–8·0, in DMPA 
users after 12 months of treatment  
Decreased 
 (Overton et al., 2008) 304 HIV-1 negative women No adjustment HR 1·32, 95% CI 1·0-1·8, comparing 





(Baeten et al., 2001) 948, Kenyan sex workers Age, education, years of sex work, parity, place of work, 
number of sex partners per week, number of sex acts per 
week, condom use 
HR 0·5, 95% CI 0·2–1·4, comparing 
DMPA users with women who were 
sterilized or non-HC users 
 
No risk 
DMPA=depot medroxyprogesterone acetate; NET-EN=norethisterone enanthate; HC=hormonal contraceptives; CI=Confidence interval; 
OR=odds ratio; hazard ratio=HR; IRR= incidence rate ratio; RH=risk hazard  
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2.4 Injectable HCs and HIV-1 shedding from HIV-1 infected women  
Injectable HC use in women already infected with HIV-1 may also influence their risk 
of transmitting HIV-1 to sexual partner/s, by increasing local HIV-1 viral loads in 
genital secretions (Heffron et al., 2012) (Table 2.2). Heffron et al. (2012) showed that 
chronically HIV-1 infected women using injectable HCs, in HIV-1 serodiscordant 
relationships with HIV-1 negative male partners, were twice as likely to transmit 
HIV-1 to their partners than women not using HCs; and this was associated with 
significantly elevated concentrations of HIV-1 RNA in genital secretions from in 
injectable HC users (Heffron et al., 2012). Relatedly, HIV-1 RNA concentrations 
were shown to be higher in genital secretions taken from naturally cycling HIV-1 
infected women during the luteal phase of menstrual cycle, when progesterone 
predominates, adding further biological plausibility to this association (Benki et al., 
2004; Reichelderfer et al., 2000). Earlier studies on the impact of injectable HC use 
on HIV-1 genital tract viral loads have been conflicting, with several reporting no 
difference in HIV-1 shedding in female genital secretions in women using injectable 
HCs compared to those not using HCs (Graham et al., 2010; Lutalo et al., 2013; 








Table 2.2 Summary of studies evaluating the relationship between injectable 
HC use in HIV-1 infected women and risk of transmission to their male partners 
Study n, population Adjusted for Injectable HC used Discription of results 







HIV-1 viral load, 
time-varying 
unprotected sex in 
last month, time-
varying pregnancy 
Not differentiated Cox HR 1·95, 95%CI 
0·99 – 3·22; MSM HR 
3·01, 95%CI 1·47 – 6·16, 
comparing injectable HC 
users with non-HC users 
(Mostad et al., 1997) 318 women in 
STI clinic 
 
CD4, other factors 
unclear 
DMPA Cervical, OR 2·9, 95% CI 
1·5–5·7 and vaginal, OR 
1·0, 95% CI 0·3–2·7, 
comparing DMPA users 
non-HC users 
(Graham et al., 2010) 102 HIV-1 
infected non-
pregnant women 
Plasma viral load, 
other factors 
unclear 
Not differentiated HR 1·70, 95% CI 1·7–
5·66, comparing DMPA 
users with non-HC users 




HIV-1 viral load DMPA OR 1·40, 95% CI 0·30 – 
6·49 comparing DMPA 
users with non-HC users 


















disease, time since 
infection 
DMPA IRR 1·2, 95% CI 0·8–1·9, 
comparing DMPA users 
with non-HC users 
 
 
However, other unidentified confounding factors are fundamental concerns in all-
observational studies such as these (Gray, 2012; Hubacher, 2012; Shelton, 2012). It is 
possible that women using injectable HCs may use condoms differently to non-HC 
users (Cushman et al., 1998; Gray, 2012; Sangi-Haghpeykar et al., 2005).  The WHO 
Expert group assessing these factors emphasized the need for studies on HIV-1–
discordant couples to quantify the effects of HC use on HIV-1 acquisition, HIV-1 
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progression in HIV-1 infected women and onward transmission of HIV-1 to men 
(WHO, 2012).  
 
2.5 Injectable HCs and rate of disease progression in HIV-1 infected women  
A randomized control trial evaluating the safety of various HC methods for use by 
HIV-1 infected women showed that HIV-1 infected women using DMPA experienced 
moderately more rapid HIV-1 rates of disease progression, measure by CD4 decline, 
than the control arm (HR 1.39; 95% CI 0.63–3.06), although this was not significant 
(Stringer et al., 2007). In contrast, observational studies have reported slower rates of 
disease progression in HC users than non-HC users (Heffron et al., 2013). To further 
confuse this issue, six additional observational studies found no increased risk for 
accelerated progression to death, onset of clinical AIDS, decrease of CD4 count <200 
or <350 cells/mm3, initiation of a highly active anti-retroviral therapy (HAART) and 
death not due to trauma with injectable HC when compared to non-use of HC 
methods (Allen et al., 2007; Heffron et al., 2013; Heikinheimo et al., 2011; Kilmarx et 
al., 2000; Morrison et al., 2011; Polis et al., 2010).  
 
A meta-analysis of available clinical data in HIV-1 infected women is needed to 
resolve this uncertainty. In 2012 and 2015, the WHO published a statement 
acknowledging that the currently available data does not establish a clear causal 
association between injectable HCs and HIV-1 shedding nor disease progression. The 
WHO expert panel further recommended that women using HCs should also be 
counselled to use condoms to prevent HIV-1 shedding and accelerated disease 
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progression (WHO, 2012, 2015). These recommendations also stressed the need for 
further research on longitudinal studies of injectable HCs impact during chronic HIV-
1 infection on viral load, CD4 cell count and disease progression, including impacts 
of initiation, or termination and total duration of injectable HC use (WHO, 2012, 
2015).  
 
2.6 Injectable HC and anti-retroviral therapy during HIV infection 
Preventing unplanned pregnancies in HIV-1 infected women can significantly 
decrease HIV-1 transmission from infected mothers to their children and improve a 
woman’s general health. Injectable HCs are widely used to prevent unplanned 
pregnancies in HIV-1 infected women, but there are concerns that simultaneous use of 
injectable HCs and highly active anti-retroviral therapy (HAART) may alter the 
effectiveness of both (Robinson et al., 2012). There are no published data on 
interactions between NET-EN and the drugs that comprise HAART, but studies have 
suggested that DMPA can negatively interact with ritonavir-boosted protease 
inhibitors and efavirenz (Cohn et al., 2007; Robinson et al., 2012). The revised WHO 
medical eligibility criteria for contraceptive use has not recommended restriction on 




This Chapter summarizes the literature around the relationship between injectable 
HCs and increased risk of HIV-1 infection in HIV-1 negative women and the impact 
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of injectable HC use on the infectiousness of HIV-1 infected women to their male 
sexual partners. Investigations of the possible biological mechanisms driving this risk 
used in vitro laboratory approaches, non-human primates models using SIV vaginal 
challenges, and in vivo clinical studies in women using injectable HCs, each 
suggesting a positive relationship between long-acting progestin containing injectable 
HCs and HIV-1 risk. The majority of evidence suggests that injectable HCs have 
limited effect on HIV-1 disease progression in chronically HIV-1 infected women and 
that injectable HCs largely does not interact with most anti-retroviral drugs 
comprising HAART. Many of the clinical studies described were not originally 
designed to assess this association and, like many observational studies, had many 
potential confounders. Of these, methodological considerations, such as semen 
contamination in the cervico-vaginal secretions, inconsistent condom use, age, parity, 
education, marital status, behavioural risk, pregnancy status, poor follow-up, 
statistical power and precision were properly controlled for in these studies (Polis and 
Curtis, 2013). Unless the effects of hormonal contraception on HIV-1 risk are 
appropriately addressed, the likelihood is that DMPA would indirectly contribute to 
increased maternal and infant mortality, increase risk of HIV-1 transmission from 













Lower concentrations of chemotactic cytokines and 
soluble innate factors in the lower female genital 




Lower concentrations of chemotactic cytokines and soluble innate 
factors in the lower female genital tract associated with use of 
injectable hormonal contraceptives 
 
3.1 Abstract 
Progesterone-based injectable HCs potentially modulate genital barrier integrity and 
regulate the innate immune environment in the female genital tract, thereby enhancing 
risk for STIs or HIV-1 infection. The effects of injectable HC use on concentrations 
of inflammatory cytokines and other soluble factors associated with genital epithelial 
repair and integrity was investigated in this Chapter. The concentrations of 42 
inflammatory, regulatory, adaptive, growth factors and hematopoetic cytokines, five 
matrix metalloproteinases (MMPs), and four tissue inhibitors of metalloproteinases 
(TIMPs) were measured in CVLs from 64 HIV-1 negative women using injectable 
HCs and 64 control women not using any HCs, in a matched case-control study. 
There were no differences between groups in the prevalence of BV Nugent score ≥7, 
or common STIs. In multivariate analyses adjusting for condom use, sex work status, 
marital status, BV and STIs, median concentrations of the chemokines eotaxin, MCP-
1, MDC, the adaptive cytokine IL-15, the growth factor PDGF-AA, and an inhibitor 
of metalloproteinases TIMP-2 were significantly lower in CVLs from women using 
injectable HCs than controls. In addition, the pro-inflammatory cytokine IL-12p40 
and the chemokine fractalkine were less likely to have detectable levels in women 
using injectable HCs compared to those not using HCs. Findings from this Chapter 
suggest that injectable HC use was associated with an immunosuppressive female 
genital tract innate immune profile. While the relationship between injectable HC use 
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and STI or HIV-1 risk is yet to be resolved, this data suggest that injectable HCs 
effects were similar between STI positive and STI negative participants.   
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3.2 Introduction 
Internationally, HCs are widely used by women to prevent unplanned pregnancies. In 
South Africa, more than half of women aged 15-49 years old use DMPA or NET-EN, 
with more than 3 times the number of women using DMPA than NET-EN 
(Department of Health et al., 2007; Sibeko et al., 2011). DMPA primarily provides 
contraceptive protection by suppressing natural cyclic fluctuations of female sex 
hormones resulting in a hypoestrogenic state (Jeppsson et al., 1982). The mechanism 
of action of NET-EN is more complex than that of DMPA. An initial suppression of 
ovulation overlaps with very high initial plasma progestogen levels, which may 
decrease after 60 days(Fotherby et al., 1978; Goebelsmann et al., 1979).  
 
As discussed in Chapter 2, high-dose DMPA use is common in the SIV vaginal 
challenge models because it results in thinning of the vaginal epithelium, which 
enhances genital SIV infection (Abel et al., 2004; Marx et al., 1996; Trunova et al., 
2006; Wieser et al., 2001). The role of DMPA in increasing risk of HIV-1 infection is 
contentious, with some studies reporting increased risks (Baeten et al., 2007a; Heffron 
et al., 2012; Hel et al., 2010; Kumwenda et al., 2008; Morrison et al., 2010; 
Ungchusak et al., 1996), and others finding no such association (Kiddugavu et al., 
2003; Kleinschmidt et al., 2007; Myer et al., 2007; Reid et al., 2010; Stringer et al., 
2009). The impact of DMPA on genital epitheial barrier intergrity is similary 
contentiuos (Kiddugavu et al., 2003; Myer et al., 2007). In addition to HIV-1, DMPA 
has also been associated with an increased risk of C. trachomatis infection and 
decreased risk of acquiring BV and T. vaginalis infections (Baeten et al., 2001; van de 
Wijgert et al., 2013). 
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It has been hypothesised that DMPA might increase HIV-1 aquisition risk by 
changing the inflammatory or chemotactic environment of the genital mucosa so as to 
increase the recruitment of HIV-1 susceptible immune cells to the mucosa (Ildgruben 
et al., 2003; Miller et al., 2000; Wieser et al., 2001; Wira et al., 2011b; Wira and 
Veronese, 2011). However, treatment of PBMCs with DMPA has been shown to 
cause reduced production of several inflammatory and adaptive cytokines (Huijbregts 
et al., 2013). At the female genital mucosa, suppression of innate immune responses 
may influence susceptibility to infections. Moreover, MMPs, which are required 
during normal reproductive processes such as menstruation (Birkedal-Hansen, 1995; 
Cawston, 1995; Lockwood and Schatz, 1996; Rodgers et al., 1994; Rodgers et al., 
1993), may influence epithelial barrier repair in the lower genital tract. MMPs are 
regulated by specific TIMPs (Fernandez-Catalan et al., 1998; Gomis-Ruth et al., 
1997), which may similarly be involved in maintainence of the lower reproductive 
tract barrier.  
 
Defining the impact of injectable HCs on female genital tract innate immunity in 
relation to susceptibility to STIs or BV, will provide important insights into biological 
co-factors influencing HIV-1 risk in women. The aim of this study was to compare 
concentrations of genital tract soluble immune mediators (including cytokines, MMPs 
and TIMPs) between women using long-acting injectable HCs and women not using 
HCs, while accounting for BV and common STIs. 
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3.3 Materials and Methods 
 
3.3.1 Study design, participants and sample collection 
This study included 64 HIV-1 uninfected women using injectable HCs (DMPA or 
NET-EN) and 64 women not using HCs, enrolled into the prospective CAPRISA 002 
observational cohort study of acute HIV-1 infection conducted at the Centre for the 
AIDS Programme of Research in South Africa (CAPRISA), in Durban, KwaZulu-
Natal Province, South Africa, as previously described (Mlisana et al., 2012; van 
Loggerenberg et al., 2012). Non-HC users were matched to injectable HC users based 
on age (within 5 years of age) at a 1:1 ratio. Demographic and clinical data were 
collected at enrolment using a structured questionnaire administered by a trained 
counsellor. Although data on type of contraception (injectable HCs, COCs, IUDs, 
condoms, diaphragms, foam and jelly, or were sterilised) was collected no 
information was collected on whether the injectable contraceptive being used was 
DMPA or NET-EN. Because of this, injectable HCs in this Chapter included a 
combination of DMPA and NET-EN users. Women using COC or any other form of 
HC were excluded from the study, with an exception of IUD users. Laboratory 
samples, including CVLs were collected from each participant at enrolment by gently 
flushing the cervix and the lateral vaginal walls with 10ml sterile normal saline, as 
previously described by Mlisana et al. (2012). Volume of saline recovered after the 
lavage were not typically recorded. CVLs were transported within 4 hours on ice from 
the site to the laboratory. In the laboratory, CVLs were centrifuged, the supernatant 
collected and stored at -80°C. The protocol for this study was approved by the Ethical 
Review Committees of the University of KwaZulu-Natal and University of Cape 
Town.   
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3.3.2 Laboratory testing for STIs and BV 
At enrollment, vulvovaginal swabs collected from the posterior fornices and lateral 
vaginal walls from each woman were tested for C. trachomatis, N. gonorrhoeae, M. 
genitalium, HSV-2 reactivation and T. vaginalis using PCR. Gram stain was 
performed to diagnose BV using Nugent score ≥7 (Mlisana et al., 2012). 
  
3.3.3 Measurement of cytokines and soluble factors in CVL 
Concentrations of cytokines, MMPs and TIMPS were measured in CVLs collected at 
enrollment. Concentrations of 42 cytokines [including IL-1α, IL-3, IL-9, IL-12p40, 
IL-15, IL-17, epidermal growth factor (EGF), platelet-derived growth factor (PDGF)-
AA, transforming growth factor (TGF)-α, vascular endothelial growth factor (VEGF), 
eotaxin/CCL11, FGF-2, FLT3 Ligand (FLT3L), fractalkine/CX3CL1, G-CSF, growth 
related oncogene (GRO) family (CXCL1-CXCL3), IFN-α, IFN-γ-induced protein 
(IP)-10/CXCL10, monocyte chemoattractant protein (MCP)-1/CCL2, MCP-3/CCL7, 
macrophage-derived chemokine (MDC)/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, 
PDGF-AB/BB, RANTES/CCL5, soluble CD40 ligand (sCD40L), soluble IL-2 
receptor α (sIL-2Rα), TNF-β, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-
10, IL-12p70, IL-13, GM-CSF, IFN-γ and TNF-α]; 4 TIMPs [TIMP-1, -2, -3, -4]; and 
5 MMPs [MMP-1, -2, -7, -9 and -10]. The Human Cytokine and High Sensitivity 
LINCOplex Premixed kits (LINCO Research, MO, U.S.A.) were used to measure 
cytokines; and the TIMP Panel 2 and MMP Panel-2 kits were used to measure TIMPs 
and MMPs, respectively (Merck-Millipore, Missouri, U.S.A.). CVLs were thawed 
overnight on ice and filtered by centrifugation using 0.2 μm cellulose acetate filters 
(Sigma, U.S.A.). All markers were measured in undiluted CVL, except for MMP-9 
(which was measured at 50-fold dilution), on a Bio-Plex 100 system (Bio-Rad 
 51 
Laboratories Inc®, Hercules, California). Bio-Plex manager software (version 5.0; 
Bio-Rad Laboratories Inc®) was used to analyse the data and all analyte 
concentrations were extrapolated from the standard curves using a 5 parameter 
logistic (PL) regression equation. Analyte concentrations that were below the lower 
limit of detection of the assay were reported as the mid-point between zero and the 
lowest concentration measured for each analyte. For IL-8, only two samples had 
readings above the upper limit of detection. For these two samples, IL-8 
concentrations were reported as halfway between the highest concentration and the 
upper limit of the standard curve. 
 
3.3.4 Statistical analyses 
Fisher’s exact test was used to compare proportions, while a t-test was used to 
compare ages between groups. To assess the effect of injectable HCs on cytokine 
levels, linear regression analysis was used. Cytokines that were undetectable in at 
least a third of women (IL-2, IL-2Rα, IL-3, IL-4, IL-10, IL-12p40, IL-12p70, IL-13, 
Fractalkine, MIP-1α, IFN-α, EGF, TFG-α, FGF-2, PDGF-AB/BB and MMP-2) were 
dichotomised (i.e. being rated as either present or absent in each woman) and logistic 
regression was used to estimate the effect of injectable HCs on the detectability of 
these cytokines. Linear and logistic regression analyses were adjusted for sex worker 
status, age, condom use at last sex act, BV and STIs. In addition, interaction terms 
were tested to assess whether injectable HCs modified the effect of STIs on cytokine 
concentrations. Because of the small number of women testing positive for cervical 
STIs, C. trachomatis, N. gonorrhoeae or M. genitalium, these STIs were grouped 
together [Gonorrhea-Chlamydia-Mycoplasma (GCM)] for the purposes of this 
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analysis. Statistical analyses were performed using SAS version 9.3 (SAS Institute 
Inc., Cary).  
 
3.4 Results 
This study included a total of 128 women, 64 of whom were non-HC users (including 
1 woman using an IUD) and 64 of whom were injectable HC users (either DMPA or 
NET-EN) (Table 3.1). Of these 128 women, 79.7% were self-reported sex workers 
and this did not differ between groups. Women using injectable HCs were less likely 
to be single than those not using injectable HCs (0.0% compared to 4.7%; p=0.057), 
and less likely to report having multiple partners (52.4% versus 65.6%), although this 
was not significant. Condom use at last sex act was similar among women using 
injectable HC and of women not using HCs (53.1% vs 65.6%, p=0.208). 
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Table 3.1 Baseline demographic and clinical characteristics  
Variables Overall Injectable-HCs users Non-HCs users P-value 
N 128 64 64  
Age (years) 28 (23-36) 28 (23-36) 29 (23-37) 0.653 
Marital status [% (n)]     
Single 2.4% (3) 0.0% (0) 4.7% (3) 0.057 
Stable partner 34.7% (44) 41.3% (26) 28.1% (18)  
Married 3.9% (5) 6.4% (4) 1.6% (1)  
Many partners 59.1% (75) 52.4% (33) 65.6% (42)  
Sex work [% (n)] 79.7% (102) 79.7% (51) 79.7% (51) 1.000 
Education [% (n)]       
<Grade 8 21.9% (28) 21.9% (14) 21.9% (14) 0.972 
Grade 8-10 29.7% (38) 28.1% (18) 31.3% (20)  
Grade 11-12 48.4% (62) 50.0% (32) 46.9% (30)  
Condom use [% (n)]     
Always use condom with steady partner(s) 25.0% (32) 20.3% (13) 29.7% (19) 0.308 
Always use condom with casual partner(s) 53.9% (69) 46.9% (30) 60.9% (39) 0.156 
Condom use at last sex act 59.4% (76) 53.1% (34) 65.6% (42) 0.208 
Positive test or culture result [% (n)]     
Genital discharge 17.2% (22) 12.5% (8) 21.9% (14) 0.241 
Bacterial vaginosis (Nugent >7) 51.2% (65) 50.8% (32) 51.6% (33) 1.000 
Trichomonas vaginalis 18.9% (24) 19.1% (12) 18.8% (12) 1.000 
Chlamydia trachomatis 6.3% (8) 4.8% (3) 7.8% (5) 0.718 
Neisseria gonorrhoeae 6.3% (8) 1.6% (1) 10.9% (7) 0.062 
Mycoplasma genitalium 1.6% (2) 3.2% (2) 0.0% (0) 0.244 
HSV-2 PCR 2.4% (3) 3.2% (2) 1.6% (1) 1.000 





3.4.1 Prevalence of BV and STIs in injectable HC versus non-HC users 
To investigate the association between injectable HC use and STIs, the prevalence of 
C. trachomatis, T. vaginalis  and BV in women using injectable HCs were compared 
to those who were not using HCs. At baseline (Table 3.1), more than half of the 
women in this cohort had BV (nugent score ≥7), and this did not differ significantly 
between women not using HCs and those using injectable HCs (51.6% and 50.8%, 
respectively; p=1.000). Nineteen percent of women were infected with T. vaginalis 
and this was similar between groups (19.1% for injectable HC users and 18.8% for 
non-HC users; p=1.000). The prevalence of C. trachomatis (6.3%), N. gonorrhoeae 
(6.3%), M. genitalium (1.6%), and HSV-2 (2.4%) were relatively low in this cohort 
and were also similar between groups (Table 3.1). 
 
3.4.2 Impact of injectable HCs on innate factors in the female genital tract  
To better understand how injectable HC use influenced the genital tract innate 
environment, the concentrations of cytokines, chemokines, growth factors and 
markers of tissue repair or remodelling (MMPs and TIMPs) were compared in CVL 
from women using injectable HCs and those not using HCs (Table 3.2). Of the 42 
chemokines, growth factors and inflammatory cytokines that were measured, 5/42 
(11.9%) had significantly decreased median concentrations in the CVL of women 
using injectable HCs than those not using HCs, after adjusting for age, condom use, 
sex worker status, marital status, STIs, and BV. This included several chemokines, 
including eotaxin [beta-coefficient (β)=-0.334, p=0.004], MCP-1 (β=-0.359, 
p=0.015), MDC (β=-0.364, p=0.003); the growth factor PDGF-AA (β=-0.506, 
p=0.001); the adaptive cytokine IL-15 (β=-0.240, p=0.038). In addition, pro-
inflammatory cytokine IL-12p40 (β=-1.059, p=0.009) and chemokine fractalkine (β=-
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0.910, p=0.028) were less likely to be detectable in women using injectable HCs 
compared to those not using HCs. While linear regression was used to estimate the 
effect of injectable HCs on concentrations of eotaxin, MCP-1, and MDC, a logistic 
regression model was fitted to estimate the effect of injectable HC use on the 
detectability of fractalkine and IL-12p40 because the concentrations of these 
cytokines were undetectable in at least a third of the women in this study. 
Furthermore, the median concentration of TIMP-2 was significantly lower in women 
using injectable HCs than those not using HCs (β=-0.207, p=0.027). In contrast, no 
differences were observed in MMP concentrations. None of the cytokines, 
chemokines, growth factors and markers of tissue repair concentrations were 
significantly different between groups. 
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Table 3.2 Influence of injectable hormonal contraceptive use on cytokine, MMP and TIMP concentrations in genital secretions  
Functional 
groups Cytokine 





(pg/ml)  IQR 
Median 






TNF-β 7.60 3.36 - 19.05 11.53 5.31 - 21.83  -0.197 (0.104) 0.061 
IL-12p40† 0.12 0.12 - 14.39 12.20 0.12 - 38.24  -1.059 (0.404) 0.009 
IL-12p70† 0.02 0.01 - 0.08 0.01 0.01 - 0.09  0.363 (0.414) 0.381 
IL1α 38.02 14.26 - 172.71 87.37 30.40 - 259.69  -0.128 (0.126) 0.311 
IL-6 2.57 0.84 - 11.79 2.56 0.36 - 16.41  0.140 (0.198) 0.481 
TNF-α 0.04 0.03 - 0.07 0.04 0.02 - 0.05  0.223 (0.114) 0.053 
IL-1β 0.79 0.14 - 5.96 0.76 0.19 - 5.81  -0.005 (0.169) 0.979 
Chemokine 
Eotaxin 0.31 0.26 - 3.09 2.32 0.31 - 5.27  -0.334 (0.114) 0.004 
MCP-1 6.33 2.80 - 19.39 13.97 4.85 - 72.18  -0.359 (0.146) 0.015 
MDC 10.97 4.60 - 33.28 35.52 12.15 - 63.15  -0.364 (0.119) 0.003 
Fractalkine† 2.13 2.13 - 23.60 18.01 2.13 - 40.10  -0.910 (0.414) 0.028 
MIP1α† 0.66 0.66 - 5.73 0.66 0.66 - 19.83  -0.422 (0.472) 0.370 
MCP-3 9.35 1.95 - 12.41 12.34 8.47 - 15.42  -0.106 (0.063) 0.097 
IP-10 22.95 3.78 - 88.25 45.96 13.30 - 182.40  -0.393 (0.211) 0.066 
GRO 370.82 134.00 - 1263.72 598.60 236.09 - 1974.89  -0.178 (0.128) 0.167 
MIP-1β 3.18 0.26 - 5.27 4.31 0.70 - 7.93  -0.028 (0.252) 0.911 
IL-8 157.89 69.74 - 510.09 131.05 54.80 - 1029.17  0.112 (0.129) 0.389 
RANTES 3.65 2.24 - 9.62 3.21 0.93 - 9.98  0.202 (0.136) 0.138 
Innate IFNα† 0.68 0.68 - 0.68 0.68 0.68 - 8.91  -0.874 (0.446) 0.050 
Hematopoietic 
IL-9 0.68 0.01 - 1.24 1.19 0.23 - 1.76  -0.319 (0.188) 0.093 
Flt3L 4.27 0.45 - 9.48 6.56 2.94 - 10.56  -0.174 (0.110) 0.116 
G-CSF 17.17 2.76 - 73.44 26.80 4.71 - 117.07  -0.256 (0.208) 0.222 
GM-CSF 0.14 0.02 - 0.38 0.13 0.01 - 0.47  0.077 (0.141) 0.588 
IL-7 0.25 0.08 - 0.41 0.25 0.02 - 0.61  -0.033 (0.123) 0.791 
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SE=standard error, CI = confidence interval. #Multivariate analysis adjusted for age, marital status, condom use, sex work, STIs and BV as co-variates. †Variables with at 
least a third of concentrations were undetectable were dichotomised and a logistic regression model was fitted to estimate the effect of injectable contraception on 
detectability of these cytokines.
IL-3 3.08 0.01 - 14.86 8.35 0.01 - 28.18  -0.229 (0.415) 0.580 
Growth Factor 
PDGF-AA 4.55 2.54 - 19.81 15.77 5.85 - 118.91  -0.506 (0.146) 0.001 
TGF-α 2.35 0.99 - 4.19 3.37 2.14 - 5.79  -0.173 (0.101) 0.089 
VEGF 73.86 17.27 - 151.91 77.09 12.95 - 120.64  -0.033 (0.100) 0.742 
PDGF-AB/BB† 0.09 0.09 - 17.43 0.09 0.09 - 38.66  -0.185 (0.417) 0.658 
 EGF† 0.56 0.56 - 2.30 0.56 0.56 - 8.61  -0.632 (0.427) 0.139 
 FGF-2† 0.30 0.30 - 8.39 5.32 0.30 - 13.15  -0.539 (0.394) 0.171 
Adaptive 
IL-15 1.54 0.30 - 1.90 2.08 1.39 - 2.52  -0.240 (0.114) 0.038 
IL-5 0.03 0.02 - 0.03 0.03 0.02 - 0.04  0.011 (0.028) 0.690 
IL-17 0.82 0.03 - 1.17 1.07 0.67 - 1.73  -0.158 (0.137) 0.251 
sCD40L 22.84 8.41 - 30.89 22.84 12.64 - 33.53  -0.007 (0.113) 0.954 
IFN-γ 1.31 0.13 - 4.51 0.67 0.01 - 3.09  0.336 (0.215) 0.121 
 IL-2† 0.08 0.01 - 0.20 0.08 0.01 - 0.19  -0.444 (0.417) 0.287 
 IL-4† 0.02 0.02 - 0.36 0.05 0.02 - 0.38  -0.300 (0.406) 0.460 
 IL-13† 0.01 0.01 - 0.01 0.01 0.01 - 0.01  0.217 (0.428) 0.612 
 sIL-2Rα† 5.88 0.57 - 10.13 6.10 0.57 - 10.70  0.143 (0.395) 0.717 
Anti-
inflammatory 
IL-1Ra 36313.59 26674.06 - 45012.00 40793.38 27693.84 - 45012.00  -0.038 (0.044) 0.381 
IL-10† 0.02 0.01 - 0.19 0.02 0.01 - 0.24  0.813 (0.429) 0.058 
MMPs 
MMP-1 5.30 2.40 - 42.71 3.92 2.40 - 53.10  0.135 (0.179) 0.454 
MMP-7 5038.05 379.42 - 23761.51 2247.97 162.27 - 26476.16  0.293 (0.358) 0.416 
MMP-9 13336.27 4963.64 - 73603.95 15753.28 4774.88 - 46728.84  0.203 (0.202) 0.318 
MMP-10 11.70 2.20 - 126.18 5.52 2.20 - 166.11  0.318 (0.235) 0.180 
 MMP-2† 118.10 118.10 - 118.10 118.10 118.10 - 118.10  0.808 (0.832) 0.332 
TIMPs 
TIMP-1 1867.65 854.01 - 6087.20 4356.19 1316.85 - 6634.26  -0.243 (0.189) 0.203 
TIMP-2 11759.57 6497.84 - 16406.50 14878.22 8023.87 - 19246.30  -0.207 (0.091) 0.027 
TIMP-3 25.45 25.45 - 32.54 25.45 25.45 - 32.54  0.029 (0.040) 0.472 
TIMP-4 3.92 3.92 - 3.92 3.92 3.92 - 3.92  0.013 (0.068) 0.849 
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 3.4.3 Impact of BV and STIs on cytokines in injectable HC versus non-HC users 
Because injectable HC use resulted in lower median concentration of genital tract cytokines 
from several different functional classes (Table 3.2), interactions between injectable HCs and 
cytokine concentrations in responses to BV or STIs in the female genital tract were assessed. 
No significant interactions were observed between injectable HC use and cytokine responses 
to BV (Table 3.3). T. vaginalis also had a limited interaction with injectable HC, with only 
Flt3L demonstrating a significant result (β-estimate of -0.194 in the injectable group vs 0.338 
in the non-injectable group, p=0.048, Table 3.4). However, significant interactions were 
found between gonorrhea, chlamydia or mycoplasma (GCM) infections and injectable HC 
use for certain cytokines, with TNF-β (p=0.022), IL-5 (p=0.015), IL-7 (p=0.036) and TIMP-4 
(p=0.003) being significantly higher in CVLs in response to GCM infections in HC users 
compared to non-HC users (Figure 3.1, Table 3.5). Furthermore, IL-12p40 (p=0.061) and 
Fractalkine (p=0.069) showed a trend towards being elevated in the GCM positive women 
using injectable HCs compared to non-HC users. However, none of these associations 
remained significant after adjusting for multiple comparisons. 
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Figure 3.1 Cytokine concentrations in CVLs from women using injectable  HCs 
(DMPA or NET-EN) compared to those not using HCs, stratified according to 
presence of discharge causing STIs (C. trachomatis, N. gonnorhoea, M. genitalium; 
GCM).  Dotted lines indicate the median concentration of each cytokine, MMP or 
TIMP in women not using HCs and who were GCM negative, as the reference group. 
** indicates significant interactions between injectable HC use and GCM with 
p<0.05, while * indicates interactions between injectable HC use and GCM with 
p<0.10. p<0.10 received an * because the sample size was too small and due to this, 
we treated p<0.010 as a cutoff instead of of a widlely used p<0.05. This was specific 
for this chapter only.   
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Table 3.3 Relationship between injectable HC use and cytokine responses to BV 
Cytokine 
Non-injectable HC group (n=64) Injectable HC group (n=64) Interaction 
p-value Est (SE) or OR 
(95% CI) p-value 
Est (SE) or OR 
(95% CI) p-value 
Log TNFB 0.140 (0.118) 0,2409 -0.069 (0.157) 0,6610 0,3318 
IL12p40* 0.42 (0.13-1.32) 0,1390 1.53 (0.46-5.11) 0,4866 0,1260 
Log IL1a 0.723 (0.171) <.0001 0.703 (0.183) 0,0003 0,6390 
IL12p70* 0.82 (0.26-2.57) 0,7372 0.49 (0.14-1.77) 0,2785 0,4571 
Log IL6 0.499 (0.304) 0,1069 0.253 (0.255) 0,3252 0,3663 
Log TNFa 0.118 (0.138) 0,3949 -0.019 (0.199) 0,9234 0,3694 
Log IL1B 0.918 (0.235) 0,0003 0.692 (0.260) 0,0102 0,3381 
Eotaxin -0.043 (0.161) 0,7890 -0.253 (0.154) 0,1065 0,2558 
MCP-1 -0.216 (0.219) 0,3266 -0.222 (0.190) 0,2499 0,7228 
MDC -0.436 (0.169) 0,0128 -0.284 (0.169) 0,0996 0,9605 
Fractalkine 1.39 (0.41-4.75) 0,6008 0.44 (0.12-1.56) 0,2028 0,2115 
MIP-1a 0.26 (0.07-0.94) 0,0401 0.10 (0.02-0.55) 0,0080 0,3005 
MCP-3 0.017 (0.091) 0,8528 -0.061 (0.093) 0,5127 0,5979 
IP-10 -0.384 (0.276) 0,1695 -0.890 (0.325) 0,0083 0,1024 
GRO -0.269 (0.201) 0,1851 -0.393 (0.148) 0,0105 0,4073 
MIP-1b 0.352 (0.346) 0,3136 -0.397 (0.356) 0,2704 0,1238 
IL-8 0.127 (0.207) 0,5439 0.151 (0.158) 0,3435 0,9376 
RANTES 0.044 (0.176) 0,8027 0.126 (0.221) 0,5719 0,8289 
IFN-a 1.31 (0.44-3.95) 0,6310 0.61 (0.15-2.48) 0,4918 0,5961 
IL-9 0.018 (0.251) 0,9427 -0.145 (0.281) 0,6078 0,5482 
Flt3L 0.072 (0.143) 0,6174 0.253 (0.149) 0,0969 0,4998 
G-CSF 0.230 (0.288) 0,4286 0.336 (0.303) 0,2723 0,8567 
GM-CSF -0.279 (0.187) 0,1419 -0.334 (0.210) 0,1171 0,4021 
IL-7 -0.472 (0.191) 0,0166 -0.435 (0.152) 0,0059 0,8176 
IL-3 1.65 (0.52-5.19) 0,3945 0.50 (0.15-1.66) 0,2569 0,2198 
PDGF-AA 0.056 (0.195) 0,7751 0.201 (0.227) 0,3784 0,8077 
EGF 0.73 (0.24-2.23) 0,5752 1.03 (0.31-3.44) 0,9581 0,7923 
TFG-a -0.110 (0.115) 0,3434 -0.161 (0.162) 0,3240 0,6214 
FGF-2 0.78 (0.25-2.44) 0,6739 0.35 (0.10-1.18) 0,0897 0,2902 
VEGF -0.072 (0.135) 0,5967 0.024 (0.154) 0,8778 0,6203 
PDGF-AB/BB 0.35 (0.10-1.25) 0,1057 0.94 (0.29-3.09) 0,9244 0,5365 
IL-15 0.088 (0.133) 0,5108 -0.075 (0.183) 0,6846 0,3678 
IL-5 -0.047 (0.041) 0,2627 -0.095 (0.039) 0,0175 0,2774 
IL-17 0.270 (0.173) 0,1236 -0.126 (0.203) 0,5396 0,0756* 
IL-2 1.10 (0.32-3.79) 0,8788 1.49 (0.43-5.19) 0,5291 
 IL-4 0.32 (0.10-1.01) 0,0515 0.45 (0.14-1.45) 0,1800 0,8555 
IL-13 0.67 (0.21-2.21) 0,5149 0.95 (0.28-3.20) 0,9278 0,9781 
sCD40L 0.010 (0.162) 0,9530 0.237 (0.158) 0,1387 0,2853 
sIL-2Ra 0.65 (0.21-2.02) 0,4558 1.60 (0.49-5.17) 0,4345 0,2773 
IFN-g 0.024 (0.325) 0,9418 -0.417 (0.286) 0,1505 0,2853 
IL-10 0.74 (0.24-2.28) 0,6001 0.60 (0.17-2.08) 0,4208 0,5990 
IL-1Ra 0.048 (0.059) 0,4232 -0.022 (0.061) 0,7234 0,4788 
MMP-1 0.447 (0.235) 0,0660 0.340 (0.296) 0,2581 0,1338 
MMP-2 8.68 (0.31-244.34) 0,2045 0.76 (0.07-7.76) 0,8188 0,0696* 
MMP-7 0.971 (0.484) 0,0538 0.473 (0.594) 0,4316 0,1969 
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MMP-9 0.317 (0.288) 0,2781 0.439 (0.291) 0,1411 0,5754 
MMP-10 0.885 (0.327) 0,0110 0.520 (0.373) 0,1732 0,0767* 
TIMP-1 0.663 (0.336) 0,0571 0.387 (0.226) 0,0971 0,4700 
TIMP-2 -0.170 (0.114) 0,1464 0.059 (0.151) 0,7009 0,4793 
TIMP-3 -0.027 (0.016) 0,1022 -0.130 (0.079) 0,1085 0,2085 





Table 3.4 Relationship between injectable HC use and cytokine responses to T. 
vaginalis 
Cytokine 
Non-injectable group (n=64) Injectable group (n=64) Interaction 
p-value Est (SE) or OR 
(95% CI) p-value 
Est (SE) or OR 
(95% CI) p-value 
Log TNFB 0.253 (0.172) 0,1460 0.264 (0.194) 0,1777 0,6397 
IL12p40* 1.11 (0.21-5.78) 0,9054 0.44 (0.10-1.99) 0,2893 0,4350 
Log IL1a 0.156 (0.249) 0,5345 0.299 (0.225) 0,1892 0,8272 
IL12p70* 3.84 (0.67-21.97) 0,1305 1.25 (0.30-5.25) 0,7618 0,3970 
Log IL6 -0.069 (0.444) 0,8764 0.094 (0.313) 0,7643 0,4874 
Log TNFa -0.112 (0.201) 0,5790 -0.013 (0.244) 0,9583 0,8530 
Log IL1B 0.238 (0.342) 0,4897 0.490 (0.319) 0,1307 0,6916 
Eotaxin -0.093 (0.234) 0,6936 -0.279 (0.190) 0,1465 0,4333 
MCP-1 -0.372 (0.319) 0,2475 0.401 (0.234) 0,0929 0,2527 
MDC 0.028 (0.247) 0,9105 0.032 (0.208) 0,8773 0,2474 
Fractalkine 4.10 (0.56-30.14) 0,1659 0.37 (0.08-1.76) 0,2135 0,0879* 
MIP-1a 0.91 (0.16-5.13) 0,9128 0.38 (0.06-2.38) 0,3034 0,2131 
MCP-3 -0.134 (0.133) 0,3181 -0.017 (0.114) 0,8804 0,6453 
IP-10 -0.618 (0.402) 0,1303 0.462 (0.399) 0,2517 0,5036 
GRO -0.001 (0.293) 0,9960 0.633 (0.182) 0,0010 0,1320 
MIP-1b 0.605 (0.505) 0,2363 -0.604 (0.438) 0,1735 0,085* 
IL-8 0.221 (0.302) 0,4685 0.502 (0.195) 0,0127 0,5838 
RANTES 0.076 (0.256) 0,7670 0.059 (0.272) 0,8289 0,3189 
IFN-a 0.70 (0.13-3.76) 0,6788 0.25 (0.02-2.51) 0,2381 0,3441 
IL-9 0.433 (0.366) 0,2423 -0.043 (0.345) 0,9015 0,3415 
Flt3L 0.338 (0.209) 0,1114 -0.194 (0.184) 0,2968 0,0481** 
G-CSF -0.181 (0.420) 0,6679 0.411 (0.372) 0,2744 0,8167 
GM-CSF 0.415 (0.273) 0,1344 -0.077 (0.258) 0,7659 0,0816* 
IL-7 0.053 (0.279) 0,8510 -0.047 (0.186) 0,8034 0,6187 
IL-3 1.09 (0.22-5.48) 0,9157 0.24 (0.06-1.01) 0,0515 0,2587 
PDGF-AA -0.244 (0.285) 0,3957 0.027 (0.279) 0,9230 0,9843 
EGF 1.39 (0.29-6.67) 0,6796 0.50 (0.09-2.78) 0,4270 0,1818 
TFG-a -0.141 (0.168) 0.137 (0.199) 0.135 (0.199) 0,5021 0,7017 
FGF-2 1.76 (0.31-9.91) 0,5227 0.33 (0.07-1.53) 0,1579 0,1138 
VEGF 0.064 (0.197) 0,7462 0.063 (0.189) 0,7404 0,9398 
PDGF-AB/BB 0.50 (0.08-3.16) 0,4582 1.45 (0.35-5.92) 0,6087 0,8745 
IL-15 0.108 (0.194) 0,5782 0.022 (0.225) 0,9211 0,8090 
IL-5 -0.044 (0.060) 0,4662 0.019 (0.047) 0,6940 0,7254 
IL-17 0.065 (0.252) 0,7985 0.382 (0.250) 0,1323 0,6550 
IL-2 N/A   0.80 (0.18-3.49) 0,7681   
IL-4 2.94 (0.51-16.88) 0,2261 0.31 (0.07-1.39) 0,1250 0,0811* 
IL-13 0.33 (0.04-2.50) 0,2838 2.12 (0.50-8.97) 0,3081 0,4429 
sCD40L -0.023 (0.237) 0,9218 -0.414 (0.194) 0,0370 0,2291 
sIL-2Ra 2.90 (0.52-16.09) 0,2244 0.32 (0.08-1.28) 0,1072 0,2134 
IFN-g -0.286 (0.474) 0,5487 -0.186 (0.352) 0,5986 0,7263 
IL-10 0.89 (0.18-4.45) 0,8839 1.02 (0.22-4.74) 0,9827 0,8151 
IL-1Ra 0.102 (0.087) 0,2427 0.027 (0.076) 0,7260 0,4863 
MMP-1 0.275 (0.303) 0,3711 0.391 (0.290) 0,1875 0,3679 
MMP-2 N/A   4.54 (0.57-36.24) 0,1537 N/A 
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MMP-7 0.046 (0.624) 0,9419 0.516 (0.583) 0,3826 0,7647 
MMP-9 -0.357 (0.371)   0.413 (0.285) 0,1576 0,8143 
MMP-10 -0.012 (0.422) 0,9775 0.302 (0.366) 0,4157 0,4630 
TIMP-1 0.373 (0.433) 0,3950 0.081 (0.226) 0,7224 0,4718 
TIMP-2 -0.021 (0.147) 0,8852 -0.045 (0.151) 0,7692 0,3319 
TIMP-3 -0.001 (0.021) 0,9740 -0.053 (0.079) 0,5065 0,8244 




Table 3.5 Relationship between injectable HC use and cytokine responses to C. 
trachomatis, N. gonnorhoea, and M. genitalium 
Cytokine 
Non-injectable HC group 
(n=64) Injectable HC group (n=64) Interaction 
p-value Est (SE) or OR 
(95% CI) p-value 
Est (SE) or OR (95% 
CI) p-value 
Log TNFB -0.412 (0.182) 0,0275 0.454 (0.275) 0,1051 0,0223** 
IL12p40* 0.88 (0.16-4.85) 0,8823 6.74 (0.66-69.02) 0,1077 0,061* 
Log IL1a 0.294 (0.264) 0,2709 0.339 (0.320) 0,2946 0,6074 
IL12p70* 0.78 (0.13-4.56) 0,7818 7.76 (0.54-110.71) 0,1306 0,2106 
Log IL6 0.636 (0.470) 0,1818 1.214 (0.446) 0,0087 0,3954 
Log TNFa 0.380 (0.213) 0,0801 0.780 (0.347) 0,0287 0,1076 
Log IL1B 0.356 (0.363) 0,3312 0.741 (0.454) 0,1088 0,8513 
Eotaxin 0.268 (0.248) 0,2850 0.422 (0.270) 0,1231 0,2776 
MCP-1 0.721 (0.338) 0,0372 0.737 (0.333) 0,0311 0,6318 
MDC 0.736 (0.262) 0,0068 0.467 (0.296) 0,1208 0,6865 
Fractalkine 0.35 (0.05-2.43) 0,2911 4.81 (0.43-53.45) 0,2011 0,0685* 
MIP-1a 8.58 (1.32-55.79) 0,0245 43.14 (1.13-1650.89) 0,0429 0,2762 
MCP-3 0.020 (0.141) 0,8874 0.123 (0.163) 0,4550 0,3921 
IP-10 1.389 (0.427) 0,0019 0.825 (0.567) 0,1519 0,8071 
GRO 0.313 (0.310) 0,3171 0.601 (0.259) 0,0241 0,5302 
MIP-1b 0.013 (0.535) 0,9809 0.763 (0.623) 0,2258 0,3116 
IL-8 0.065 (0.320) 0,8390 0.480 (0.277) 0,0885 0,7030 
RANTES 0.631 (0.271) 0,0238 0.654 (0.387) 0,0967 0,9032 
IFN-a 1.31 (0.24-7.19) 0,7571 1.84 (0.22-15.70) 0,5766 0,5242 
IL-9 0.107 (0.389) 0,7844 0.478 (0.491) 0,3344 0,5341 
Flt3L -0.025 (0.222) 0,9119 0.511 (0.261) 0,0557 0,1481 
G-CSF 1.025 (0.446) 0,0253 1.419 (0.529) 0,0098 0,6122 
GM-CSF 0.420 (0.289) 0,1521 0.771 (0.367) 0,0406 0,4856 
IL-7 0.151 (0.296) 0,6119 0.813 (0.265) 0,0034 0,0356** 
IL-3 0.65 (0.12-3.56) 0,6204 2.81 (0.24-32.98) 0,4119 0,2258 
PDGF-AA 0.453 (0.302) 0,1390 1.080 (0.396) 0,0087 0,1035 
EGF 2.08 (0.39-11.15) 0,3916 4.31 (0.59-31.51) 0,1506 0,4594 
TFG-a 0.340 (0.178) 0,0611 0.658 (0.283) 0,0240 0,1043 
FGF-2 1.94 (0.32-11.70) 0,4690 1.98 (0.23-17.04) 0,5345 0,7728 
VEGF -0.040 (0.208) 0,8477 0.266 (0.269) 0,3285 0,3985 
PDGF-AB/BB 12.72 (1.75-92.34) 0,0119 3.67 (0.48-27.98) 0,2099 0,6855 
IL-15 0.199 (0.206) 0,3384 0.102 (0.319) 0,7512 0,9304 
IL-5 0.067 (0.064) 0,2946 0.228 (0.067) 0,0013 0,0151** 
IL-17 0.409 (0.267) 0,1316 0.575 (0.356) 0,1118 0,6629 
IL-2 N/A 
 
3.04 (0.25-37.42) 0,3850 
 IL-4 1.24 (0.21-7.23) 0,8090 1.80 (0.22-14.49) 0,5826 0,5397 
IL-13 5.19 (0.77-34.85) 0,0899 5.00 (0.68-36.61) 0,1129 0,7035 
sCD40L -0.062 (0.251) 0,8046 0.125 (0.275) 0,6511 0,3841 
sIL-2Ra 0.41 (0.07-2.59) 0,3467 2.67 (0.25-28.20) 0,4138 0,1435 
IFN-g 0.054 (0.502) 0,9140 0.313 (0.500) 0,5340 0,3875 
IL-10 1.41 (0.24-8.34) 0,7047 1.87 (0.16-21.32) 0,6146 0,6485 
IL-1Ra -0.103 (0.092) 0,2647 0.109 (0.107) 0,3153 0,2746 
MMP-1 0.541 (0.332) 0,1135 1.303 (0.586) 0,0332 0,7424 
MMP-2 15.27 (0.54-430.22) 0,1095 13.71 (0.40-472.02) 0,1470 0,5269 
MMP-7 0.955 (0.685) 0,1731 0.248 (1.177) 0,8345 0,2877 
MMP-9 0.820 (0.407) 0,0527 1.713 (0.576) 0,0055 0,2148 
MMP-10 0.799 (0.463) 0,0942 0.824 (0.740) 0,2737 0,5375 
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TIMP-1 -0.449 (0.475) 0,3518 1.118 (0.459) 0,0204 0,1779 
TIMP-2 0.237 (0.161) 0,1523 0.255 (0.307) 0,4130 0,9846 
TIMP-3 -0.013 (0.023) 0,5641 -0.052 (0.160) 0,7463 0,7807 





3.5 Discussion  
Concentrations of several cytokines and soluble factors were reduced in CVLs of 
women using injectable HC compared to women who were not using HCs, after 
controlling for age, condom use, sex work, STIs and BV. Despite this reduction of 
innate immune responses in the female genital tracts of women using injectable HCs, 
no differences in prevalence of BV or STIs were found.  
 
Although animal studies using high dose DMPA, have demonstrated that DMPA has 
immunosuppressive properties both systemically and in the reproductive tract, these 
studies found that DMPA exerted on effect on viral load and pathogenesis (Abel et 
al., 2004; Bamberger et al., 1999; Genesca et al., 2007; Gillgrass et al., 2003; Hel et 
al., 2010; Hughes et al., 2008; Huijbregts et al., 2013; Kleynhans et al., 2013; 
Kleynhans et al., 2011; Koubovec et al., 2004; Trunova et al., 2006). Fewer studies 
have been conducted in humans and these have predominantly been performed using 
PBMCs (Hughes et al., 2008, Kleynhans et al., 2011), with the exception of 
Huijbregts et al. (2013) who reported reduced cervicovaginal production of IFN-α in 
women using injectable HCs, the other human studies suggested that DMPA use may 
actually increase inflammation within the female genital tract (Baeten et al., 2001; 
Ghanem et al., 2005).  In this study, decreased chemotactic cytokine (including 
eotaxin, fractalkine, MCP-1 and MDC in the multivariate analyses) concentrations 
observed in women using HCs might influence the trafficking of immune cells to the 
female genital tract. Fractalkine has been reported to play a role in the recruitment of 
immune cells to the endometrium, which may be influenced by the presence of 




interference with chemotaxis, mechanistic studies have not been done to test the 
relationship between HCs and trafficking of cells within genital tissues.  
 
In the interaction term analysis, it was hypothesized that HC use had a limited impact 
on cytokine responses to trichomoniasis and gonorrhea, chlamydia and mycoplasma 
infections, but did not modify the relationship between cytokine concentrations and 
BV. This analysis suggested that women with gonorrhea, chlamydia and mycoplasma 
(GCM) infections who were using HCs had increased concentrations of TNF-β, IL-5, 
IL-7, TIMP-4, IL-12p40 and Fractalkine relative to women with GCM infections who 
were not using HCs. In addition, the effect size of the relationship between T. 
vaginalis and Flt3L concentrations was larger in women using injectable HCs 
compared to non-HC users. However, these associations should be interpreted 
conservatively as none of these associations was significant after adjusting for 
multiple comparisons and sample sizes for these analyses were relatively small.  
 
High dose DMPA administration to macaques is associated with thinning of the 
vaginal epithelium (Abel et al., 2004; Genesca et al., 2007; Trunova et al., 2006; 
Wieser et al., 2001). In this study, significantly reduced concentrations of PDGF-AA 
were found in CVL from women using injectable HC compared to women not using 
injectable HCs. This growth factor has been reported to play an important role in 
restoring the barrier function of the female genital tract following injury, and reduced 
expression may influence the ability of the epithelial barrier to be regenerated and 
repaired (Werner and Grose, 2003). Growth factors enhance epithelial repair by 




(Werner and Grose, 2003), and as such, a decrease in these factors could lead to 
weakened epithelial barriers and reduced epithelial healing in women using injectable 
HCs. 
 
MMPs and TIMPs play an important role in the degradation and remodeling of the 
extracellular matrix in the upper reproductive tract during normal reproductive 
processes (Birkedal-Hansen, 1995; Cawston, 1995; Lockwood and Schatz, 1996; 
Rodgers et al., 1994; Rodgers et al., 1993). Previous studies have shown that 
progesterone suppresses the epithelial cell-specific MMPs, working cooperatively 
with TGF-β to regulate epithelial-specific MMP-7 expression (Bruner et al., 1995; 
Osteen et al., 1994). In contrast, in the lower reproductive tract, this study found no 
difference between MMP concentrations in women using injectable HCs compared to 
those who were not using HC. Previously, Vincent et al. (2002) found that women 
using DMPA had decreased TIMP-1 and -2 concentrations in their endometrial 
epithelium and an altered local MMP:TIMP balance in their upper reproductive tracts 
compared to women not using HCs. Similarly,  decreased TIMP-2 concentrations 
were observed in this study in secretions from the lower reproductive tracts of women 
using injectable HC compared to those not using HCs. Reduced concentrations of 
TIMPS may alter the MMP/TIMP ratio which could lead to decreased epithelial 
barrier integrity. 
 
A limitation of this study is that it was not possible to differentiate DMPA from NET-
EN users within the injectable HC user group although these progestin-based HCs 




or systematically from women who do not use hormonal contraceptives. Another 
limitation of this study was that stage of the menstrual cycle was not standardized in 
this cohort although many women using DMPA and Net-EN were not menstruating. 
In addition, data on prior DMPA or NET-EN use before the time point at which CVL 
was performed was not available and the length of time on injectable HCs may have 
an impact of the effect that was measured.  
 
In conclusion, this Chapter shows reductions in CVL concentrations of several 
chemokines (directing cellular movement within tissue), in addition to an array of 
proinflammatory and adaptive cytokines, growth factors, and TIMPs in the lower 
female genital tract of women using injectable HCs. While this study was 
underpowered to demonstrate the relationship between injectable HC use and STI or 
HIV-1 risk, the data suggest that injectable HCs effects were similar between STI 
positive and STI negative participants. Large-scale randomized clinical trials 
assessing the impact of progestin-derivatives (DMPA or NET-EN) on local and 
systemic innate and adaptive immune environment, as well as STIs, are needed to 
further investigate the mechanism(s) by which DMPA or NET-EN might increase risk 













Influence of semen on inflammatory and innate 






Influence of semen on inflammatory and innate cytokine responses in 
the female genital tract 
 
4.1 Abstract 
Semen contains cytokines and activated immune cells that may influence the immune 
environment of the female genital tract. Inflammatory cytokine concentrations in 
female genital secretions may influence HIV-1 risk, although the effect of recent 
sexual intercourse on the cytokine milieu of cervicovaginal secretions has rarely been 
measured in previous studies. The influence of semen exposure on CVL cytokine 
concentrations was investigated in this Chapter from 46 HIV-1 negative women, who 
had no evidence of BV or an STI, by assessing the presence of Y-chromosome by 
real-time PCR (evidence of unprotected intercourse >48 hours prior to sampling), and 
PSA by ELISA (evidence of unprotected intercourse ≤48 hours prior to sampling). As 
in the previous Chapter, concentrations of 42 cytokines, 5 MMPs and 4 TIMPs were 
measured by luminex. Y-chromosome was detected in 50% (23/46) of CVLs, while 
PSA was detected in 57% (13/23) of Y-chromosome positive women. More than one 
third of women (39%, 5/13) determined to have recent sex (PSA+) reported condom 
use at their last sex act. CVLs collected from PSA+ women had lower concentrations 
of IL-12p70, sIL-2Rα and IL-2, after adjusting for confounders. Similarly, fractalkine, 
FGF-2, GM-CSF, IP-10, and TNF-α were decreased CVLs from PSA+ women, 
although not significantly after adjusting for multiple comparisons. Concentrations of 
TIMP-1 and MMP-9, both associated with tissue remodelling in the female 
reproductive tract, were higher in CVLs from PSA+ women. These findings suggest 










Despite improvements in the formatting and framing of sexual behaviour 
questionnaires, over-reporting of adherence and safe sexual behaviours have been 
identified as shortcomings in several biomedical prevention studies (Turner and 
Miller, 1997; Zenilman et al., 1995). Over-reporting of condom use may lead to 
inaccurate estimates of the influence of interventions such as vaginal microbicides on 
risk for HIV-1 and sexual transmitted infections, as sub-analyses are often based on 
the frequency of unprotected sex. 
 
The presence of semen in the vagina during unprotected sex has been associated with 
short-term activation of mucosal immunity (Robertson, 2005; Robertson et al., 2009; 
Sharkey et al., 2012). In addition to spermatozoa, seminal fluid contains potent anti-
inflammatory cytokines (TGF-β, IL-10, and PGE2), and pro-inflammatory cytokines 
[IL-8, secretory leukocyte protease (SLP)-1], all with the capacity to alter the immune 
environment of the vaginal mucosa (Denison et al., 1999; Sharkey et al., 2007). 
Seminal fluid also contains signaling molecules that induce expression of IL-1β, IL-6 
and leukemia inhibitory factor (LIF) by endometrial epithelial cells in vitro (Gutsche 
et al., 2003; Sharkey et al., 2012). Expression of these cytokines is known to trigger 
the recruitment and activation of macrophages, DCs and granulocytes (Kachkache et 
al., 1991; McMaster et al., 1992; Prakash et al., 2003; Sharkey et al., 2012). Seminal 
fluids increased ectocervical numbers of CD14+ macrophages, CD1a+ DCs and CD8+ 
T-cells, and decreased numbers of CD4+ T cells 12 hours after unprotected  sexual 
intercourse (Sharkey et al., 2012). Expression of genes involved in inflammation, 
including those encoding inflammatory cytokines CSF-2, IL-6, IL-8 and IL-1α, were 




were not observed in women who engaged in protected intercourse (Sharkey et al., 
2012). Moreover, in vitro studies suggested that cervical tissue exposed to seminal 
fluids were responsible for the increased production of several MMPs by ectocervical 
epithelial cells (Denison et al., 1999; Sharkey et al., 2007). Therefore, objective 
assessment of semen exposure is important to aid in accurate interpretation of data in 
studies of the immunological environment in the female genital tract. 
 
Reliable methods have been developed to measure biomarkers of semen exposure to 
reduce reliance on self-reporting in studies investigating immunological factors in the 
female genital tract, risk of infection or probability of pregnancy (Mauck et al., 2007; 
Walsh et al., 2003). PSA and the Y-chromosome are semen markers that have 
previously been used as indicators of the presence of semen in female genital fluids 
(Bahamondes et al., 2008; Chomont et al., 2001a; Chomont et al., 2001b; Graves et 
al., 1985; Kamenev et al., 1989; Minnis et al., 2009; Roewer, 2009). PSA 
concentrations in vaginal fluid can be detected at concentrations ≥1ng/ml up to 48 
hours after unprotected sexual intercourse (Graves et al., 1985; Kamenev et al., 1989; 
Lawson et al., 1998; Macaluso et al., 1999). Although PSA is relatively sensitive, the 
utility of PSA as a surrogate indicator for unprotected sex is limited by its rapid decay 
curve (within 48 hours) (Macaluso et al., 1999; Negri et al., 2000; Obiezu et al., 
2001). In comparison, Y-chromosome PCR is a highly stable, sensitive, and specific 
method to detect spermatozoa-associated DNA fragments of the sex-determining 
region (SRY) and testis-specific protein Y-encoded (TSPY) genes of the Y-
chromosome that are not present on the X-chromosome (Jacot et al., 2013; Kastelic et 
al., 2009; Reynolds and Varlaro, 1996; Roewer, 2009; Sullivan et al., 1993). Y-




seminal fluids (Chomont et al., 2001b; Jadack et al., 2006; Kastelic et al., 2009; 
Zenilman et al., 2005).  
 
Detecting the presence of semen in genital fluids using these biomarkers provide 
objective tools to measure exposure to semen, allowing for accurate assessment of 
unprotected sex during HIV-1 prevention trials, and effects of semen on the 
immunological environment of the female genital tract. In this study, the presence of 
PSA and Y-chromosomes in CVL collected from HIV-1 uninfected women at high 
risk of HIV-1 infection was assessed to investigate the influence of recent sexual 
activity on the cytokine milieu and soluble factors of cervicovaginal secretions in the 
FGT. In addition, the presence of PSA and Y-chromosomes were also used to 
determine concordance between self-reporting of consistent condom use and the 






4.3 Materials and Methods 
 
4.3.1 Study design, participants and sample collection 
A total of 242 women were enrolled into the prospective CAPRISA 002 observational 
cohort study of acute HIV-1 infection, as previously described (van Loggerenberg et 
al., 2008). Demographic and clinical data were collected at enrolment using a 
structured questionnaire. CVL samples were collected at enrolment from 227 (94%) 
of these women and 69 (30%) were from women who had no evidence of STI or BV.  
Because STIs and BV may independently influence the cytokine environment in CVL 
(Masson et al., 2014), women with laboratory-diagnosed STIs and BV were not 
included in this study. At enrollment, vulvovaginal swabs collected from the posterior 
fornices and lateral vaginal walls were tested for C. trachomatis, N. gonorrhoeae, M. 
genitalium, HSV-2 reactivation and T. vaginalis by PCR. Gram stain was performed 
to diagnose BV using Nugent criteria, and Nugent ≥7 were considered to have BV 
(Mlisana et al., 2012). Women with any STIs or BV. CVLs from the 69 BV/STI 
negative women were then screened for PSA and Y-chromosome DNA. Further, 
because cytokine concentrations are higher in CVLs from younger women compared 
to older women (Masson et al., 2015), Y-chromosome positive and Y-chromosome 
negative women were age-matched for subsequent cytokine analyses. All Y-
chromosome positive women (n=23) were included in subsequent cytokine analyses 
and an age-matched control group of women (n=23) was randomly selected from the 
group of women without evidence of semen exposure at a 1:1 ratio using SAS version 





CVLs were collected by gently flushing the cervix and the lateral vaginal walls with 
10 ml sterile normal saline (Masson et al., 2014; van Loggerenberg et al., 2008). 
CVLs were centrifuged and the supernatant fraction was collected, aliquoted and 
stored at -80°C for measurement of PSA, cytokine, MMP and TIMP concentrations. 
The CVL pellet was stored at -80oC for DNA extraction for the Y-chromosone PCR. 
The protocol for this study was approved by the Ethical Review Committees of the 
University of KwaZulu-Natal and University of Cape Town, South Africa. 
 
4.3.2 Measurement of cytokine, MMP and TIMP concentrations 
The concentrations of 42 cytokines, 5 MMPs and 4 TIMPS were measured in CVL 
supernatants from these women, according to the method described in Chapter 2. The 
cytokine panel included IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 
(CXCL8), IL-9, IL-10, IL-12p40, IL-10, IL-12p70, IL-13, IL-15, IL-17, EGF, PDGF-
AA, TGF-α, VEGF, eotaxin/CCL11, FGF-2, FLT3L, fractalkine/CX3CL1, G-CSF, 
GM-CSF, GRO, IFN-α and IFN-γ, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, 
MDC/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AB/BB, RANTES/CCL5, 
sCD40L, sIL-2Rα, TNF-α, TNF-β (High Sensitivity Human Cytokine LINCOplex 
Premixed kits, LINCO Research, MO, U.S.A.). MMP and TIMP panels included 
MMP-1, MMP-2, MMP-7, MMP-9, MMP-10, TIMP-1, TIMP-2, TIMP-3 and TIMP-
4 (MILLIPLEX® MAP Human MMP or TIMP Panel 2, Merck-Millipore, Missouri. 
USA). Assays were performed according to the manufacturer’s protocol. CVLs were 
thawed overnight on ice and filtered by centrifugation using 0.2 μm cellulose acetate 
filters (Sigma, U.S.A.). All markers were measured in undiluted CVL, except for 
MMP-9 (which was measured at 50-fold dilution), on a Bio-Plex 100 system (Bio-




Bio-Rad Laboratories Inc®) was also used to analyse the data and all analyte 
concentrations were extrapolated from the standard curves using a 5 PL regression 
equation. Analyte concentrations that were below the lower limit of detection of the 
assay were reported as the mid-point between zero and the lowest concentration 
measured for each analyte.  
 
4.3.3 ELISA to detect PSA 
Measurement of PSA (also known as human tissue kallikrein-3) was performed on 
CVL supernatants to detect the presence of male semen. Briefly, 50µl of CVL 
supernatant was used to detect PSA, with the upper limit of detection of 60 ng/ml and 
a threshold of positivity of 0.94 ng/ml, according to the manufacturer’s protocol 
(R&D Systems, Minneapolis, MN). Each sample was assayed in duplicate. Every 
plate included PSA standards (provided in the kit) and a negative control containing 
sterile PCR-grade water and reaction mix, as proposed by the manufacturer. The 
average absorbance values for each set of reference standards, control, and sample 
were measured at 450 nm wavelength using a VersaMax™ absorbance microplate 
reader (Molecular Devices, LLC). 
 
4.3.4 Detection of Y-chromosome   
DNA was extracted from CVL pellets using the Roche® MagNAPure LC DNA 
Isolation Kit I (Roche Applied Science, Indianapolis, IN), according to the 
manufacturer’s protocol. To control for the integrity and quantity of the extracted 
DNA, a 268 base-pair fragment of the human β-globin gene was amplified (Bauer et 




CAT CCA CGT TCA CC), and GH20 (GAA GAG CCA AGG ACA GGT AC) 
(PrimerDesign Ltd, UK). A region of the TSPY1 gene on the Y-chromosome (not 
found on the X-chromosome) was amplified using a real time qPCR assay 
(PrimerDesign Ltd, UK). The assay was performed in triplicate for each sample. 
qPCR was carried out using the Roche LightCycler® 480 system (Roche Diagnostics, 
GmbH). The negative control (containing no template) and an extraction control 
(PrimerDesign Ltd, UK) were included in each run. Detection of the Y-chromosome 
and analysis were performed according to the manufacturer’s protocol (PrimerDesign 
Ltd, UK). 
 
4.3.5 Statistical analyses 
Descriptive statistics were used to describe demographic characteristics. Fisher’s 
exact test and Wilcoxon rank sums tests were used to compare categorical variables 
and continuous data between groups, respectively. To assess the effect of semen 
exposure on cytokine concentrations, a linear regression model was fitted to log-
transformed cytokine concentrations. As in Chapter 3, cytokines with at least a third 
of concentrations undetectable (including IL-2, IL-2Rα, IL-3, IL-4, IL-10, IL-12p40, 
IL-12p70, IL-13, Fractalkine, MIP-1α, IFN-α, EGF, TFG-α, FGF-2, PDGF-AB/BB 
and MMP-2) were dichotomised and a logistic regression model was fitted to estimate 
the effect of semen exposure on detectability of these cytokines. These models were 
adjusted for marital status, number of sexual partners, injectable hormonal 
contraception and sex worker status. Adjustment for multiple comparisons was 
conducted using the false discovery rate to reduce false positive results (Columb and 
Sagadai, 2006). Statistical analyses were performed using SAS version 9.3 (SAS 





This study included 46 HIV-1 negative women at high risk for HIV-1 infection, with 
no evidence of any other STI or BV, to quantify the frequency of CVL samples 
containing semen, and the influence of semen on cytokine concentrations (Table 4.1). 
Overall, the median age of the women was 40 years (interquartile range (IQR) 35-43), 
with about half of them (56.5%) being in stable relationships. Women were 
considered at high risk for HIV-1 infection as 34/46 (73.9%) self-identified as sex 
workers, with some women participated in sex work while being in a stable or 
married relationship (56.5%, 26/46).   
 
Only half of the women reported using condoms at their last sex act (54.4%, 25/46), 
with condoms being used more often with casual partners than with stable partners 
(56.5% vs. 24.4%, p=0.0006). Forty percent (18/46) of the women reported never 
using condoms with their stable partners compared to only 13.0% (6/46) reporting 
never using condoms with their casual sex partners (p=0.0005). Half of these women 
(50%, 23/46) tested positive for Y-chromosome in CVL pellets by both SRY PCR 
and real-time PCR [Y-chromosome being stable up to 15 days post-exposure 
(Zenilman et al., 2005)], while 13 of these 23 (57%) also tested positive for PSA 
antigen [PSA only being stable for 48 hours post-exposure (Macaluso et al., 1999)]. 
All PSA positive CVL samples were also Y-chromosome positive (indicating more 
recent sexual intercourse) but only 10/23 (44%) of Y-chromosome positive CVLs 





Fifty four percent (25/46) of women reported condoms at their last sex act. Of these, 
8/25 (32.0%) tested positive for Y-chromosome and 5/25 (20.0%) also tested positive 
for PSA, suggesting that either condom use was likely over-reported or that their last 
sex act was protected, but that women may have engaged in unprotected sex before 
their last sex act. Women who reported never used a condom with their stable partners 
were more likely to have positive PSA and Y-chromosome results (p=0.012). PSA 
and Y-chromosome were detected more frequently in the CVL samples from women 
not using injectable hormonal contraception than injectable hormonal contraception 


























Y-chromosome+ Y-chromosome- p-value 
Percentage (n/N) 46 28.3% (13/46) 71.7% (33/46)  50.0% (23/46) 50.0% (23/46)  
Age; Median (IQR) 40 (35-43) 42 (37-44) 40 (34-43) 0.272 40 (35-44) 40 (34-43) 0.743 
Marital status [% (n/N)]: 
       
Single 10.9% (5/46) 15.4% (2/13) 9.1% (3/33) 0.798 8.7% (2/23) 13.0% (3/23) 0.687 
Stable partner/married 56.5% (26/46) 53.9% (7/13) 57.6% (19/33) 
 
52.2% (12/23) 60.9% (14/23) 
 
Many partners 32.6% (15/46) 30.8% (4/13) 33.3% (11/33) 
 
39.1% (9/23) 26.1% (6/23) 
 
Highest education [% (n/N)]: 
       
< Grade 8 32.6% (15/46) 53.9% (7/13) 24.2% (8/33) 0.093 39.1% (9/23) 26.1% (6/23) 0.570 
Grade 8-10 41.3% (19/46) 38.5% (5/13) 42.4% (14/33) 
 
34.8% (8/23) 47.8% (11/23) 
 
> Grade 10 26.1% (12/46) 7.7% (1/13) 33.3% (11/33) 
 
26.1% (6/23) 26.1% (6/23) 
 
Contraception use [% (n/N)]: 
       
Injectable 23.9% (11/46) 15.4% (2/13) 27.3% (9/33) 0.473 17.4% (4/23) 30.4% (7/23) 0.491 
Non-injectable 76.1% (35/46) 84.6% (11/13) 72.7% (24/33) 
 
82.6% (19/23) 69.6% (16/23) 
 
Sex worker [% (n/N)] 73.9% (34/46) 76.9% (10/13) 72.7% (24/33) 1.000 73.9% (17/23) 73.9% (17/23) 1.000 




Condom use with stable partner 
[% (n/N)]:  
 





61.5% (8/13) 31.3% (10/33) 0.201 
 
60.9% (14/23) 18.2% (4/23) 0.012 
Less than half the time 35.6% (16/45) 23.1% (3/13) 40.6% (13/33) 
 
26.1% (6/23) 45.5% (10/23) 
 
More than half the time 24.4% (11/45) 15.4% (2/13) 28.1% (9) 
 
13.0% (3) 36.4% (8) 
 





   
 
   
Never 13.0% (6/46) 23.1% (3/13) 9.1% (3) 0.467 17.4% (4) 8.7% (2) 0.265 
Less than half the time 30.4% (14/46) 30.8% (4/13) 30.3% (10) 
 
39.1% (9) 21.7% (5) 
 
More than half the time 56.5% (26/46) 46.2% (6/13) 60.6% (20) 
 
43.5% (10) 69.6% (16) 
 




4.4.1 Presence of semen altered cytokine profiles in CVLs 
Women who had recent unprotected sex had decreased concentrations of IL-2 (p=0.043), IL-
12p70 (p=0.020), and IL-2Rα (p=0.018), compared to women who tested negative for both 
PSA and Y-chromosome (Table 4.2). In addition, fractalkine (p=0.053), FGF-2 (p=0.095), 
GM-CSF (p=0.094), and TNF-α (p=0.08) concentrations tended to be reduced in PSA+ 
women, although not after adjusting for multiple comparisons. In contrast, concentrations of 
soluble factors TIMP-1 (p=0.039) and MMP-9 (p=0.095) were higher in women who had 
recent unprotected sex compared to women who tested negative for both PSA and Y-




Table 4.2 Relationship between cytokine concentrations and recent semen exposure (≤48 hrs post-sex) in the female genital tract 
Functional 
groups Cytokine 




Median (pg/ml)  IQR Median (pg/ml) IQR   Beta coefficient (SE)  P value 
Pro-
inflammatory 
TNF-β 4.56  2.49-7.77 3.77  2.49-6.74  -0.325 (0.203) 0.118 
IL-12p40† 19.57  0.12-67.85 5.28 0.12-23.06  -0.189 (0.967) 0.845 
IL-12p70† 0.01  0.01-0.04 0.01 0.01-0.01  -2.529 (1.086) 0.020 
IL1α 25.76  15.35-70.12 30.05  21.16-99.74  0.207 (0.220) 0.354 
IL-6 1.04  0.37-15.33 2.15  0.21-9.24  -0.482 (0.374) 0.206 
TNF-α 0.03  0.02-0.04 0.03  0.01-0.03  -0.280 (0.156) 0.080 
IL-1β 0.24  0.06-0.94 0.77  0.04-2.01  -0.142 (0.286) 0.621 
Chemokine 
Eotaxin 3.57  0.26-6.48 2.29  0.26-3.31  -0.143 (0.270) 0.598 
MCP-1 13.3  4.20-77.18 9.41  4.56-72.49  -0.222 (0.287) 0.444 
MDC 34.09  11.90-60.59 36.66  11.48-60.77  -0.083 (0.204) 0.686 
Fractalkine† 9.83  2.13-59.55 2.13  2.13-18.01  -1.788 (0.926) 0.053 
MIP1α† 0.66  0.66-36.15 0.66  0.66-14.92  -0.124 (0.853) 0.885 
MCP-3 11.41  7.56-16.31 9.35  7.56-11.81  -0.154 (0.125) 0.224 
IP-10 88.54  37.94-211.19 49.73  11.97-186.60  -0.486 (0.294) 0.106 
GRO 400.86  276.49-1554.91 456.21  251.64-618.42  -0.214 (0.227) 0.352 
MIP-1β 2.89  0.01-8.02 2.28  0.01-6.26  -0.687 (0.599) 0.259 
IL-8 147.34  52.26-350.76 428.19  43.64-905.69  0.194 (0.271) 0.478 
RANTES 3.65  2.75-6.93 3.21  2.50-9.11  -0.391 (0.290) 0.185 
Innate IFNα† 1.36  0.68-22.17 0.68  0.68-5.41  -0.968 (0.851) 0.256 
Hematopoietic 
IL-9 0.38  0.01-1.94 0.01  0.01-1.79  -0.293 (0.412) 0.481 
Flt3L 3.66  0.45-9.78 3.66  0.45-4.27  -0.288 (0.239) 0.235 
G-CSF 29.96  6.02-104.06 5.54  3.76-50.87  -0.667 (0.438) 0.136 
GM-CSF 0.19  0.01-0.54 0.05  0.01-0.16  -0.517 (0.300) 0.094 




SE=standard error, CI = confidence interval, IQR = interquartile range. #Multivariate analysis adjusted for age, marital status, number of partners, injectable hormonal 
contraception and sex work as co-variates. †Variables with at least a third of concentrations were undetectable were dichotomised and a logistic regression model was fitted 
to estimate the effect of semen exposure on detectability of these cytokines and other soluble factors associated with genital epithelial repair and integrity. Bold indicates 
p<0.05 that were significant before adjusting for multiple comparisons.  None of the comparisons remained significant after adjusting for multiple comparisons (FDR).  
IL-3 5.64  0.01-28.00 0.01  0.01-10.42  -0.340 (0.818) 0.678 
Growth Factor 
PDGF-AA 8.1  4.78-61.91 103.19  4.95-217.97  0.248 (0.258) 0.344 
TGF-α 2.77  1.16-7.72 2.5  0.13-6.65  -0.284 (0.237) 0.239 
VEGF 37.89  8.64-99.70 60.25  17.27-77.93  -0.067 (0.179) 0.709 
PDGF-AB/BB† 10.57  0.09-109.37 0.09  0.09-35.49  -0.996 (0.838) 0.235 
 EGF† 0.56  0.56-6.02 0.56  0.56-11.42  0.532 (0.888) 0.549 
 FGF-2† 9.29  0.30-17.52 0.3  0.30-5.32  -1.428 (0.855) 0.095 
Adaptive 
IL-15 1.42  0.07-2.34 0.97  0.04-2.08  -0.289 (0.284) 0.315 
IL-5 0.03  0.02-0.03 0.03  0.03-0.04  -0.043 (0.043) 0.325 
IL-17 0.6  0.03-1.55 0.34  0.03-1.42  -0.250 (0.298) 0.408 
sCD40L 18.39  9.45-30.05 14.74  12.64-22.84  -0.278 (0.203) 0.179 
IFN-γ 3.48  0.27-4.89 4.01  0.07-4.89  -0.006 (0.459) 0.990 
 IL-2† 0.05  0.01-0.20 0.01  0.01-0.08  -1.961 (0.969) 0.043 
 IL-4† 0.02  0.02-0.47 0.02  0.02-0.20  -0.417 (0.864) 0.630 
 IL-13† 0.01  0.01-0.01 0.01  0.01-0.01  -1.105 (0.876) 0.207 
 sIL-2Rα† 6.1  1.74-12.34 0.57  0.57-6.10  -2.490 (1.052) 0.018 
Anti-
inflammatory 
IL-1Ra 34235.15  23157.59-45012.00 25248.88  22666.51-31845.50  -0.077 (0.075) 0.312 
IL-10† 0.02  0.01-0.16 0.02  0.02-0.24  -0.286 (0.968) 0.767 
MMPs 
MMP-1 2.4  2.40-3.11 2.4  2.40-22.57  0.304 (0.331) 0.366 
MMP-7 623.26  8.10-3546.13 925.5  8.10-4130.87  0.002 (0.718) 0.998 
MMP-9 6269.25  2925.21-23888.75 22178.59  3600.58-62381.61  0.578 (0.334) 0.095 
MMP-10 2.2  2.20-5.52 2.2  2.20-44.45  0.295 (0.411) 0.479 
 MMP-2† 118.1  118.10-118.10 118.1  118.10-118.10  - - 
TIMPs 
TIMP-1 901.93  130.04-5526.97 4012.86  2262.04-8631.68  0.997 (0.460) 0.039 
TIMP-2 17281.32  8597.14-21926.34 14827.82  13307.34-21156.46  0.124 (0.199) 0.538 
TIMP-3 25.45  25.45-32.54 25.45  25.45-32.54  0.020 (0.031) 0.527 




Women who were Y-chromosome positive but PSA negative (suggesting unprotected sex 
>48 hours but <15 days) had lower concentrations of IL-5 but higher concentrations of 
PDGF-AA than women negative for both PSA and Y-chromosome (p=0.029 and p=0.041, 
respectively, Table 4.3). In addition, concentrations of TNF-α (p=0.06) and IL-1β (p=0.06) 
tended to be decreased in women who tested positive for Y-chromosome and negative for 
PSA compared to women who tested negative for both PSA and Y-chromosome, although 
not significantly after adjustment for multiple comparisons.  
Table 4.3 Relationship between cytokine concentrations and semen exposure (>48 hrs post-sex) in the female genital tract 
Functional 
groups Cytokine 
Condom use or no sex (n=23) >48 hours Post-sex (PSA negative and Y-chromo positive)(n=10)  
Multivariate# 
Median 
(pg/ml) IQR Median (pg/ml) IQR   Beta coefficient (SE) P value 
Pro-
inflammatory 
TNF-β 4.56 2.49-7.77 8.42 6.04-15.56  0.311 (0.218) 0.163 
IL-12p40† 19.57 0.12-67.85 9.61 0.12-49.65  -0.329 (0.992) 0.740 
IL-12p70† 0.01 0.01-0.04 0.01 0.01-0.04  -0.855 (0.993) 0.389 
IL1α 25.76 15.35-70.12 46 20.53-87.56  0.117 (0.236) 0.623 
IL-6 1.04 0.37-15.33 1.13 0.35-4.04  -0.543 (0.402) 0.185 
TNF-α 0.03 0.02-0.04 0.03 0.02-0.04  -0.323 (0.167) 0.060 
IL-1β 0.24 0.06-0.94 0.11 0.05-0.17  -0.597 (0.307) 0.060 
Chemokine 
Eotaxin 3.57 0.26-6.48 1 0.26-5.38  -0.190 (0.289) 0.516 
MCP-1 13.3 4.20-77.18 8.72 4.56-26.15  -0.247 (0.308) 0.429 
MDC 34.09 11.90-60.59 44.06 41.26-77.17  0.213 (0.219) 0.335 
Fractalkine† 9.83 2.13-59.55 5.98 2.13-61.22  -1.078 (0.997) 0.280 
MIP1α† 0.66 0.66-36.15 0.66 0.66-20.24  -0.601 (0.916) 0.512 
MCP-3 11.41 7.56-16.31 10.58 4.24-14.77  -0.112 (0.134) 0.406 
IP-10 88.54 37.94-211.19 70.55 44.48-171.58  0.210 (0.315) 0.511 
GRO 400.86 276.49-1554.91 988.34 523.20-2761.13  0.291 (0.244) 0.241 
MIP-1β 2.89 0.01-8.02 1.28 0.01-4.60  -0.189 (0.643) 0.771 
IL-8 147.34 52.26-350.76 80.93 19.83-596.50  -0.257 (0.291) 0.384 
RANTES 3.65 2.75-6.93 2.98 1.85-7.25  -0.341 (0.311) 0.281 
Innate IFNα† 1.36 0.68-22.17 0.68 0.68-5.65  -1.123 (0.956) 0.241 
Hematopoietic 
IL-9 0.38 0.01-1.94 1.1 0.01-2.92  0.528 (0.442) 0.240 
Flt3L 3.66 0.45-9.78 5.3 0.45-8.16  -0.011 (0.256) 0.965 
G-CSF 29.96 6.02-104.06 19.42 3.07-60.40  -0.365 (0.470) 0.442 
GM-CSF 0.19 0.01-0.54 0.18 0.01-0.87  -0.243 (0.322) 0.455 




SE=standard error, CI = confidence interval, IQR = interquartile range. #Multivariate analysis adjusted for age, marital status, number of partners, injectable hormonal 
contraception and sex work as co-variates. †Variables with at least a third of concentrations were undetectable were dichotomised and a logistic regression model was fitted 
to estimate the effect of semen exposure on detectability of these cytokines and other soluble factors associated with genital epithelial repair and integrity. Bold indicates 
p<0.05 that were significant before adjusting for multiple comparisons.  None of the comparisons remained significant after adjusting for multiple comparisons (FDR).
IL-3 5.64 0.01-28.00 8.35 0.01-54.16  0.981 (0.956) 0.305 
Growth Factor 
PDGF-AA 8.1 4.78-61.91 44.23 22.66-170.18  0.587 (0.277) 0.041 
TGF-α 2.77 1.16-7.72 2.83 1.59-5.45  0.272 (0.255) 0.292 
VEGF 37.89 8.64-99.70 89.01 49.14-132.04  0.277 (0.192) 0.157 
PDGF-AB/BB† 10.57 0.09-109.37 0.09 0.09-41.33  -1.132 (0.933) 0.225 
 EGF† 0.56 0.56-6.02 1.37 0.56-8.54  1.182 (0.987) 0.231 
 FGF-2† 9.29 0.30-17.52 0.3 0.30-17.52  -1.404 (0.941) 0.136 
Adaptive 
IL-15 1.42 0.07-2.34 1.54 0.75-3.17  0.402 (0.305) 0.195 
IL-5 0.03 0.02-0.03 0.03 0.02-0.03  -0.105 (0.046) 0.029 
IL-17 0.6 0.03-1.55 0.76 0.03-1.45  0.063 (0.320) 0.845 
sCD40L 18.39 9.45-30.05 28.49 22.84-36.09  0.119 (0.218) 0.589 
IFN-γ 3.48 0.27-4.89 2.19 0.01-4.89  -0.562 (0.492) 0.261 
 IL-2† 0.05 0.01-0.20 0.06 0.01-0.08  -0.637 (1.026) 0.535 
 IL-4† 0.02 0.02-0.47 0.3 0.02-0.38  1.671 (1.069) 0.118 
 IL-13† 0.01 0.01-0.01 0.01 0.01-0.01  -1.137 (0.959) 0.236 
 sIL-2Rα† 6.1 1.74-12.34 4.25 0.57-10.92  -1.754 (1.145) 0.126 
Anti-
inflammatory 
IL-1Ra 34235.15 23157.59-45012.00 39327.04 31096.05-45012.00  0.086 (0.080) 0.293 
IL-10† 0.02 0.01-0.16 0.02 0.01-0.06  -0.864 (1.032) 0.403 
MMPs 
MMP-1 2.4 2.40-3.11 2.4 2.40-2.40  -0.228 (0.312) 0.471 
MMP-7 623.26 8.10-3546.13 162.27 8.10-654.99  -1.023 (0.677) 0.142 
MMP-9 6269.25 2925.21-23888.75 13071.56 3757.91-21198.43  -0.171 (0.315) 0.592 
MMP-10 2.2 2.20-5.52 2.2 2.20-2.20  0.295 (0.411) 0.479 
 MMP-2† 118.1 118.10-118.10 118.1 118.10-118.10  - - 
TIMPs 
TIMP-1 901.93 130.04-5526.97 3195.76 561.91-4998.14  0.579 (0.424) 0.183 
TIMP-2 17281.32 8597.14-21926.34 15600.36 11444.55-20848.70  0.191 (0.184) 0.307 
TIMP-3 25.45 25.45-32.54 25.45 25.45-32.54  0.003 (0.029) 0.920 
TIMP-4 3.92 3.92-3.92 3.92 3.92-3.92  -0.051 (0.124) 0.683 
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4.5 Discussion 
Despite improvements in the framing of sexual behavior questionnaires, self-reporting does 
not always yield accurate information; with self-reported condom use biased towards over-
reporting (Brener et al., 2003; Durant and Carey, 2000; Mauck et al., 2007; Stuart and 
Grimes, 2009; Turner and Miller, 1997). Inaccurate self-reported condom use data may lead 
to imprecise estimates of the biological effects in HIV-1/STIs intervention studies, and 
knowledge of the potentially confounding presence of semen in genital specimens may be a 
necessary prerequisite for the accurate study of mucosal immunity. The present study found 
that about half of the CVL samples collected from sexually active women contained semen 
markers (PSA and/or Y-chromosome), although nearly a third of women reported condom 
use at their last sexual act. All PSA positive samples were also positive for Y-chromosome 
(suggesting sex within 48 hours), while only about half of Y-chromosome positive samples 
were also positive for PSA (suggesting sex between 48 hours and 15 days prior to sampling).  
 
One fifth of PSA positive and over 30% of Y-chromosome positive women reported that they 
had used a condom at their last sex act. Women who reported less frequent or no condom use 
were more likely to test positive for either semen marker. The increased presence of semen 
markers in CVLs from women in stable relationships may be due to several factors, including 
marriage and the perception of reduced risk of STIs/HIV-1, desire to conceive, opposition to 
condom use by male partner, late use or early removal of condoms. Semen markers were 
detected more frequently in women not using injectable hormonal contraception compared to 
those using injectable contraception, although this difference was not statistically significant. 
This may be due to the fact that women who were not using injectable contraception were 
more likely to be married, have a stable partner, or were trying to conceive. 
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Previous studies have shown that semen induces an acute inflammatory response and 
increases recruitment of immune cells to the female genital tract after sex (Robertson, 2005, 
2007; Robertson et al., 2009; Sharkey et al., 2012). This study found that CVLs with semen 
present had reduced concentrations of inflammatory IL-12p70, and adaptive cytokines IL-2, 
IL-2Rα and IL-5, but increased expression of the growth factor PDGF-AA and soluble 
factors MMP-9 and TIMP-1, thought to be involved in tissue remodelling and repair in the 
reproductive tract. IL-12p70 and IL-2 in CVLs may be associated with T-cell activation while 
IL-5 may be involved in B cell stimulation and differentiation (Olivier et al., 2014; Randall et 
al., 1993). Recent sex (<48 hours, PSA+) was associated with increased production of TIMP-
1 which is known to inhibit gelatinases MMP-2 and -9 involved in remodelling processes of 
structural proteins in the reproductive tract (Rodgers et al., 1993). Seminal fluids (which can 
range in volume from 0.1 to 10 ml, Rehan et al., 1975) might dilute vaginal secretions and 
this might lead to lower concentrations of some cytokines in secretions. Sex which has taken 
place >48 hours before sample collection (such as those negative for PSA but positive for Y-
chromosome) was associated with increased CVL concentrations of the growth factor PDGF-
AA, reported to restore barrier function in the female genital tract and enhance epithelial 
repair by stimulating mitosis, spreading and migration of epithelial cells (Werner and Grose, 
2003).  
 
A limitation of this study is that women infected with STIs were excluded (because STIs also 
drive inflammatory responses in the genital tract), and most of these excluded women were 
young, hence a relatively small sample size. The influence of semen exposure on genital 
cytokines was also investigated cross-sectionally instead of longitudinally, where analytes are 
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assessed in the same women before and after sex. Furthermore, because cytokine 
concentrations are higher in CVLs from younger women compared to older women, Y-
chromosome positive and Y-chromosome negative women were age-matched for subsequent 
cytokine analyses. All limitations mentioned above are being addressed in further studies. 
 
In conclusion, condom use was not accurately reported in this cohort of women at high risk 
for HIV-1 infection, confirming the importance of routine objective screening for the 
presence of semen, especially in the context of HIV-1/STI prevention trials. These findings 
suggest that the presence of PSA and Y-chromosome may influence the cytokine profile in 
the female genital tract and should be taken into consideration when investigating 











In vivo and in vitro effects of injectable hormonal 
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CHAPTER 5 
In vivo and in vitro effects of injectable hormonal contraceptives on innate 
immune cell activation and cytokine responses 
5.1 Abstract  
Suppression of host immune responses in women using injectable HCs has been proposed as 
a biological mechanism that may contribute to increased risk for HIV-1 acquisition. 
Monocytes, macrophages and DCs have been shown to be susceptible to immunosuppression 
following DMPA exposure at physiological concentrations. The aim of this Chapter was (1) 
to investigate the in vivo impact of injectable HCs on blood monocytes and DCs from women 
using DMPA compared to those using NET-EN, and (2) to compare the in vitro effects of 
DMPA to natural progesterone and cortisol on DC subsets in blood from healthy women not 
using any form of HC. In vivo experiments included PBMCs from 98 HIV-1 uninfected 
women (40 DMPA users, 40 NET-EN users and 18 non-HC users). For whole blood 
experiments, blood from women not on HCs was incubated in the presence or absence of 
increasing concentrations of the exogenous and natural hormones (DMPA, cortisol and 
progesterone) and TLR4 (LPS) or TLR9 (CpG) agonists were added. Functional (intracellular 
TNF-a and IL-6 production) and activation phenotype (CD40 and CD86 expression) of mDC 
(HLA-DR+CD11c+CD123-) subsets were assessed by flow cytometry. Plasma cytokine 
concentrations were measured by Luminex. Findings in this Chapter suggest that in vivo 
injectable HC use did not affect numbers of circulating monocytes from full blood counts or 
plasma cytokine levels in HIV-1 uninfected women using DMPA or NET-EN. DMPA did not 
alter the level of monocyte activation (measured by CD40, CD86 and HLA-DR expression), 
following in vitro stimulation with TLR ligands LPS and CpG. However, DMPA 
significantly decreased the production of pro-inflammatory TNF-α by mDCs following in 
vitro stimulation with LPS- or CpG (p=0.0286). In addition, DMPA-treated mDCs showed 
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impaired capacity to produce IL-6 after LPS stimulation relative to the control. These in vitro 
experiments suggest that DMPA was capable of down-modulating cytokine production by 





Injectable HCs have been associated with reduced host resistance to pathogens, such as C. 
trachomatis, N. gonnorhoea, and HPV by modulating innate mucosal defenses (Bamberger et 
al., 1999; Koubovec et al., 2005; Koubovec et al., 2004; Morrison et al., 2014). Previous in 
vivo studies and results from Chapter 3 showed that injectable HCs can have an effect on host 
immunity, by down-regulating production of several proinflammatory cytokines (IL-1α, IL-9, 
IL-12p40, IL-15, IL-17, MIP-1α, IFNα, Eotaxin, Fractalkine, EGF, FGF2, PDGF-AA, TGF-
α, MCP-1, IL-1ra, IL-6, IL-13, TNF-α and GM-CSF) but also increasing cellular 
susceptibility to HIV-1 infection by up-regulating HIV-1 co-receptors CXCR4 and CCR5 on 
activated T-cells (Hughes et al., 2008; Huijbregts et al., 2013).  
 
Several studies have demonstrated that injectable HCs inhibit systemic regulators of cellular 
and humoral immunity (Hughes et al., 2008; Huijbregts et al., 2013). Injacteble HCs also 
reduce circulating monocyte numbers (Kleynhans et al., 2013; Kleynhans et al., 2011) and 
suppressing cytokine production by DCs (Hughes et al., 2008; Huijbregts et al., 2013; 
Huijbregts et al., 2014; Michel et al., 2015). DCs and monocytes are central to host 
immunity, as they are major antigen presenting cells that recognise and respond early to 
pathogens in the body, influencing the development of adaptive immunity (Banchereau and 
Steinman, 1998). DCs are phenotypically and functionally divided into plasmacytoid DCs 
(pDCs), myeloid DCs (mDCs), and tissue-resident Langerhans cells (LCs) (Muller-Trutwin 
and Hosmalin, 2005; Shey et al., 2015). Monocytes and myeloid DCs express TLR-2 and 
TLR-4, pDCs express TLR-7 and TLR-9, and LCs express TRL-2, TLR -4 and TLR -9 
(Iijima et al., 2008). HLA class I/II molecules expressed by DCs and co-stimulatory markers 
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for T and B cells (including CCR7, CD40, CD80 and CD86) were upregulated following 
antigen capture that make them better antigen-presenting cells (Iwasaki and Medzhitov, 2004; 
Seder et al., 1993). Following HIV-1 infection, mDCs secrete a series of pro-inflammatory 
cytokines (including IL-1β, IL-6, IL-10, IL-12 and TNF-α), while pDCs secrete type I 
interferons, and IL-6 upon TLR-7/8 or TLR-9 stimulation (Palucka et al., 2010). However, 
the addition of exogenous syntheic progestins (including DMPA) in cultured human pDCs 
have been shown to downregulate TNF-α and IFN-α production by pDCs exposed to 
exogenous TLR -7, -8, and 9 ligands (Hughes et al., 2008; Huijbregts et al., 2013; Michel et 
al., 2015).  
 
Monocytes and DCs are important regulators of T cell differentiation, determining the switch 
between maturation to Th1, Th2, Th17 or Treg phenotypes (Kaiko et al., 2008; Zhu et al., 
2010). Since previous studies have shown that DMPA impacts on monocyte and DC lineage 
cells (Hughes et al., 2008; Huijbregts et al., 2013; Kleynhans et al., 2013; Kleynhans et al., 
2011; Michel et al., 2015), the impact of injectable HC use on systemic cytokines, and 
numbers of circulating monocytes in women using DMPA or NET-EN was investigated in 
this Chapter. In addition, the ex vivo function of monocyte lineage cells, and the impact of in 
vitro addition of DMPA on mDC and pDC activation and intracellular cytokine production 
was evaluated.   
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5.3 Materials and Methods 
5.3.1 Study design, samples size and inclusion criteria 
For the in vivo or ex vivo studies, PBMCs from 98 women who had previously participated in 
the CAPRISA 004 tenofovir 1% gel vaginal microbicide trial, who were either using DMPA 
(N=40), NET-EN (N=40) or not using HCs (N=18; tubal ligation), were included in this 
retrospective study (Figure 5.1) (Abdool Karim et al., 2010a). Unlike the CAPRISA002 trial 
where it was not possible to differentiate the type of injectable HC being used by women, the 
CAPRISA004 trial questionnaire collected information on whether the women were using 
DMPA or NET-EN (Sibeko et al., 2011). All women were in the placebo arm of the 
CAPRISA004 trial (Abdool-Karim et al., 2010). To account for age, half of the women were 
aged 15-25 years and half were >30 years old in the DMPA and NET-EN groups. Women 
taking any steroid treatment (including hormonal contraceptives such as IUDs and COCs) 
were excluded. For the in vitro studies, whole blood was obtained from four healthy female 
volunteers who were not using any HCs. Demographic and clinical data were collected at 
enrolment using a structured questionnaire administered by a trained counsellor. Data were 
collected on whether the women were using injectable HCs (DMPA or NET-EN), COCs, 
IUDs, condoms, diaphragms, foam and jelly, or who were sterilised.  Laboratory samples, 
including vaginal aspirates, CVLs, cytobrushes, vaginal swabs, serum, plasma and PBMCs 
were collected from each participant throughout the trial. PBMCs were isolated from whole 
blood by Ficoll treatment using a standard protocol and stored in liquid nitrogen. Full blood 
counts, including an automated differential count, was performed on each patient sample 
using Sysmex KX21 hematology analyzer according to the manufacturer’s protocol (Roche 
Molecular Systems, Inc, Germany) by the Global Clinical and Viral Laboratory 
(Amanzimtoti, South Africa). The protocol for this study was approved by the Ethical 
Review Committee of the University of KwaZulu-Natal.          .        
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Figure 5.1 Summary of study design for ex vivo study. PBMCs from 98 HIV-1 uninfected women (40 DMPA users, 40 NET-EN users and 
18 non-HC users as controls) from the CAPRISA 004 were stratified by age.  
 
98 PBMCs from HIV-uninfected women  
80 injectable HC user PBMCs 
40 DMPA users 
40 NET-EN users 
40 DMPA users 
20 (15 - 25 years) 
20 (>30 years) 
40 NET-EN users 
20 (15 - 25 years) 
20 (>30 years) 
18 Non-HC user PBMCs (controls) 
women who had tubal ligation (22 - 28 years) 
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5.3.2 Ex vivo characterization of PBMCs from women using injectable HCs 
Cryopreserved PBMCs from HIV-1 negative women who were either users of DMPA, NET-
EN or no HCs were rapidly thawed in water bath at 37°C and washed three times with warm 
R10 culture medium [RPMI culture medium (Lonza, Cologne, Germany) supplemented with 
1% penicillin/streptomycin (PenStrep; Gibco, Darmstadt, Germany) and 10% heat-
inactivated fetal calf serum (FCS ; Biochrom AG, Berlin, Germany)]. After thawing, PBMCs 
were rested for 2 hours and viability was determined using trypan blue staining. After resting, 
thawed cells were incubated with 20μl LIVE⁄DEAD® Fixable Violet Dead Cell Stain for 20 
minutes at room temperature, then washed twice with 1X PBS. The cells were then stained 
with antibodies for monocytes and activation markers for 60 minutes at room temperature in 
the dark with the following markers for innate cells: Alexa Fluor® 700 anti-HLA-DR, 
Cyanine 5.5 (Per CP-Cy5.5)-labeled anti-CD123 (pDCs), APC/Cy7 anti-CD11c (mDCs), 
Qdot 655 anti-CD14 (monocytes; Thermo Fisher Scientific, Waltham, MA), 
Allophycocyanin (APC)-labeled anti-CD86 (B7-2) and FITC-labeled anti-CD40 as markers 
of DC activation. At least 50,000 events were captured using a LSRII flow cytometer (BD 
Immunocytometry Systems). Fluorescence minus one (FMO) staining was used to set gates 
to differentiate negative and positive populations (Perfetto et al., 2004). FlowJo v9.7 (Tree 
Star, CA, USA) was used to analyze the data. Results from single-stained and unstained 
mouse kappa beads were used for colour compensation. Cell doublets were excluded using 
forward scatter-area versus forward scatter-height parameters. T cells, B cells and NK cells 
were also excluded from the analyses. The mean fluorescent intensity (MFI) for HLA-DR, 
CD40 and CD86 were determined in FlowJo. All data have been corrected for background, 
using the unstimulated condition.  
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5.3.3 Measurement of plasma cytokines  
Concentrations of 12 cytokines in plasma from 100 women (68 DMPA users, 14 NET-EN 
users and 18 not using any HCs) were measured using Luminex (by Dr Lenine Julie 
Liebenberg; CAPRISA Lab, Durban, South Africa). These included: IL-1α, IL-1β, MCP-
1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, IL-6, IL-7, IL-8 (CXCL8), IL-10, GM-CSF, IP-10, 
and TNF-α using the Human Cytokine and High Sensitivity LINCOplex Premixed kits 
(LINCO Research, MO, USA). Plasma samples were thawed overnight on ice and filtered by 
centrifugation using 0.2 μm cellulose acetate filters (Sigma, U.S.A.). All markers were 
measured in undiluted CVL on a Bio-Plex 100 system (Bio-Rad Laboratories Inc®, Hercules, 
California). Bio-Plex manager software (version 5.0; Bio-Rad Laboratories Inc®) was used 
to analyse the data and all analyte concentrations were extrapolated from the standard curves 
using a 5 parameter logistic (PL) regression equation. Analyte concentrations that were below 
the lower limit of detection of the assay were reported as the mid-point between zero and the 
lowest concentration measured for each analyte.  
 
5.3.4 Measurement mDC and pDC function and activation 
Whole blood from healthy women not on HCs were used for in vitro experiments. For 
measurement of intracellular cytokine production by DC subsets, whole blood (400µl) was 
incubated with DMPA (Sigma, catalogue number M1629-1G, U.S.A.), cortisol (Sigma, 
catalogue number H4001-1G, U.S.A.) and progesterone (Sigma, catalogue number P8783-
5G, U.S.A.) at varying concentrations (1 mM, 10 mM, 100 mM) and then stimulated for 6 
hours with either LPS (final concentration of 2 μg/ml; a TLR4 ligand;  Invivogen, San Diego, 
California, USA) or CpG (final concentration of 1 μg/ml, a TLR9 ligand, Invivogen, San 
Diego, California, USA). Untreated cells were included as a negative control. For 
measurement of DC intracellular cytokine production, cells in whole blood were incubated 
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for 60 minutes at 37°C in a humid incubator with 5% CO2, after which brefeldin A (10 μg/ml) 
was added (Sigma, catalogue number B7651, U.S.A.). Incubation was continued for an 
additional 5 hours at 37°C in a humid incubator with 5% CO2. For measurement of DC 
activation, whole blood was stimulated as above but for 18 hours without brefeldin A added. 
After either a 6 hour (when cytokine production was being measured) or an 18 hour 
stimulation (when DC activation was being measured), red cells in whole blood were lysed 
with 1ml BD FACS lysing solution (BD, New Jersey, USA) for 10 minutes at room 
temperature and stored at -80°C until needed for immunostaining for flow cytometry. In 
batches, the frozen cells were thawed and stained with antibodies for DC lineage markers and 
cytokines. 
 
5.3.4.1 Flow cytometry of DC subsets for intracellular cytokine production  
For intracellular staining of cytokines to measure DC subset function, hormone-treated cells 
were washed twice with 3 ml of BD Perm wash buffer, centrifuging each time for 5 minutes 
at 388 x g. Staining was performed for 60 minutes at room temperature in the dark with the 
following markers for innate cells: Alexa Fluor® 700 anti- HLA-DR, Cyanine 5.5 (Per CP-
Cy5.5)-labeled anti-CD123 (pDCs), APC/Cy7 anti-CD11c (mDCs), Qdot 655 anti-CD14 
(monocytes; Thermo Fisher Scientific, Waltham, MA), and APC anti-IL-6 and PE Cyanine 7 
(PE-Cy7) labeled anti-TNF-α (BioLegend, San Diego, California) as functional markers. In 
addition, cells were also stained (in the same panel) with PE-labeled anti-CD66ace (to 
exclude neutrophils; BD, New Jersey, USA) and other dump channel markers such as Pacific 
Blue labeled anti-CD3 (T cells), CD19 (B cells) and CD56 (NK cells) (BioLegend, San 
Diego, California). After staining, cells were resuspended in 1 ml of BD Perm wash buffer 
and centrifuged for 5 minutes at 388 x g.  
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For staining cell surface markers to measure DC activation, treated cells were washed once 
with 3ml of 1% FCS PBS, centrifuging each time for 5 minutes at 388 x g. Staining was 
performed for 60 minutes at room temperature in the dark with the following markers for 
innate cells: Alexa Fluor® 700 anti- HLA-DR, Cyanine 5.5 (Per CP-Cy5.5)-labeled anti-
CD123 (pDCs), APC/Cy7 anti-CD11c (mDCs), Qdot 655 anti-CD14 (monocytes; Thermo 
Fisher Scientific, Waltham, MA), and Allophycocyanin (APC)-labeled anti-CD86 (B7-2) and 
FITC-labeled anti-CD40 as markers of DC activation. As with the intracellular staining panel, 
cells were stained in the same panel with PE-labeled anti-CD66ace and dump channel 
markers.  
 
At least 500,000 events were acquired using a FACSDiva flow cytometer (BD 
Immunocytometry Systems). Gates differentiating negative and positive populations were set 
by FMO staining (Perfetto et al., 2004). Flow cytometry data was analysed using FlowJo v9.7 
(Tree Star, CA, USA). Results from single-stained and unstained mouse kappa beads were 
used to calculate compansations. Cell doublets were excluded using forward scatter-area 
versus forward scatter-height parameters while cytokine co-expression by DC susbsets was 
assessed by Boolean gating. T cells, B cells, NK cells and neutrophils were also excluded 
from the analyses. The MFI for HLA-DR, CD40 and CD86 and frequencies of TNF-α and 
IL-6 positive cells were determined in FlowJo. All data has been corrected for background 
using unstimulated data.  
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5.3.5 Statistical analysis  
Descriptive statistics were used to compare demographic characteristics. Mann-Whitney U 
test was applied for non-parametric independent sample comparisons and Wilcoxon signed 
rank tests were applied to matched samples for non-parametric comparison. Kruskal-Wallis 
(Nonparametric One-Way ANOVA) tests were used for non-parametric assessments of 
variation between groups. P values of <0.05 were considered statistically significant. 
Statistical analyses were performed using GraphPad Prism version 6 (GraphPad Software, 
San Diego, CA, U.S.A.) and SAS version 9.3 (SAS Institute Inc., Cary).   
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5.4 Results 
Table 5.1 summarizes the characteristics of the HIV-1 uninfected women included in the ex 
vivo study. Their median age was 24 years (IQR 21 -31), and almost all (96/98) were in stable 
relationships. More than 80% of the women reported using condoms at their last sex act 
(81/98). Age, relationship status and condom use did not differ between groups (DMPA, 
NET-EN and controls). 
 
Table 5.1 Demographics of women included in the ex vivo study  
  Overall Controls DMPA users NET-EN users 
N 98 18 40 40 
Median Age [median (IQR)] 24 (21-31) 33 (29 - 34) 23 (20 - 28) 24 (21 -29) 
Relationship status [% (n/N)]     
Casual 2 (2/98) 6 (1/18) 2 (1/40) 0 (0/40) 
Stable 98 (96/98) 94 (17/18) 98 (39/40) 100 (40/40) 
Condom use at last sex act [% 
(n/N)] 83 (81/98) 67 (12/18) 88 (35/40) 85 (34/40) 
IQR = interquartile range. Control were women not using any form of HC (tubal ligation) 
 
5.4.1 Effects of injectable HC use on monocyte and DC subsets 
Since previous studies have suggested that DMPA use may interfere with functional ability of 
monocyte lineage cells (Kleynhans et al., 2013), the impact of DMPA use on full blood 
counts and blood monocyte numbers was evaluated in women who were known to be using 
either DMPA, NET-EN or no/non-injectable HCs (Table 5.2). No differences in the numbers 
of circulating monocytes in women using injectable HC were noted compared to non-HC 
users (p=0.512). Additionally, similar numbers of circulating platelets, lymphocytes, 
basophils, neutrophils and eosinophils were found in both groups. Haemoglobin was slightly 
lower in women not using any HC (median 13.1 g/dL, IQR 12.25-13.50) compared to 
injectable HC users (median 14 g/dL, IQR 13.30-14.60; p=0.078), although not significantly. 
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Table 5.2 Comparison of full blood counts of women using injectable HCs and those not using HCs 






34 33.00-34.40 0.579 




3.88 2.98-4.48 0.974 




2.09 1.89-2.24 0.217 




0.38 0.32-0.46 0.512 




0.1 0.07-0.19 0.379 




0.02 0.01-0.02 0.564 
IQR = interquartile range; p-values were calculated using Kruskal-Wallis ANOVA tests (non-parametric). 
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To determine whether DMPA use influenced monocyte activation, HLA-DR expression by 
CD14+ monocytes was measured in PBMCs from women using DMPA, NET-EN or non-
injectable HCs. Figure 5.2A summarizes the gating strategy to identify monocytes. The 
frequency of circulating monocytes was not different in DMPA users compared to non-HC 
users (median 4.44% of  HLA-DR+ cells (IQR, 2.23 – 9.41) versus 2.33% (IQR, 1.66 – 7.07); 
p=0.220) (Figure 5.2B). Similarly, no difference in the numbers of circulating monocytes in 
NET-EN users compared to non-HC users [4.69% of HLA-DR+ cells (IQR, 2.24 – 8.12) vs 
2.33% (IQR, 1.66 – 7.07); p=0.216] were found. DC activation markers (CD40 and CD86 on 
CD11c+ mDCs and CD123 pDCs) has not been reported here as these populations were not 






Figure 5.2 Influence of injectable HC use on frequency of monocytes in blood. (A) 
Gating strategy used to identify CD14+ monocytes in stored PBMCs. 
CD3/CD56/LIVE⁄DEAD- population was used to identify monocytes (CD14+HLA-DR+). (B) 
Impact of DPMA (blue dots) or NET-EN (red dots) use on frequencies of monocytes in blood 
from DMPA (n=40) and NET-EN (n=40) users compared to non-HC users (n=18). Bars 
indicate median values; significance was determined using the Mann-Whitney test. P-values 
<0.05 were considered significant. 
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5.4.2 Impact of injectable HCs on innate immune factors in the female genital tract  
Previous studies have demostrated that DMPA suppresses production of several cytokines, 
particularly those related to monocyte lineage function (Hughes et al., 2008; Huijbregts et al., 
2013; Kleynhans et al., 2013). To investigate this, the influence of injectable HC on the 
systemic innate environment was measured by comparing the concentrations of IL-1α, IL-1β, 
IL-6, IL-7, IL-8, IL-10, GM-CSF, IP-10, and TNF-α in CVL from women using either 
DMPA, NET-EN, or those not using HCs. None of the cytokines typically produced by DCs 
and monocytes (including IL-1β, IL-6, IL-10 and TNF-α) were significantly different 
between groups (Figure 5.3). Concentrations of IL-8, IP-10, and MCP-1 tended to be lower in 
women using DMPA and NET-EN compared to non-HC controls, although not significantly. 
This is interesting because MCP-1, IP-10 and IL-8 are all involved in chemoattraction of 
monocytes or macrophages to sites of infection. The lower concentrations of these specific 
cytokines in women using injectable HCs suggest that injectable HCs may inhibit migration 








Figure 5.3 Influence of DMPA or Net-EN use on plasma cytokine concentrations 
compared to those not using HCs. β-coefficients were calculated using logistic regression. A 
positive β-coefficient indicates that higher concentrations of the cytokine are associated with 
DMPA or NET-EN use, while a negative β-coefficient indicates that the cytokine 
concentration is more likely to be lower in plasma from women who were using DMPA or 
Net-EN compared to non-HC users. 
 
5.4.3 Effect of exogenous hormones on mDC lineage activation  
To evaluate whether exogenous addition of DMPA influenced monocyte and DC activation 
or cytokine production, whole blood from healthy female donors not using HCs were 
stimulated with LPS (TLR4) or CpG (TLR9) with exogenous addition of natural 
(progesterone) or synthetic hormones (DMPA) or cortisol at varying concentrations (1, 10 


















and 100 nM). Figure 5.4 and 5.5 shows the gating strategy used to evaluate cytokine 
production (IL-6 and TNF-a) and cellular activation (CD40 and CD86 expression), 
respectively. For this analysis, monocytes were defined as HLA-DR+ CD14+ cells; mDCs 
were defined as HLA-DR+CD14-CD11c+CD123- cells; and pDCs were defined as HLA-
DR+CD14-CD11c-CD123+ cells.  
 
While both LPS and CpG increased mDC activation, with higher MFI expression of CD40 on 
CD11c+ cells, DMPA-, progesterone- and cortisol-treatment did not influence the level of 
mDC activation induced by these TLR agonists (Figure 5.6). In contrast to CD40, CD86 
expression on mDCs was not increased by LPS or CpG stimulation and not affected by 
exogenously added hormones or cortisol (Figure 5.7). Similar analysis of CD14+ monocytes 




Figure 5.4 Gating strategy used to identify DC subsets and cytokine production of TNF-α 
and IL-6 that were either unstimulated (control), stimulated with LPS/CpG or a combination 
of LPS/CpG and hormone (DMPA, cortisol and progesterone). TNF-α production was 
defined by CD14- CD11c+ cells while IL-6 was defined by CD14- CD11c+ cells following 
stimulation of PBMCs with either CpG or LPS for 6 hours. 
LYMPHOCYTES SINGLETS LEUKOCYTES CD14 AND HLA-DR POPULATION 
CD11c and CD123 POPULATION  TNF-α (UNSTIMULATED) TNF-α (CpG Stimulation) 
IL-6 (UNSTIMULATED) IL-6 (CpG stimulation) IL-6 (CpG + DMPA stimulation) 
TNF-α (CpG + DMPA Stimulation) 
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Figure 5.5 Gating strategy for analysis of DC subset activation (CD86 and CD40). Whole 
blood was either unstimulated (control), or stimulated with LPS/CpG or a combination of 
LPS/CpG and hormone (DMPA, cortisol and progesterone). Activation markers were defined 
as CD86 and CD40 following stimulation of PBMCs with either CpG or LPS.   
LYMPHOCYTES SINGLETS LEUKOCYTES CD14 (monocytes) and HLA-DR populations 
CD11c (mDCs) and CD123 (pDCs) CD40 expression (mDC activation marker) 
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Figure 5.6 Effect of DMPA, cortisol and progesterone on CD40 expression (MFI) by mDCs stimulated with LPS (top panels) or CpG 
(bottom panels). Whole blood was either not stimulated (black bars), or stimulated with LPS/CpG (red bars), in the presence of DMPA (purple 
bars), cortisol (brown bars) or progesterone (blue bars). DMPA, progesterone and cortisol were used at varying concentrations (1, 10 and 100 
nM). Box plots show the median, 25th and 75th percentile values, while whiskers show the 90 and 10% ranges; significance was determined 




























































































































































































































Figure 5.7 Effect of DMPA, cortisol and progesterone on CD86 expression (MFI) by mDCs stimulated with LPS (top panels) or CpG 
(bottom panels). Whole blood was either not stimulated (black bars), or stimulated with LPS/CpG (red bars), in the presence of DMPA (purple 
bars), cortisol (brown bars) or progesterone (blue bars). DMPA, progesterone and cortisol were used at varying concentrations (1, 10 and 100 
nM). Box plots show the median, 25th and 75th percentile values, while whiskers show the 90 and 10% ranges; significance was determined 



























































































































































































































5.4.4 Impact of exogenous HCs on mDC function 
To investigate whether DMPA use has an impact on DC function in vitro, the in vitro effects 
of DMPA at physiological concentrations were compared to endogenous progesterone. MPA 
levels in the serum of DMPA users range from 4.5 to 65 nM a few days after administration 
of the 150 mg dose which then platueaus to about 2.6 nM for three months (Hapgood, 2013; 
Hiroi et al., 1975; Shrimanker et al., 1978). The levels of endogenous progesterone in the 
serum of premenopausal women varies from 0.65 nM to about 80 nM between the follicular 
and luteal phases, respectively (Africander et al., 2011). In this study, IL-6 (Figures 5.8) and 
TNF-α production (Figures 5.9) by mDCs was assessed following stimulation with LPS/CpG, 
in the presence of DMPA, cortisol or progesterone at varying concentrations (1, 10 and 100 
nM)., as a measure of mDC function. Both DMPA and progesterone significantly reduced 
mDC TNF-α production following LPS and CpG stimulation, with DMPA having a stronger 
effect at all concentration measured (Figure 5.8). In contrast, cortisol did not effect TNF-α 
production by stimulated mDCs. 
 
Similarly, DMPA and progesterone significantly inhibited LPS-induced IL-6 production by 
mDCs (Figure 5.9). Only varying concentrations of progesterone inhibited CpG-induced IL-6 
production by mDCs while DMPA and cortisol did not (Figure 5.9). Due to the fact that only 
small populations of CD14+ monocytes and CD123+ pDCs were identified in this analysis, 
LPS/CpG-induced IL-6 or TNF-α production by these subsets was not shown in this Chapter.  
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Figure 5.8 Effect of DMPA, cortisol and progesterone on TNF-α production by mDCs stimulated with LPS (top panels) or CpG (bottom 
panels). Whole blood was either not stimulated (black bars), or stimulated with LPS/CpG (red bars), in the presence of DMPA (purple bars), 
cortisol (brown bars) or progesterone (blue bars). DMPA, progesterone and cortisol were used at varying concentrations (1, 10 and 100 nM). 
DMPA and progesterone but not cortisol suppresses TNF-α production by activated mDCs stimulated with LPS or CpG ligands. Box plots show 
the median, 25th and 75th percentile values, while whiskers show the 90 and 10% ranges; significance was determined using the Mann-Whitney 
test for non-parametric data. P-values <0.05 were considered significant. 
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Figure 5.9 Effect of DMPA, cortisol and progesterone on IL-6 production by mDCs stimulated with LPS (top panels) or CpG (bottom 
panels). Whole blood was either not stimulated (black bars), or stimulated with LPS/CpG (red bars), in the presence of DMPA (purple bars), 
cortisol (brown bars) or progesterone (blue bars). DMPA, progesterone and cortisol were used at varying concentrations (1, 10 and 100 nM). 
DMPA and progesterone but not cortisol suppresses IL-6 production by mDCs stimulated with LPS or CpG ligands. Box plots show the median, 
25th and 75th percentile values, while whiskers show the 90 and 10% ranges; significance was determined using the Mann-Whitney test. P-values 









































































































































































































































In this Chapter, hormone-mediated effects on monocyte and DC subset function and 
activation were evaluated: (1) in vivo from blood collected from HIV-uninfected women 
using injectable HCs; and (2) in vitro from blood from women using no HCs that was treated 
with exogenous synthetic and natural hormones (DMPA or progesterone) compared to 
cortisol. No differences were found in full blood counts, systemic cytokine concentration, or 
monocyte or DC lineage frequencies between women using DMPA versus those not using 
HCs, suggesting that HCs did not influence gross monocyte lineage counts. However, DMPA 
and progesterone decreased the production of TNF-α and IL-6 but not activation of mDCs in 
vitro, suggesting that immunomodulation of DC subsets can occur in the presence of HCs and 
their natural derivatives. 
  
Kleynhans et al. (2011) perviously reported that women infected with tuberculosis who were 
concomitantly using DMPA and glucocorticoids had significantly lower numbers of blood 
monocytes. Furthermore, they also showed that mice treated with DMPA showed suppression 
in monocyte lineage-specific cytokines (Kleynhans et al., 2013; Kleynhans et al., 2011). In 
this study, injectable HC use had no effect on numbers of circulating monocytes in women 
using HCs compared to non-HC users. In addition, DMPA, cortisol and progesterone did not 
effect the function of monocytes following TLR stimulation with LPS and CpG, in in vitro 
experiments. It is possible that the effect of DMPA on monocytes observed in the previous 
study was due to the glucocorticoid rather than DMPA treatment. Heimbeck et al. (2010) also 
showed decreased numbers of circulating monocytes in individuals using glucocorticoid 
therapy, suggesting that glucocorticoid therapy rather than DMPA may influence monocyte 
numbers (Heimbeck et al., 2010).  
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DMPA has previously been shown to inhibit activation of DCs by the TLR3 agonist 
polyinosinic:polycytidylic acid, measured by increased expression of CD40 and ability to 
promote allogeneic CD4+ and CD8+ T cell proliferation (Quispe Calla et al., 2015). In mice 
treated with DMPA or progesterone, decreased expression of CD40 (Vicetti Miguel et al., 
2012) and CD86 (Xu et al., 2011) was reported. These studies suggest that the mechanism by 
which DMPA and/or progesterone inhibit in vivo T cell priming and virus-specific T cell 
expansion was via impaired DC activation and function (Vicetti Miguel et al., 2012; Xu et al., 
2011). None of the hormones tested in vitro in this study affected CD40 and CD86 expression 
by mDCs following stimulation with TLR ligands, although CD86 expression under the 
conditions and concentrations used was not increased by either LPS or CpG stimulation. 
 
Previous in vitro studies have shown that DMPA decreases the ability of pDCs to respond to 
stimulation by TLR7/8 and TLR9 ligands, measured by production of IFN-α and TNF-α 
(Huijbregts et al., 2013; Michel et al., 2015). DMPA use has been associated with down-
regulation of several cytokines, including IL-6, in mouse serum (Kleynhans et al., 2013) and 
human cervicovaginal secretions (Hughes et al., 2008). In this study, endogenously added 
DMPA and progesterone decreased LPS- and CpG-induced TNF-α production by mDCs at 
varying concentrations (1, 10 and 100 nM). In addition, mDCs treated with DMPA or 
progesterone displayed impaired capacity to produce IL-6 after LPS stimulation, independent 
of dose concntration, even at concentration (1 nM) lower than the peak and plateau levels 
found in the serum of women using DMPA. Only progesterone treatment inhibited 
production of IL-6 following CpG stimulation. Hartmann et al. (1999) reported kinetic 
differences in LPS- and CpG-induced cytokine expression by monocytes (4 hours versus 10 
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hours of stimulation, respectively), and that these ligands use different intracellular pathways 
for their stimulatory activity. Furthermore, in presence of pathogens, IL-6 production 
increased activation, proliferation, apoptosis and differentiation of the immune cells 
(Nakajima et al., 1989), while TNF-α was found to initiate an inflammatory cascade of 
cytokines, thereby recruiting macrophages and neutrophils to the site of infection (Bahia and 
Silakari, 2010). IL-6 and TNF-α are also responsible for maturation and migration of 
dendritic cells to the lymph nodes; thereby influencing the development of adaptive immunity 
(Banchereau and Steinman, 1998). Therefore, it is possible that the impairment in the ability 
of DCs to produce these cytokines might lead to reduced immune response against invading 
pathogens. 
 
In this study, cortisol did not affect mDC cytokine production after LPS stimulation. The 
failure of cortisol to decrease cytokine expression may be due to its inability to bind to the 
glucocorticoid receptor complex, as some cytokine genes are regulated by this receptor 
(Bamberger et al., 1999). DMPA and progesterone are known to bind with high affinity to the 
glucocorticoid receptor (Bamberger et al., 1999). The results in this Chapter are in contrast 
with previous in vitro studies (Hughes et al., 2008; Kleynhans et al., 2013; Kleynhans et al., 
2011) that suggest DMPA mirrors the effect of cortisol instead of its intended analog, 
progesterone. 
 
Some limitations of this study were that it focused exclusively on mDC lineages, and other 
HIV-1 target cells, such as monocytes , pDCs and CD4+ T cells, were not evaluated. In 
addition, PBMCs used for in vivo studies were >10 years old, with relatively poor viability 
that may have influenced the results.  
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In summary, results from this Chapter suggests that DMPA and its natural analogue 
progesterone down-regulated certain characteristics of mDC function. These results provide 
evidence for the biological effects of DMPA on host immunity. More intensive and detailed 
studies into the biological effect of HCs on immunity is critical to ensure effective, safe HCs, 
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CHAPTER 6 
Influence of injectable HCs on vaginal epithelial thickness, mucosal 
cytokines, HIV-1 target cell density and depth in the female genital tract 
during acute HIV-1 infection 
 
6.1 Abstract 
Vaginal epithelial thinning and/or increased density of mucosal HIV-1 target cells are 
possible mechanisms by which injectable HCs may increase risk for HIV-1 infection in HIV-
1 negative women. In women already infected with HIV-1, particularly during acute infection 
when viral loads peak, alterations in the genital epithelium may increase risk for HIV-1 
transmission to sexual partners. Here, the influence of injectable HCs on genital epithelial 
thickness, mucosal HIV-1 target cell density and depth in recently HIV-1 infected women 
was investigated. CD4+ T cell and CD68+ macrophage density, both target cells for HIV 
infection, was measured in vaginal tissue biopsies from acutely-infected women who were 
either using injectable HCs or not using injectable HCs by immunohistochemical and 
immunofluorescent staining. Concentrations of 48 cytokines and HIV-1 concentrations were 
measured in CVL. Blood CD4 counts and plasma viral loads were performed during acute 
infection and 12 months post-infection. Overall, vaginal epithelial thickness was similar in 
women using injectable HCs (median 356.9 µm/cc; IQR 302.0-414.2) compared to non-
injectable HC users (361.4; 271.0-409.4). The frequency of CD4+ T cells in the vaginal 
squamous epithelium of injectable HC users was significantly higher than non-injectable HC 
users [(median 33 cells/mm2; IQR 23 -74) versus (24; 17-43), p=0.028]. CD68+ target cell 
density did not differ between women using injectable HCs and those not using injectable 
HCs [(median 23 cells/mm2, IQR 17 – 30) versus (21, 15 - 28), p=0.439], although CD68+ 
macrophages were closer to the vaginal lumenal surface in women using injectable HC than 
those not using non-injectable HC users (median 97µm, IQR 81.3 – 117. versus 158, 131.8 – 
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163.8; p=0.021). Furthermore, the frequency of mucosal CD68+ macrophages during the 
acute infection were positively associated with the concentration of the CCR5 agonist 
RANTES (beta coefficient (β)=0.779, p=0.024), in addition to macrophage chemotactic 
cytokine MCP-1 (β=0.453, p=0.041), IP-10 (β=0.568, p=0.042), IL-7 (β=1.332, p=0.018), IL-
9 (β=0.336, p=0.015), and IL-17 (β=1.058, p=0.007) in CVL, after adjusting for multiple 
comparisons. Injectable HC use was not associated with higher genital HIV-1 concentrations 
or more rapid disease progression (measured by CD4 counts or plasma viral loads at 12 
months post-infection). It was concluded that women using injectable HC users had increased 
frequencies of CD4+ T cells in their vaginal stratified epithelium than those not using 
injectable HCs. CD68+ macrophages correlated with a broad panel of mucosal cytokines and 





6.2 Introduction  
The mucosal epithelium of the lower female reproductive tract provide the first line of 
defence against pathogen entry and mediate the initial host immune response against STIs, 
including HIV-1 (Kaushic, 2011; Wira et al., 2005a; Wira et al., 2005b). This is also the 
surface through which HIV-1 is transmitted from an HIV-1 infected women to her sexual 
partner (Yi et al., 2013). The genital mucosa is also thought to serve as a discrete site for 
HIV-1 infection, replication and pathogenesis by providing the virus with a steady supply of 
susceptible target cells (Zhang et al., 1999).  
 
The epithelial barrier of the genital mucosa is also thought to be influenced by hormones, 
inflammation and infection (Murphy et al., 2014). Studies in naturally cycling non-human 
primates have demonstrated the effect of hormones on the vaginal epithelium during the 
menstrual cycle, reporting a thicker epithelial barrier during the estrogen-dominant follicular 
phase and thinner epithelia during the progesterone-dominant luteal phase (Poonia et al., 
2006; Veazey et al., 2012). Non-human primate studies have also suggested dramatic atrophy 
of the vaginal epithelium following administration of DMPA, although the amounts of 
DMPA used in these models is generally much higher than typically used in humans per 
kilogram body weight (Smith et al., 2000; Smith et al., 2004; Trunova et al., 2006). A similar 
but less pronounced hormonal effect on vaginal epithelial thickness is seen in humans, with 
decreased number of epithelial layers or reduced barrier thickness being reported during the 
luteal than follicular phase in naturally cycling women (Mauck et al., 1999; Patton et al., 
2000) and in women using DMPA (Mauck et al., 1999). In both humans and non-human 
primate studies, thinning of the genital tract epithelium during either the luteal phase of the 
menstrual cycle or in those treated with DMPA, has been associated with increased 
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susceptibility to certain STIs, including HIV-1, HPV and C. trachomatis (Baeten et al., 2005; 
Marx et al., 1996). 
  
DMPA may alternatively contribute to HIV-1 pathogenesis by facilitating closer contact 
between target cells in the mucosa and HIV-1 particles because of thinner epithelium 
(Chandra et al., 2013; Ildgruben et al., 2003; Miller et al., 2000; Wieser et al., 2001; Wira et 
al., 2011b). DMPA may influence the density of intracellular junction proteins between 
epithelial cells, potentially allowing better penetration of HIV-1 and facilitating better contact 
with mucosal target cells (Chandra et al., 2013). Chandra et al. (2013) showed that vaginal 
biopsies from HIV-1 uninfected women treated with DMPA had higher numbers of CD4+ T 
cells and macrophages expressing HLA-DR and CCR5 than non-HC counterparts. However, 
earlier studies reported no link between recruitment or activation of HIV-1 susceptible target 
cells and injectable HC use, despite resulting in decreased epithelial thickness (Bahamondes 
et al., 2000; Bahamondes et al., 2014; Kiddugavu et al., 2003; Mauck et al., 1999; Myer et 
al., 2007). 
 
Acute HIV-1 infection has been associated with increased genital tract inflammatory cytokine 
responses in women (Roberts et al., 2012), that may result in increased permeability of the 
mucosal epithelial barrier, allowing HIV-1 easier passage across the mucosal epithelium 
(Nazli et al., 2010). Inflammatory responses at the genital mucosa have also been shown to 
enhance HIV-1 pathogenesis, by recruiting highly-activated HIV-1 target cells to the site of 
initial viral infection and replication (Abel et al., 2005; Li et al., 2009; Meier et al., 2007). In 
DMPA-treated macaques infected with SIV, cervicovaginal concentrations of MIP-1α, MIP-
1β and MIP-3α resulted in recruitment of CCR5+ and CD4+ T cells in the endocervical 
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epithelium (Li et al., 2009). Furthermore, spread of SIV-infected cells from the genital 
mucosa to ensure a productive systemic infection, correlated with this pro-inflammatory 
cytokine gradient (Li et al., 2009). In humans, concentrations of IL-1β, IL-6, and IL-8 in 
CVLs from HIV-1 acutely infected women correlated inversely with CD4+ T cell counts in 
blood, suggesting the level of genital inflammation present during acute infection predicted 
adverse CD4 decline during acute infection (Bebell et al., 2008). Increased recruitment of 
activated HIV-1 target cells to the genital epithelium was shown to facilitate local HIV-1 
replication and result in increased local genital HIV-1 shedding from HIV-1 infected women, 
potentially placing their male partners at higher risk of HIV-1 infection (Gordon et al., 1999; 
Rottman et al., 1997). In both humans and non-human primates studies, higher levels of T 
cell activation in blood and plasma viral loads during acute infection predicted faster rates of 
mucosal and systemic CD4 cell decline and more accelerated disease progression (Brenchley 
et al., 2004; Douek et al., 2009; Hazenberg et al., 2003; Silvestri et al., 2003).  
 
The aim of this Chapter was to investigate the effect of injectable HC use on vaginal 
epithelial thickness, availability or depth of HIV-1 targets cells at the genital mucosa and the 
rate of HIV-1 disease progression (higher viral loads at set-point and CD4 decline to 12 
months post-infection) during acute HIV-1 infection. A better understanding of the impact of 
injectable HC use on density and depth of activated HIV-1 target cells at the mucosa in the 
presence of genital inflammation during acute infection could lead to better interventions 
aimed at blocking HIV-1 transmission from an infected women to her partner. In addition, it 
would also identify therapeutic targets to block male-to-female transmission. 
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6.3 Materials and Methods 
6.3.1 Study participants and sample collection 
This retrospective study used 49 cervicovaginal biopsies collected from consenting HIV-1 
infected women who had previously participated in the CAPRISA 004 tenofovir 1% gel 
vaginal microbicide trial, during acute infection (Abdool Karim et al., 2010a). In addition to 
the cervicovaginal biopsies, matching CVLs, vaginal swabs, and plasma were also collected 
during this acute infection visit. Vaginal biopsies were snap frozen in liquid nitrogen within 6 
hours of collection. CVLs (10ml saline) were collected as described previously in Chapter 3 
(section 3.1). CVLs were processed within 6 hours of collection, centrifuged at 388 x g upon 
receipt in the CAPRISA laboratory, and the supernatant fraction stored at -80°C for 
measurement of cytokine concentrations and viral loads. Detailed behavioural, structural, and 
clinical patient information were collected at enrolment into the acute infection study using a 
structured questionnaire. Data on HC use was collected. Vaginal swabs from each women 
were also screened for T. pallidum, C. trachomatis, N. gonorrhoeae, M. genitalium, T. 
vaginalis, HSV-2 and BV as previously described in Chapter 3. CD4 counts and plasma viral 
loads were performed on each women every month for the first 12 months. Plasma RNA 
concentrations were measured by the ROCHE COBAS Ampliprep-COBAS TaqMan version 
2.0 assay (Roche Molecular Systems, Inc, Germany) (Abdool Karim et al., 2010a). Genital 
tract viral load testing was done using Nuclisens Easyq HIV-1 (version 1.2) according to the 
manufacturer’s protocol (BioMérieux, France) by the the National Health Laboratory Service 
(NHLS) Clinical Virology laboratory (Groote Schuur Hospital, Cape Town). The detection 
limit of this assay was ≥50 RNA copies/ml. The protocol for this study was approved by the 
Ethical Review Committee of the University of KwaZulu-Natal. 
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6.3.2 Processing of vaginal biopsies 
Cervicovaginal biopsies, snap frozen in liquid nitrogen, were embedded in optimum cutting 
temperature (OCT, Sakura, Torrance, CA, USA) medium in a cryomold to ensure optimum 
orientation and longitudinal sectioning of the epithelium and then transferred to -20°C. The 
frozen block was adhered to the cryosectioning chuck at -20°C to ensure the optimal 
temperature for sectioning, 12 µm sections were cut onto glass slides using the Tissue-Tek® 
Cryo3® Plus Microtome/Cryostat (Sakura, Torrance, CA, USA), fixed with isopropanol and 
methanol, and stained with either (i) hematoxylin and eosin (H&E) (to distinguish the 
stratified squamous epithelium) and (ii) with fluorescently-labelled antibodies against HIV-1 
target cells (Cyanine 5 labelled CD4 or DakoCytomation CD68 antibodies; to quantify HIV-1 
target cell density within tissue).  
 
For H&E staining, vaginal biopsy sections were transfered into isopropanol for two minutes, 
then into methanol for 2 minutes and then rinsed in running tap water for 1 minute. Sections 
were incubated in haematoxylin for 5 minutes and rinsed in running tap water for 5 minutes. 
The slides were then incubated in eosin for 1 minute. Slides were rehydrated by dipping in 
absolute ethanol ~20 times. Slides were subsequently washed 3 times with tap water, 
remaining liquid suctioned and mounted in fluorescent mounting medium (DAKO S3023) 
and covered with a coverslip. The edges were sealed with clear nail varnish; dried in the dark 
for 15 minutes and stored in the slide box at 4°C until imaged using a Zeiss AxioScope light 
microscope interfaced with the AxioVision (4.8.2 version) under 10X magnification. 
 
Immunohistochemical staining of CD4 and CD68 cells was performed to investigate target 
cell recruitment in vaginal mucosa, in the laboratory of Prof Thomas Hope at Northwestern 
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University, Chicago (S. Ngcapu, 2014 Fogarty training fellowship). The slides were warmed 
at room temperature for 5 to 10 minutes and tissue sections were outlined with a PAP pen 
(Sigma-Aldrich, MO,USA). Slides were fixed at room temperature by placing a freshly made 
solution of 3.7% formaldehyde in Pipes buffer onto the slide for 10 minutes. Slides were then 
washed 3 times with PBS and the remaining liquid was suctioned.  
 
For CD4 staining, slides were incubated with 1:200 dilution of the conjugated primary 
antibody directed against CD4 (OKT4 mouse, Sigma-Aldrich, MO,USA) diluted in donkey 
serum blocking solution (10% normal donkey serum, 0.1% Triton X-100/0.01%NaN3 and 1X 
PBS) at room temperature for 60 minutes. Slides were washed 3 times with PBS, and the 
remaining liquid suctioned. Tissue sections were then incubated with hoechst DAPI (staining 
nuclear material; DAPI used at 1:25000 dilultion; Invitrogen, CA, USA) diluted in donkey 
serum blocking solution in the dark at room temperature for 10 minutes. The slides were 
washed 3 times with PBS, remaining liquid suctioned and the tissue sections were finally 
mounted in fluorescent mounting medium (DAKO S3023, CA, USA) using a 20 mm 
coverslip (Thermo Fisher Scientific, MA,USA). The edges of the coverslip were sealed with 
clear nail varnish; dried in the dark for 15 minutes and stored in slide box at 4°C until 
imaged.  
 
For CD68 staining, slides were initially stained with a 1:200 dilution of unconjugated primary 
anti-CD68 (DakoCytomation clone EBM11, Dako, CA, USA; diluted in donkey serum 
blocking solution) at room temperature for 60 minutes. Slides were washed 3 times with PBS 
and the remaining liquid was suctioned. After washing, the slides were incubated with 1:500 
dilution of the secondary antibody (donkey anti-mouse Rhodamine Red X in donkey serum 
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blocking solution) in the dark at room temperature for 25 minutes. Slides were then washed 3 
times with PBS, remaining liquid suctioned. Finally, slides were then incubated with a 
1:25000 dilution of hoechst DAPI (to stain nuclear material) diluted in donkey serum 
blocking solution in the dark at room temperature for 10 minutes. The slides were washed 3 
times with PBS, remaining liquid suctioned and mounted in fluorescent mounting medium 
(DAKO S3023) and a coverslip applied. The edges of the coverslip were sealed with clear 
nail varnish; dried in the dark for 15 minutes and stored in slide box at 4°C until imaged. 
 
Vaginal biopsy tissue sections, stained with H&E stains, were viewed on the Zeiss 
AxioScope Light Microscope interfaced with the AxioVision image analysis software 
programme (4.8.2 version, Zeiss, Oberkochen, Germany). Consecutive lengths (parallel lines) 
of mucosa were archived from each vaginal biopsy sample, with care taken to avoid oblique 
and transverse areas. Images were archived-1ed at 10x magnification and stored as .zvi files. 
Slides were viewed in a blinded fashion by 3 independent assessors, with two assessors using 
the manual measurements (Sinaye Ngcapu and Dr Desh Archary, CAPRISA Mucosal 
Laboratory, Durban) and the third using automated measurements (Dr Ann Carias, 
Northwestern University, Chicago, USA; using specially created algorithms using IDL 
software, Exelis, VA, USA). Approximately 3 - 4 interactive length measurements of 
mucosal thickness were manually performed by drawing parallel lines from the epithelium-
lamina propria border to the stratum basale (including any lamina propria papillae) and 
images generated were stored with MS.zvi extension. Information of evident microabrasions 
or tears in the mucosal epithelium was also noted for each sample. Using the automated 
system, algorithms in IDL software enabled drawing of two distinct lines, at the luminal 
surface and where cellular junctions were robust. The distance (thickness) was then 
calculated from each individual point from line A to the closest distance of another point on 
 134 
line B, and vice versa. Approximately 2000-7000 interactive length measurements of 
mucosal thickness were performed per image analysed. Consecutive lengths of mucosal 
epithelium were archived from each sample with care taken to avoid oblique and transverse 
areas. This data was extrapolated onto an excel file for unblinding. 
 
For immunofluorescent staining of HIV-1 target cells in vaginal biopsies, images were 
obtained by deconvolution microscopy on a DeltaVision RT system (Applied Precision, LLC, 
WA, USA) collected on a digital camera (CoolSNAP HQ; Photometrics, AZ, USA) using a 
40x oil objective, and performed at the Hope Laboratory, Northwestern University, Chicago, 
USA. All images were archived at 40x magnification and stored as z-stacks. SoftWoRx 
analysis software (MT, USA) was used to measure the shortest distance of intra-epithelial 
target cells to the surface of tissue epithelium. The cell density was calculated using the 
following formula:  
Nc/A; A = Ni x I1 x I2 x p
2  
Where Nc = number of cells, I1 = y pixel size, A = area surveyed, I2 = x pixel size, Ni = 
number of images, p2 = pixel size in μm squared 
 
6.3.3 Measurement of cytokine concentrations in CVLs 
The concentrations of 48 cytokines were measured in CVL specimens by Luminex 
multiplexing assays, according to the method described in Chapter 2. These included pro-
inflammatory IL-1β, IL-1α, IL-6, IL-12p70, IL-12p40, IL-18, TNF–α, TNF-β, macrophage 
migration inhibitory factor (MIF), TNF-related apoptosis inducing ligand (TRAIL)], anti-
inflammatory (IL-1Rα, IL-10), chemokines (IL-8, IL-16, IP-10, MCP-1, MCP-3, MIP–1α, 
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MIP-1β, RANTES, cutaneous T-cell attracting chemokine (CTACK), GRO-α, IFN-α2, 
monokine induced by gamma-Interferon (MIG), eotaxin) adaptive (IFN-γ, IL-2, IL-2RA, IL-
4, IL-5, IL-13, IL-15, IL-17), and growth-related cytokines [IL-3, IL-7, IL-9, FGF, G-CSF, 
GM–CSF, hepatocyte growth factor (HGF), nerve growth factor (NGF)-β, platelet derived 
growth factor (PDGF)-β, stem cell factor (SCF), stem Cell Growth Factor (SCGF)-β, stromal 
derived factor (SDF)-1α, and VEGF, leukemia inhibitory factor (LIF), macrophage colony-
stimulating factor (M-CSF)] were measured using Bio-Plex Pro Human Cytokine kits and a 
Bio-Plex MagPix Array Reader (Bio-Rad Laboratories, CA, USA). Prior to assays, CVL 
supernatants were pre-filtered using 0.2µm Costar Spin-X cellulose acetate filters (Sigma-
Aldrich, MO,USA). All assays were performed according to the manufacturer’s protocol and 
samples were assessed in duplicates. Bio-Plex Suspension Array Reader (Bio-Rad 
Laboratories, CA, USA) was used to collect multiplex data. All analyte concentrations were 
extrapolated from the standard curves using a 5 PL regression equation. As in Chapter 2, 
cytokine levels below the lower limit of detection of the assay were reported as the mid-point 
between the lowest concentration measured for each cytokine and zero. 
 
6.3.4 Statistical analyses  
Descriptive statistics were used to describe acutely infected women from which vaginal 
biopsies were obtained. In order to determine factors associated with CD4 and CD68 cell 
density, specifically the effect of injectable HCs, a general linear model was fitted to each of 
these outcomes. Adjusted models included variables age, marital status, condom use, 
injectable HC use, CAPRISA 004 arm assignment, plasma viral load, presence of sexually 
transmitted infections and bacterial vaginosis. To determine the effect of individual cytokines 
on CD4 and CD68 cell density, general linear models were fitted to each of these separately, 
along with each cytokine, while adjusting for age, marital status, condom use, injectable use, 
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CAPRISA 004 arm assignment, plasma viral load, presence of sexually transmitted infections 
and bacterial vaginosis. Spearman’s rank correlation was used to explore the relationship 
between experts measuring epithelial thickness. 
 
Disease progression was defined as having two consecutive CD4 cell counts below 350 
cells/µl, after the first 6 months of HIV-1 infection. Time to disease progression was 
calculated from estimated date of infection, and participants who did not reach this endpoint, 
were censored at their last visit. Proportional hazards regression models were fitted to time to 
disease progression, in order to determine the effect of CD4 and CD68 cell density around the 
time of infection. Data was analysed using SAS version 9.3 (SAS Institute Inc., NC, USA) 




Forty nine vaginal biopsies were collected from acutely HIV-1 infected women (Table 6.1). 
Of these, 8/49 (16.3%) were using no or non-injectable HCs [3 were using condoms only, 4 
were using COCs and 1 was using a non-hormonal IUD] and 41/49 (83.7%) were using 
injectable HCs (36 were using DMPA and 5 were using NET-EN). The earliest time point 
post-infection for HIV-1 infected women using injectable HCs was median of 46 days (range 
32-66) while non-injectable HC users were enrolled 77 days (46-129) post-infection 
(p=0.147). Women using no or non-injectable HCs were similar in age to those using 
injectable HCs [median 23 years (range 22-28) and 25 years (22-28), respectively, p=0.737]. 
Women reported similar condom use at last sex act [61% (25/41) in injectable HC users 
compared; 75% (6/8) in no or non-injectable HC users; p=0.693). The majority of women 
(66%, 27/41) were in the placebo arm of the CAPRISA 004 1% Tenofovir microbicide trial, 
and this did not differ between injectable HC users and those using no or non-injectable HCs. 
The median CD4+ T-cell counts and viral load measurements at the acute infection time point 
(when vaginal biopsies were collected) was 528 cells/µl (range 419-774) and 26 300 RNA 
copies/ml (3330-105000), respectively, and did not differ if women were using injectable 
HCs or not (p=0.582 and p=0.335, respectively). 
 
During acute HIV-1 infection, more than half (56%) of the women had BV (Nugent score 
≥7), and this did not differ significantly between women not using injectable HCs and those 
using injectable HCs (p=0.681). Similarly, 21% of women were infected with C. trachomatis 
and this did not differ significantly between groups (p=1.000). The prevalence of T. vaginalis 
(12%), N. gonorrhoeae (5%), M. genitalium (9%), and HSV-2 (14%) were relatively low in 
this cohort and were not significantly different in groups (Table 6.1). 
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Median (IQR) or % (n) 
Injectable HCs users 
(N=41) 
Median (IQR) or % (n) 
Non-injectable HCs users 
(N=8) 
Median (IQR) or % (n) 
p-value 
Age 24 (22 – 28.0) 25 (22.0 – 28.0) 23 (21.7 – 28.0) 0.737 
Stable partner 76 (37/49) 73 (30/41) 88 (7/8) 0.660 
Highest level of schooling 12.0 (11.0 – 12.0) 12.0 (11.0 – 12.0) 11.5 (11 – 12.0) 0.281 
Treatment arm     
Tenofovir 37 (18/49) 34 (14/41) 50 (4/8) 0.443 
Placebo 63 (31/49) 66 (27/41) 50 (4/8)  
Days post infection 49 (32.0 – 89.0) 46 (32.0 – 66.0) 77 (45.8 – 129.0) 0.147 
CD4 count (cells/µl) 528 (414.0 – 771.0) 528 (419.0 – 774.0) 578 (328.0 – 762.0) 0.582 
Plasma viral load (RNA 
copies/ml) 26300 (3330.0 – 105000.0) 22000 (3290.0 – 104000.0) 58350 (11890.0 – 342500.0) 0.335 
Genital viral load (RNA 
copies/ml) 7 (2/30*) 585 (399 – 771) - - 
Condom use at last sex act 63 (31/49) 61 (25/41) 75 (6/8) 0.693 
STIs:     
Bacterial vaginosis 56 (24/43) 58 (21/36*) 43 (3/7) 0.681 
Trichomonas vaginalis 12 (5/43) 14 (5/36*) ND 0.572 
Neisseria gonorrhoeae 5 (2/43) 6 (2/36*) ND 1.000 
Chlamydia trachomatis 21 (9/43) 22 (8/36*) 14 (1/7) 1.000 
Mycoplasma genitalium 9 (4/43) 11 (4/36*) ND 1.000 
Herpes simplex virus type 2 14 (6/43) 17 (6/36*) ND 0.567 
Abbreviations: IQR, interquartile range; ND=no data available; *data was only available for women
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6.4.1 Influence of measurement method on vaginal epithelial thickness 
To evaluate whether the different epithelial thickness measuring methods and/or inter-
individual variability introduced any variance in the measurements taken, all images were 
measured by 3 independent assessors using two different measurement platforms, one manual 
and the other fully automated using IDL software (Figure 6.1 and 6.2). No significant 
difference in epithelial thickness, measured manually between independent assessors, was 
observed (median 355 µm, 300 – 414 for assessor 1 versus 363, 304 – 417 for assessor 2; 
p=0.981) (Figure 6.2). Although epithelial thickness measurements correlated positively 
between assessor 1 and 2, this was not significant (Rho=-0.462, p=0.134). Comparing manual 
and fully automated measurement, results were significantly different (median 355 µm, 300 – 
414  for manual assessor 1 versus 254, 197 – 323 for automated assessor 3, p=<0.0001). 
Manual measurements from assessor 1 did not correlate with those of automated assessor 3 
(Rho=0.107, p=0.464). Because the automated method measurement takes into account the 
whole of the stratified squamous epithelium, including sinuous patterning of the epithelial 
rete pegs that extend into the dermal papillae that are probably major contributors to the 
variability in measurements, automated measurements were used for all the subsequent 
analyses presented in this Chapter. The manual method was concluded to be outdated 
allowing only few interactive measurements (3 to 4) compared to 2000-7000 interactive 
measurements done using automated IDL software. In addition, the automated method was 





















Figure 6.1 Vaginal epithelial thickness measurements in biopsy tissues collected from 
acutely HIV-1 infected women, who were either using injectable HCs or not. (A) Manual 
measurements were performed by drawing lines from the epithelium-lamina propria border to 
the stratum basale (including any lamina propria papillae). The dotted circle represents the 
microabrasions which may be due to flash freezing were visible in a number of biopsies 
assessed. (B) Automated random measurements (performed using IDL software, represented 
by multiple white lines) were done by calculating thickness following 2000-7000 interactive 
measurements from each individual point between line A (green line) to the closest distance 





Figure 6.2 Comparison of epithelial thickness measurements from three different 
experts. Assessor 1 and 2 used the manual counting method while assessor 3 used an 
automated method in IDL. Manual measurements were performed by drawing approximately 
3 to four interactive length measurements lines from the epithelium-lamina propria border to 
the stratum basale (including any lamina propria papillae) while automated measurements 
were done by calculating thickness following 2000-7000 interactive measurements that 
covered the whole stratified squamous epithelium including sinuous patterning of the 
epithelial rete pegs that extend into the dermal papillae. 
 
6.4.2 Relationship between injectable HC use and vaginal epithelial thickness in HIV-
1 infected women 
 
Because previous studies in non-human primates and humans have suggested that DMPA use 
results in thinning of the vaginal epithelium, the influence of injectable HC use on vaginal 






































































thickness was observed in women using injectable HCs compared to those using no or non-
injectable HCs (Table 6.2, p=0.970). Similarly, epithelial thickness was similar if women 
were stratified according to whether they were using DMPA (p=0.679) or NET-EN (p= 
0.583) compared to no or non-injectable HC users.  
 
Table 6.2 Vaginal epithelial thickness in women using injectable HCs 
Groups N Median thickness (µm) (IQR) p-value 
Non-injectable HCs* 8 361.4 (271.0 – 409.4) - 
Injectable HCs:  41 356.9 (302.0 – 414.2) 0.970 
DMPA 36/41 355.9 (280.8 – 414.2) 0.679 
NET-EN 5/41 340.8 (244.8 – 410.2) 0.583 
Abbreviations: IQR, interquartile range; *Non-injectable HCs include 2/8 no contraception users, 1/8 women 
using condom only, 4/8 using COCs and 1/8 who used an IUD. 
 
6.4.3 Relationship between injectable HCs and vaginal target cell density and depth in 
HIV-1 infected women  
Thirty of the 49 vaginal biopsies were stained for CD4+ (representing T cells) and CD68+ 
(representing macrophages) HIV-1 target cell density and depth (two representative images 
Figure 6.3 and 6.4). Of these 30 vaginal biopsies, 24 were from injectable HC users (22 
DMPA and 2 NET-EN) and 6 were from non-injectable HC users (4 COC users, 1 IUD and 1 
woman not using any form of HC). The median number of CD4+ T cells within the 
squamous epithelium was 31 cells/mm2 (IQR, 20 - 64) (Table 6.3). HIV-1 infected women 
using injectable HCs had significantly higher numbers of CD4+ T cells within the vaginal 
squamous epithelium than women using no or non-injectable HCs (p=0.028), after adjusting 
for age, condom use, study arm, marital status, plasma viral load, any STIs or BV.  
 143 
 
CD68+ macrophages were slightly less dense within the stratified squamous epithelium of 
acute infection vaginal biopsies, with a median number of 23 cells per mm2 of tissue (IQR, 16 
- 30) (Figure 6.4). Unlike CD4+ T cells, no difference in numbers of CD68+ macrophages 
was found between HC and non-HC groups (p=0.439) or between DMPA and non-HC 
groups (p=0.439) (Table 6.3). Furthermore, there was no significant correlation between 






Figure 6.3 CD4+ T cells in vaginal biopsies from acutely HIV-1 infected women. CD4+ 
cells are shown in red, E-cadherens junctions are shown in green, and DAPI is shown in blue 
(40X). The shortest distance of intra-epithelial target cells (yellow circle and horizontal line) 







CD4+ T cells 
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Figure 6.4 CD68+ macrophages in vaginal biopsies from acutely HIV-1 infected women. 
CD68+ cells are shown in red, E-cadherens junctions are shown in green, and DAPI is shown 
in blue (40X). The shortest distance of intra-epithelial target cells (yellow circle and 
horizontal line) to the surface of tissue epithelium (yellow vertical line) was also measured. 
*IQR: interquartile range; #Multivariate analysis adjusted for Age, injectables, condom use, study arm, marital 








HIV target cell depth in the tissue, measured by the distance between CD4+ or CD68+ cells 
and the vaginal lumenal interface in vaginal biopsies was evaluated (Table 6.4, Figures 6.3 
and 6.4). CD4+ cells were a median distance of 136 µm from the vaginal lumen, with depth 
ranging from 59 – 297 µm. According to Carias et al. (2013), HIV-1 can passively diffuse to 
an average depth of 6.98 ± 0.19µm into undisrupted squamous. However, HIV-1 can breach 
the 10 - 20 μm thick layer of columnar epithelial and migrate to depths of 50 μm (which was 
the physical limit of the field microscope used) within the epithelium to reach the underlying 
target cells (Carias et al., 2013). Taking this as an arbitrary cut-off at which HIV-1 would 
have easy access to available target cells, ~2 of the 30 CD4+ cells counted in sections 
evaluated would be within this cut-off. Vaginal CD4+ target cell density did not differ 
between acutely HIV-1 infected women using injectable HCs compared to those not using or 
using non-injectable HCs [median 121μm (89 – 204) versus 113 (82 – 187); p=0.951] (Table 
6.4).  
 
In contrast to the CD4+ target cells, CD68+ macrophages were closer to the lumen in women 
using injectable HC compared to non-injectable HC users (median 97, IQR 81 – 117 versus 
158, IQR 132 – 164; p=0.021). Similarly, CD68+ macrophages were near the lumen in 
women using DMPA compared to non-DMPA users (median 98, IQR 71 – 129 versus 158, 
IQR 132 – 164; p=0.026) (Table 6.4). 
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Table 6.4  Target cell depth in vaginal biopsies of women using injectable HCs versus non-injectable users 
Groups 
CD4+ T cells      CD68+ Macrophages 
N Median depth in µm (IQR) P value  Median depth in µm (IQR) P value 
Non-injectable HCs 6/30 113 (82 – 187) -  158 (132 – 164) - 
Injectable HCs  24/30 121 (89 – 204) 0.951  97 (81 – 117) 0.021 
DMPA 22/30 121 (87 – 205) 0,905  98 (71 – 129) 0,026 
NET-EN 2/30 116 (91 – 141) 0,722  104 (92 – 116) 0,167 
Abbreviations: IQR, interquartile range; DMPA- depot medroxyprogesterone acetate; NET-EN - norethisterone enanthate; Non-injectble HCs include (condom only (1/6), 
combined oral contraception (4/6) and intrauterine device (1/6)]. 
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6.4.4 Impact of injectable HCs on genital tract cytokines concentrations  
To better understand how injectable HC use influenced the genital tract innate immune 
environment and HIV-1 target cell recruitment, the concentrations of 42 cytokines, 
chemokines and growth factors were measured in matching CVLs from these acutely HIV-1 
infected women (Table 6.5). CVL concentrations of MIP-1α ([beta-coefficient (β)=0.365, 
p=0.089], IL-13 (β=0.108, p=0.086), IL-4 (β=0.186, p=0.062) and IL-10 (β=0.193, p=0.088) 
were higher in women using injectable HCs compared to those not using injectable HCs, 
although these were not significant (Table 6.5). None of the other chemokines, growth factors 
and inflammatory cytokines were significantly different. 
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Table 6.5 Influence of injectable hormonal contraceptive use on cytokine concentrations in matching genital secretions  
Functional 
groups Cytokine 
Injectable HC users Non-injectable HC users 




(pg/ml) IQR  
Beta coefficient 
(SE) P value 
Pro-
inflammatory 
TNF-β 0.54 0.29 - 1.01 0.63 0.47 - 0.74 
 
0.206 (0.363) 0.580 
IL-12p40 2.94 2.80 - 3.07 2.86 2.82 - 2.96 
 
0.083 (0.140) 0.564 
IL-12p70 1.24 1.02 - 1.58 1.05 0.72 - 1.24 
 
0.421 (0.306) 0.192 
IL-1α 1.83 1.44 - 2.44 1.51 1.38 – 2.00 
 
0.546 (0.388) 0.183 
IL-18 2.67 1.80 - 3.36 2.79 2.44 - 2.96 
 
-0.023 (0.701) 0.974 
IL-6 0.40 0.26 - 0.76 0.24 0.17 - 0.56 
 
0.218 (0.384) 0.580 
TNF-α 0.65 0.49 - 0.86 0.54 0.23 - 0.65 0.349 (0.223) 0.141 
IL-1β 1.39 0.83 - 1.92 1.00 0.54 - 1.28 
 
0.545 (0.511) 0.305 
TRAIL 1.50 1.01 - 2.24 1.69 0.59 - 1.89 
 
1.470 (1.045) 0.183 
MIF 2.72 1.56 - 3.38 2.88 1.53 - 3.71  0.740 (0.858) 0.404 
Chemokine 
Eotaxin 0.88 0.85 - 0.96 0.85 0.85 - 0.86 0.102 (0.063) 0.129 
MCP-1 1.29 1.22 - 1.41 1.29 1.18 - 1.44 
 
-0.018 (0.122) 0.886 
MIG 3.00 2.72 - 3.35 2.86 2.32 - 3.16 
 
0.295 (0.430) 0.505 
CTACK 1.66 1.43 - 2.06 1.78 1.56 - 1.85 
 
0.115 (0.297) 0.703 
MIP-1α 0.16 0.16 - 0.24 0.19 0.10 - 0.35 0.365 (0.199) 0.089 
MCP-3 1.64 1.54 - 1.95 1.74 1.49 - 1.82 
 
0.149 (0.232) 0.531 
IP-10 2.52 2.14 - 3.06 2.58 2.02 - 3.02 
 
0.328 (0.478) 0.504 
IL-16 2.04 1.70 - 2.42 2.14 1.68 - 2.19 
 
0.348 (0.360) 0.351 
GRO 2.58 1.57 - 3.01 2.36 1.90 - 2.97 
 
0.252 (0.535) 0.644 
MIP-1β 0.77 0.61 - 1.07 0.59 0.49 - 1.32 
 
0.024 (0.259) 0.927 
IL-8 2.43 1.87 - 3.02 2.14 1.65 - 2.73 
 
0.765 (0.648) 0.258 
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RANTES 1.18 1.01 - 1.53 1.08 0.96 - 1.39  0.106 (0.285) 0.716 
Innate IFN-α2 1.52 1.25 - 1.81 1.61 1.42 - 1.678  0.085 (0.245) 0.734 
Hematopoietic 
IL-9 0.60 0.60 - 0.69 0.60 0.61 - 0.64 
 
0.127 (0.075) 0.114 
G-CSF 1.71 1.42 - 2.58 1.55 1.17 - 2.00 
 
0.082 (0.485) 0.867 
GM-CSF 2.12 2.08 - 2.15 2.14 2.08 - 2.17 
 
0.006 (0.027) 0.837 
M-CSF 2.07 1.71 - 2.20 1.69 1.62 - 2.07 
 
0.372 (0.304) 0.242 
IL-7 0.075 0.02 - 0.18 0.09 0.02 - 0.16 0.143 (0.125) 0.271 
IL-3 2.40 2.16 - 2.74 2.44 2.36 - 2.52  0.080 (0.246) 0.750 
Growth 
Factors 
HGF 1.79 1.43 - 2.55 1.80 1.61 - 2.09 
 
0.244 (0.487) 0.624 
LIF 1.35 1.00 - 1.89 1.49 1.20 - 1.59 
 
0.163 (0.384) 0.678 
SCF 1.21 0.84 - 1.51 1.12 0.94 - 1.24 
 
0.314 (0.326) 0.354 
SCGF- β 2.52 2.13 - 3.00 2.60 2.41 - 2.72 
 
0.291 (0.461) 0.538 
SDF-1α 2.27 0.79 - 2.67 2.35 1.77 - 2.48 
 
0.342 (0.720) 0.642 
Β-NGF 0.18 0.18 - 0.78 0.30 0.08 - 0.45 0.220 (0.563) 0.702 
VEGF 2.20 2.03 - 2.60 2.08 1.80 - 2.23 
 
0.378 (0.339) 0.284 
PDGF-AB/BB 0.92 0.84 - 1.26 0.64 0.52 - 1.00 
 
0.305 (0.247) 0.238 
Basic FGF 1.29 1.25 - 1.37 1.33 1.21- 1.45  0.016 (0.123) 0.895 
Adaptive 
IL-15 1.32 1.32 - 1.32 1.32 1.32 - 1.34 
 
0.002 (0.013) 0.889 
IL-5 0.05 0.05 - 0.05 0.12 0.24 - 0.84 0.206 (0.149) 0.190 
IL-17 1.46 1.46 - 1.47 1.46 1.46- 1.46 
 
0.125 (0.089) 0.185 
IFN-γ 1.74 1.46 - 1.91 1.74 1.57 - 1.74 
 
0.177 (0.198) 0.388 
IL-2 1.20 1.20 - 1.20 1.20 1.20 - 1.20 
 
0.018 (0.011) 0.142 
IL-4 0.05 0.05 - 0.05 0.12 0.04 – 0.28 0.186 (0.091) 0.061 
IL-13 0.47 0.47 - 0.57 0.47 0.47 - 0.47 0.108 (0.058) 0.086 
sIL-2Rα 1.95 1.64 - 2.37 2.01 1.77- 2.14  0.159 (0.322) 0.630 
Anti-
inflammatory 
IL-1Ra 3.90 3.62 - 4.24 3.91 3.83 - 4.03 
 
0.254 (0.439) 0.573 
IL-10 0.98 0.89 - 1.14 1.03 0.92- 1.10  0.193 (0.105) 0.085 
SE=standard error, CI = confidence interval. #Multivariate analysis adjusted for age, condom use, study arm, marital status, plasma viral load, any STIs and BV 
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6.4.5 Relationship between genital cytokine concentrations and target cell densities 
Of the 42 growth factors and cytokines measured, 6/42 (18.4%) were associated with higher 
frequencies of CD68+ macrophages, after adjusting for age, marital status, condom use, 
injectable hormonal contraceptive use, study arm, any STI, BV and plasma viral load (Figure 
6.5). These included the chemokines RANTES (β=0.779, p=0.024), MCP-1 (β=0.453, 
p=0.041), and IP-10 (β=0.568, p=0.042); growth factors IL-7 (β=1.332, p=0.018), and IL-9 
(β=0.336, p=0.015); and the adaptive cytokine IL-17 (β=1.058, p=0.007). In addition, eotaxin 
(β=0.049, p=0.05); PDGF-AA/BB (β=0.593, p=0.05) and GRO (β=-0.223, p=0.06) 
concentrations tended to be associated with increased frequencies of CD68+ macrophages, 
although weakly. No association was found between any of the CVL cytokines measured and 
vaginal CD4+ T cell densities (Figure 6.5). 
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Figure 6.5 Relationship between HIV-1 target cell densties in vaginal biopsies during acute HIV-1 infection and genital cytokine 
concentrations. Dotted line indicates the effect of cytokine to target cells (for example: for every 1 log increase in RANTES, CD68+ cells in the 
vaginal biopsy increases by 15 cell/mm2). Colour and ** indicates significant interaction between target cells and cytokine concentration with 























































































































































































































































































































































6.4.6 Genital cytokine concentrations and the depth of target cells 
The relationship between cytokines and the depth of target cells to the vaginal lumen was 
assessed (Figure 6.6). Counterintuitively, an inverse relationship was found between the 
depth of CD68+ macrophages in biopsy tissues and CVL concentrations of certain cytokines, 
including growth factors β-NGF (β=-0.809, p=0.043), SCGF-β (β= -0.652, p=0.048), and LIF 
(β= -0.540, p=0.049); pro-infammatory cytokine IL-18 (β=-1.105, p=0.017); and chemokine 
IFN-α2 (β=-0.351, p=0.041), after adjusting for age, marital status, condom use, injectable 
hormonal contraceptive use, study arm, any STI, BV, CD4+ and CD68+  cell density, 
epithelial thickness and plasma viral load. Furthermore, although not significant, CVL 
concentrations of IL-1β (β=-0.692, p=0.051); IL-6 (β=-0.453, p=0.069); CTACK (β=-0.394, 
p=0.068); GRO (β=-0.696, p=0.066); HGF (β=-0.624, p=0.077); IL-2Rα (β=-0.413, 
p=0.079); SDF-1α (β=-0.908, p=0.085) and TNF-β (β=-0.438, p=0.096) were negatively 
associated with the depth of CD68+ macrophages. This analysis suggests that CD68+ 
macrophages are further away from the vaginal lumen in women with the highest lumenal 
concentrations of cytokines. 
 
In contrast to this finding for CD68+ cells, the depth of CD4+ T cells in the tissues were 
positively associated with CVL cytokine concentrations: including IL-1β (β=0.712, p=0.047), 
IL-6 (β=0.635, p=0.017); and MIP-1α (β=0.293, p=0.033), after adjusting for age, marital 
status, condom use, injectable hormonal contraceptive use, study arm, any STI, BV, CD4+ 
and CD68+ cell density, epithelial thickness and plasma viral load (Figure 6.6). Similarly, 
although not significantly, a positive association was found between CVL concentrations of 
G-CSF (β=0.662, p=0.061); IL-8 (β=0.817, p=0.090) and GRO (β=0.699, p=0.079) and 
CD4+ T cell depth in biopsies.  Unlike CD68+ cells, this finding suggests that CD4+ cells are 
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closer to the vaginal lumen in women with the highest vaginal lumen concentrations of pro-
inflammaorty cytokines.  
 
6.4.7 Factors associated with recruitment of HIV-1 target cells in vaginal biopsies 
In order to evaluate other factors that influenced the density of HIV-1 target cells in vaginal 
biopsies during acute HIV-1 infection, age, marital status, CD4 counts, plasma viral loads, 
any STIs and BV were considered as drivers of CD4+ and CD68+ target cell density. An 
inverse relationship was observed between CD68+ cells and acute infection plasma viral 
loads (Table 6.6). For every 1 Log increase in plasma viral loads, CD68+ cell density in 
vaginal tissue decreased 5 cells/µm, after adjusting for age, study arm, any STI or BV 
(p=0.048). There was no difference between other factors (age, study arm, any STI or BV) 




Figure 6.6 Relationship between HIV-1 target cell depth in vaginal biopsies during acute HIV-1 infection and genital cytokine 
concentrations. Dotted line indicates the effect of cytokine to target cells depth. Colour and ** indicates significant interaction between target 
cells and cytokine concentration with p<0.05 while colour and * indicates interaction between target cells and cytokine concentration with 
p<0.10. 
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Table 6.6 Factors associated with CD4 and CD68 cell density in vaginal biopsies 
 
Variable 
CD4+ T cells 
  




p-value Adjusted Beta estimate (SE) p-value  
Unadjusted Beta 
estimate (SE) p-value 
Adjusted Beta 
estimate (SE) p-value 
Age (per 1 year increase) 1.467 (1.067) 0.181 1.542 (1.100) 0.178  -0.287 (0.418) 0.499 -0.570 (0.453) 0.225 Marital status Single vs stable 
partner 
12.891 
(12.004) 0.293 7.252 (12.979) 0.583  5.818 (4.545) 0.212 5.423 (5.349) 0.324 
Condom use at last sex act No 
vs Yes 
-0.357 
(11.577) 0.976 10.452 (12.867) 0.427  3.670 (4.363) 0.408 -1.567 (5.303) 0.771 
004 arm Placebo vs Tenofovir -35.156 (14.850) 0.026 -34.054 (16.855) 0.059  2.640 (6.233) 0.675 -2.369 (6.946) 0.737 
Plasma viral load (per 1 log 
increase) 6.410 (5.504) 0.255 7.437 (6.225) 0.248  -3.202 (2.063) 0.133 -5.434 (2.565) 0.048 
Any STI 21.342 (11.120) 0.066 10.628 (13.538) 0.443  4.820 (4.337) 0.277 8.576 (5.579) 0.142 
BV (Nugent score 7-10) 10.100 (11.672) 0.395 5.332 (11.175) 0.639   0.927 (4.414) 0.835 -0.493 (4.605) 0.916 
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6.4.8 Influence of injectable HC use on rate of HIV-1 disease progression 
Furthermore, the rationale for investigating the influence of vaginal target cell density on rate 
of progress was that this high influx of target cells in the vaginal epithelium noted in this 
study would potentially result in higher seeding of an individual during acute infection with 
HIV and more rapid spread to systemic circulation, potentially also associated with more 
severe loss of CD4 in women using injectable HCs. In support of this hypothesis, previous 
work from our group has suggested that acute infection CVL cytokine levels predicted worse 
CD4 T cell loss during acute infection (Bebell et al., 2008) and more severe CD4 loss over 
the first year in addition to higher viral loads at set-point (Roberts et al., 2012). These 
previous studies did not directly assess target cell density in vaginal tissues. In this Chapter, 
we assessed the influence of injectable HC use on the rate of HIV-1 disease progression, 
disease progression was measured by plasma viral loads at 12 months post-infection and 
blood CD4 decline <350 cell/µl after 6 months post infection (at two consecutive visits). 
Injectable HC users had comparable plasma viral loads at 12 months post-infection to non-
injectable HC users [median Log RNA copies/ml 4.34 (IQR 2.72-4.79) and 3.55 (IQR 3.16-
4.49), respectively, p=0.7558; adjusted for age, injectables, condom use, study arm, marital 
status, any STIs or BV. Only 2/30 acutely HIV-1 infected women had detectable HIV-1 in 
their genital secretions (CVL) so analysis of vaginal HIV-1 target cell density and HIV-1 
genital shedding was not possible in this study.  
 
Of the 30 acutely HIV-1 infected women with vaginal biopsies imaged in this study, 10/30 
(33.3%) progressed to CD4 < 350 cells/µl within 2 years of HIV-1 infection (considered 
rapid disease progressors), of which 7/10 were DMPA users 3/10 were non-progressors. No 
significant association was found between injectable HC use and these markers of disease 
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progression, after adjusting for age, marital status, condom use, study arm assignment, any 
STI, BV, plasma viral load.  
 
6.4.9 Influence of vaginal target cell density on rate of HIV-1 disease progression 
To assess the influence of vaginal target cell density on the relative rate of HIV-1 disease 
progression; disease progression was defined as having two consecutive CD4 counts < 350 
cells/µl at any time point after 6 months post infection. Of the 30 acutely HIV-1 infected 
women with vaginal biopsies imaged in this study, 11/30 reached this endpoint, at a median 
of 10 months post infection (IQR, 6 - 17 months). All those who reached this endpoint did so 
within 24 months of HIV-1 infection and were classified as rapid disease progressors. 
However, there was no significant association found between vaginal target cell density 
during acute HIV-1 infection on rate of HIV-1 disease progression, after adjusting for age, 
marital status, condom use, injectable hormonal contraception, study arm assignment, any 
STI, BV, plasma viral load (Table 6.7). 
 
Table 6.7 HIV-1 target cell density and rate of HIV-1 disease progression 
Abbreviations: IQR, interquartile range; adjusted for Age, Injectables, condom use, study arm, marital status, 
plasma viral load, any STIs and BV 
  
Unadjusted HR 
(95% CI) p-value 
Adjusted HR 
(95% CI) p-value 
CD4+ vaginal density  0.98 (0.96-1.01) 0.233 0.97 (0.92-1.03) 0.298 
 
    




Previous studies have suggested that injectable HC use might facilitate contact 
between cervico-vaginal mucosal target cells and HIV-1 by reducing the integrity 
and/or thickness of vaginal epithelium and density of tight junction proteins (Chandra 
et al., 2012; Ildgruben et al., 2003; Miller et al., 2000; Wieser et al., 2001; Wira et al., 
2011a). In this study comparing vaginal epithelial thickness in acutely HIV-1 infected 
women using DMPA, Net-EN or non-HCs, no difference was observed between those 
using injectable HCs and non-HC users in vaginal epithelial thickness. Injectable HC 
use may also alter the inflammatory and/or chemotactic environment of the genital 
mucosa (Ildgruben et al., 2003; Miller et al., 2000; Wieser et al., 2001; Wira et al., 
2011b; Wira and Veronese, 2011) and this may indirectly increase the recruitment of 
HIV-1 susceptible immune cells to the mucosa. Vaginal biopsies from acutely HIV-1 
infected women using injectable HCs had increased frequencies of genital CD4+ T 
cells compared to non-injectable HC users. Unlike HIV-1 negative women discussed 
in Chapter 3, injectable HC use in acutely HIV-1 infected women was not associated 
with lower concentrations of cytokines or growth factors in genital secretions. 
However, several chemokines, hematopoietic and adaptive cytokines in CVLs during 
acute infection were associated with increased frequencies of vaginal tissue CD68+ 
macrophages, but not CD4+ cells. Those women with the highest plasma viral loads 
during acute infection had the lowest numbers of CD68+ cells in vaginal tissue.  
 
Studies have suggested that the thickness of the stratified squamous epithelium is 
altered by DMPA use (Smith et al., 2000; Smith et al., 2004; Trunova et al., 2006) 
and hormonal fluctuations during the menstrual cycle (King, 1983; Owen, 1975; 
 
 160 
Poonia et al., 2006; Veazey et al., 2012). In this study, epithelial thickness was similar 
in women using injectable HCs compare to non-injectable HC users. This study did 
find a difference in epithelial thickness measurement depending on the method used 
to calculate thickness, with the automated method being adopted for all subsequent 
analysis because of its ability to make thousands of measurements in an unbiased 
way. In agreement with this observation about measurement bias, Chandra and 
colleagues observed up to a 34% inter-observer variability in measurements using 
different methods of measurement (Chandra et al., 2013). They have suggested that 
the conflicting results reported in the literature to date on epithelial thickness 
following HC use may reflect differences in the method of measurement, observer 
bias, timing of tissue sampling, pharmacokinetics, and inter-individual variability in 
the biological response to DMPA. Through automated measurements, the whole 
stratified squamous epithelium including sinuous patterning of the epithelial rete pegs 
that extend into the dermal papillae was included in all measurements. A recent study 
suggest that a non-viable stratum corneum from the viable stratum malpighii should 
be measured instead, to exclude the variance that may occur from the epithelial rete 
pegs (Tjernlund et al., 2015).  
 
Studies have suggested that DMPA may influence the frequency of immune cells in 
the vaginal mucosa (Chandra et al. 2012; Ildgruben et al. 2003; Miller et al. 2000). In 
this Chapter, women using injectable HCs had increased numbers of CD4+ T cells in 
their vaginal stratified epithelium compared to non-HC users. In HIV negative 
women, previous studies found no difference in numbers of CD4+ T cells in the 
stratified epithelium post DMPA treatment (Chandra et al., 2013; Mitchell et al., 
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2014). The increased numbers of CD4+ T cells observed in the current study may be 
due to the fact that these women were already HIV-1 infected at the time of biopsy 
collection. CD68+ cells in women who use injectable HCs were not significantly 
different from non-injectable HC users. Density of vaginal immune cells did not 
predict faster disease progression rates. 
 
Previous studies suggested that blood HIV-1 RNA concentrations positively predicted 
risk for heterosexual transmision of HIV-1 (Mayaux et al., 1997; Mock et al., 1999; 
Quinn et al., 2000). Baeten et al. (2007) suggested that DMPA use influenced how 
infectious an HIV-1 infected women was to her sexual partner as well as the rate at 
which she progressed during her clinical course of HIV-1 infection (Baeten et al., 
2007b). In this study, women using DMPA did not have higher viral load set-points or 
more severe CD4 decline over 12 months than women using non-HCs, suggesting that 
the rate of disease progression was similar.  
 
Acutely HIV-1 infected women in this study who had the higher concentrations of 
pro-inflammatory cytokines RANTES, MCP-1, IP-10, and IL-17; and 
adaptive/hematopoetic cytokines IL-9 and IL-7 in CVLs also had the highest numbers 
of CD68+ macrophages in the vaginal stratified epithelium. RANTES is part of the β-
chemokine family, upregulated during inflammation, and responsible for the 
recruitment of lymphocytes (including basophils, eosinophils, natural killer cells and 
monocytes) to the site of infection (Baggiolini et al., 1997). RANTES, like MCP-1, 
has variable affinities for its receptors CCR1, CCR2, CCR3, CCR4 and CCR5, which 
are expressed on the surface of mature macrophages (Baggiolini et al., 1997; Decrion 
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et al., 2005; Kaufmann et al., 2001). In addition, MCP-1 promotes immune cell 
activation and recruitment (Decrion et al., 2005). IP-10 is a biomarker for antiviral 
immune responses (Luster et al., 1985), while IL-17 plays a vital role in pathogen 
clearance and mediates pro-inflammatory responses by increasing the production of 
several other cytokines (Freel et al., 2010). This suggests that these cytokines have a 
potential to increase the risk of HIV-1 acquisition, promoting activation and 
recruitment of HIV-1 target cells to the genital mucosa. 
 
Although CD68+ macrophage density did not change with HC use, this study also 
found that CD68+ macrophage density in vaginal biopsies decreased by 5 cell/mm2 of 
tissue with every 1-Log increase in plasma viral load. Like CD4+ T cell and DCs, 
macrophages are the first immune cells to fight the virus at mucosal surface and may 
also be infected. Macrophages produce cytokines that recruit CD4+ T cell to the site 
of infection and support viral pathogenesis by increasing the number of primary target 
cells available for HIV-1 replication during acute HIV-1 infection (Cicala et al., 2011; 
Koppensteiner et al., 2012). In this study, the density of CD4+ target cells in vaginal 
tissue did not correlate with the density of CD68+ macrophages. In tissues, 
macrophages are long-lived reservoirs of HIV-1 and contibute to the inability to 
achieve complete HIV-1 clearance during acute infection (Galiwango et al., 2012; 
Wu, 2011). These findings support evidence that vaginal macrophages are available to 
become productively infected during early HIV-1 infection. 
 
Genital tract cytokine concentrations did not predict vaginal CD4+ T cell densities. 
Previous studies have shown that pro-inflammatory cytokines in the genital tract 
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during acute HIV-1 infection were associated with decreased CD4+ T cell counts in 
blood and increased viral loads during both acute infection (Bebell et al., 2009) and at 
12 months post-infection (Roberts et al., 2012). In this study, CD4+ T cells in the 
stratified squamous epithelium of the vagina from acute infection tended to be 
negatively associated with pro-inflammatory cytokine concentrations (including IL-
12p70, IL-1β, IL-6, TNF-α, IL-12p40, IL-18, IL-1α, MIF, TNF- β and TRAIL). 
Plasma viral load was also not associated with vaginal CD4+ T cell depletion. 
 
A limitation of this study is that HIV-1 target cells and epithelial thickness were 
measured in tissue available from women after they seroconverted only, who were 
predominantly injectable HC users, and no control groups including HIV-1 infected 
women from other low risk communities or women who remained uninfected from 
the same CAPRISA 004 communities were available for this study. This study is also 
relatively small.  
 
In conclusion, injectable HC users had increased frequencies of CD4+ T cells in their 
vaginal stratified epithelium than in women not using injectables. However, injectable 
HC use was not associated with thinning of the vaginal epithelial barrier or faster 
HIV-1 disease progression. Although there was no injectable use effect, the density of 
CD68+ macrophages in cervicovaginal tissue correlated with a broad panel of 
mucosal cytokines and inversely correlated with plasma viral loads during acute HIV-
1 infection. This study provides valuable insight into possible underlying mechanisms 
by which genital inflammation may increase HIV-1 risk and subsequent clinical 

















The impact of injectable HCs on HIV-1 acquisition and transmission is a major public 
health concern, especially in sub-Saharan Africa, where injectable HCs is the most 
popular HC choice in women, and HIV-1 prevalence and incidence rates especially in 
young women remains high (Abdool Karim et al., 2010, Van Damme et al., 2012). 
This unresolved dilemma has millions of young women having to choose between 
reliable fertility control methods and the possibility of increased HIV-1 risk and less 
effective contraception with possible reduced HIV-1 risk. There are several scientific 
and ethical challenges in resolving this dilemma through randomized controlled trials 
including that of removing user method choice for fertility control options. 
Understanding biological and immunological effects of hormonal contraceptive use 
could provide information to move forward with this dilemma. If biological 
mechanisms for DMPA-induced HIV-1 risk were clearly demonstrable, more 
informed policy measures could be implemented in terms of balancing fertility control 
and HIV-1 risk reduction needs of women in sub-Saharan Africa. The aims of this 
dissertation were to investigate the biological effects of injectable HC use on the 
innate environment in the genital tract in HIV-1 negative women at high risk of HIV-
1 infection, and HIV-1 infected women during acute HIV-1 infection.  Chapter 3 
demonstrated that injectable HC use down-modulates expression of specific 
chemokines (eotaxin, MCP-1, MDC), adaptive cytokines (IL-15), growth factors 
(PDGF-AA) and an inhibitor of metalloproteinase (TIMP-2), while the pro-
inflammatory cytokine IL-12p40 and chemokine fractalkine were less likely to be 
detected in CVL collected from women at high risk for HIV-1 infection. These 
findings suggest that the immunosuppressive effects of injectable HCs within the 
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female genital tract could modulate susceptibility to HIV-1 acquisition. The presence 
of semen was further found to suppress some of these markers (IL-12p70, sIL-2Rα 
and IL-2) (Chapter 4), suggesting that exposure to semen in the female genital 
mucosa may promote an environment conducive to facilitating male-female HIV-1 
acquisition.  
 
Chapter 5 studied the effects of exogenous DMPA or progesterone on activation and 
cytokine production by innate monocyte and DC subsets. This included ex vivo 
experiments in PMBCs from women using DMPA and in vitro experiments in whole 
blood stimulated with exogenous hormones or DMPA. The use of DMPA or NET-EN 
had no effect on numbers of circulating monocytes. However, DMPA treatment 
decreased the capacity of mDCs to produce TNF-α and IL-6 in response to TLR 
stimulation. These findings suggest that the impairment in the ability of DCs to 
produce these cytokines might lead to reduced immune response against invading 
pathogens and therefore contribute to the observed increased in HIV-1 acquisition in 
DMPA users.  
 
During acute and early HIV-1 infection, in studies using vaginal biopsies (Chapter 6), 
vaginal epithelial thickness was found to be similar in women using injectable HC 
compared to non-injectable HC users. However, the frequency of CD4+ T cells in the 
vaginal squamous epithelium of injectable HC users was significantly higher than 
non-injectable HC users. Injectable HC use was not associated with higher genital 
HIV-1 concentrations or more rapid disease progression. The findings in Chapter 6 
suggest that modulation of cytokine and epithelial barrier factors in the genital tract 
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rather than epithelial thinning might underly altered HIV-1 acquisition risk in DMPA 
users. 
 
7.1 Injectable HCs modulate soluble genital immune mediators  
Genital tract epithelial and immune cells confer protection against pathogens by 
secreting a range of antimicrobial peptides, cytokines and chemokines that have 
inhibitory effects against HIV-1 and other STIs, including recruitment and activation 
of immune target cells (Murphy et al., 2014). DMPA use may increase a woman’s 
susceptibility to HIV-1 infection by modulating soluble immune mediators that 
increase recruitment of HIV-1 susceptible immune cells to the mucosa (Ildgruben et 
al., 2003, Miller et al., 2000, Wieser et al., 2001, Wira et al., 2011, Wira and 
Veronese, 2011). In non-human primates, the high doses of DMPA that are typically 
used have immunosuppressive properties both systemically and in the genital tract 
(Abel et al., 2004, Genesca et al., 2007, Gillgrass et al., 2003). The effects of 
injectable HC use on concentrations of soluble inflammatory cytokines were 
investigated in Chapter 3. HIV-1 negative women using injectable HCs had lower 
concentrations of several chemokines (eotaxin, MCP-1, MDC), the adaptive cytokine 
IL-15, growth factor PDGF-AA, and TIMP-2 (involved in tissue remodeling) in 
secretions from the lower female genital tract than women not using HCs, confirming 
that injectable HCs influence the genital immune environment that may reduce 
women’s genital mucosal barrier function. Decreased chemokine concentrations in 
women using injectable HCs might influence the trafficking of immune cells to the 




In support of decreased immune defenses, previous studies have reported an 
association between DMPA use and the increased prevalence of cervical candidiasis, 
and infections with C. trachomatis, N. gonorrhoeae, and M. genitalium (Wand and 
Ramjee, 2012, Baeten et al., 2001, Morrison et al., 2004). The increased prevalence of 
common STIs may influence risk for HIV-1 acquisition by altering inflammatory 
responses or by physically disrupting the mucosal barrier (Baeten et al., 2007a). In 
Chapter 3, the prevalence of STIs were similar in women using injectable HCs to 
those not using HCs, although women using injectable HCs with gonorrhea, 
chlamydia and mycoplasma infections had increased TNF-β, IL-5, IL-7, TIMP-4, IL-
12p40 and Fractalkine concentrations compared to women not using HCs with these 
infections. Similarly, women infected with T. vaginalis who were using injectable 
HCs had higher CVL Flt3L concentrations than women not using HCs. The pro-
inflammatory cytokine IL-12p40 promotes production of IFN-γ in CD8+ T cells and 
DC migration to the site of infection, while TNF-β is a key mediator of epithelial cell 
inflammatory responses (Svanborg et al., 1999). From these findings, it was assumed 
that increased IL-12p40 and TNF-β, found normally during mucosal inflammation, 
are crucial features of mucosal immune defense against infections such as C. 
trachomatis. IL-7, also influenced by DMPA use in women with an STI, regulates 
survival, proliferation and repertoire diversity of memory T cells and facilitating 
better CD4 reconstitution in HIV-1 infected patients receiving IL-7 therapy (Mackall 
et al., 2011). These characteristics of IL-7 potentially place DMPA users, infected 
with STIs, at a higher risk of HIV-1 infection by acting on CD4 cell survival and 
proliferation to provide susceptible targets for infection. Despite suppressed genital 
cytokine responses in injectable HC users, higher inflammatory and adaptive cytokine 
responses in the genital tracts of women using injectable HCs who have certain STIs 
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may place them at greater risk of HIV-1 infection compared to women not using HCs. 
A limitation of Chapter 3 and 4, in which women from CAPRISA002 were included, 
was that it was not possible to differentiate DMPA from NET-EN users in the 
injectable HC group as this information was not collected. In addition, we did not 
monitor the stage of the menstrual cycle in this cohort, nor collect longitudinal data on 
DMPA or NET-EN use prior sampling. Furthermore, this was a cross-sectional study 
so the direct effects of contraceptive initiation could not be addressed. Although 
several important possible confounders were accounted for in each analysis (such as 
condom use, sex work, marital status, BV and certain STIs), other factors [such as 
vaginal cleansing (douching), sexual practices (drying, lubricants) and STIs like 
HPV] were not assessed. 
The effects of injectable HC use on concentrations soluble factors associated with 
genital epithelial repair and integrity were investigated, including growth factors 
(PDGF-AA, TGF-α, VEGF, PDGF-AB/BB, EGF, FGF-2), MMPs (MMP-1, MMP-2, 
MMP-7, MMP-9, MMP-10), and TIMPs (TIMP-1, TIMP-2, TIMP-3 and TIMP-4). 
Lower concentrations of PDGF-AA, reported to be involved in enhancing epithelial 
repair and restoring barrier function in the female genital tract (Werner and Grose, 
2003), was observed in HIV-1 negative women using injectable HCs compared to 
women not using HCs. Growth factors have been shown to play an important role in 
restoring genital barrier function by stimulating mitosis, encouraging the spreading 
and migration of epithelial cells in airways following injury (Werner and Grose, 
2003). As such, decreased expression of these factors could lead to a compromised 
epithelial barrier and reduced epithelial healing in women using injectable HCs.  
CVLs of women using injectable HCs had lower concentrations of the inhibitor of 
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MMP, TIMP-2, compared to those not using any HCs, although MMP concentrations 
were similar between groups (Chapter 3). Furthermore, women using injectable HCs 
who had gonorrhea, chlamydia and mycoplasma infections had higher TIMP-4 
concentrations in CVL compared to those not using HCs who had these infections 
(Chapter 3). MMPs and their tissue inhibitors (TIMPs) are responsible for genital 
mucosal epithelial tissue degradation, particularly during menstruation when the 
endothelium of the uterus undergoes major remodeling (Birkedal-Hansen, 1995, 
Cawston, 1995, Lockwood and Schatz, 1996, Rodgers et al., 1994, Rodgers et al., 
1993). Unlike TIMP-4 that binds to MMP-14 required for monocyte migration 
(Lockwood and Schatz, 1996), TIMP-2 inhibits activation of MMP-2, which is 
involved in epithelial tissue remodeling (Rodgers et al., 1993). Thus a decrease in 
TIMP-2 concentrations will alter the MMP:TIMP ratio. This could lead to enhanced 
overall activity of MMPs in the reproductive tract and consequently, a weakened 
epithelial barrier integrity, making the genital tract susceptible to pathogens. Estrogen 
has been shown to influence vaginal epithelial tight junction proteins and thereby 
impact on the integrity of the epithelium (Gorodeski, 2007). Modulation of TIMP-2 
reported in Chapter 3 suggests that HCs may have an indirect effect on the epithelial 
barrier integrity in the genital tract, through the modulation of epithelial barrier 
factors. Future studies should include more epithelial repair markers to elucidate this 
mechanism.  
 
7.2 Influence of semen on cytokine responses in the lower reproductive tract 
Epidemiologic studies that have suggested an association between injectable HC use 
and increased risk for HIV-1 acquisition were not specifically designed to assess this 
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association. Some important methodological considerations, such as presence of 
semen markers which may confound studies of the mechanisms driving this risk, were 
not evaluated as a result (Polis and Curtis, 2013).  Bias reporting of condom use and 
safe sexual behavior has been identified as shortcomings in several biomedical 
prevention studies (Turner and Miller, 1997; Zenilman et al., 1995). Previous studies 
have shown that semen contains high concentrations of anti-inflammatory cytokines 
(including TGF-β, IL-10, PGE2), inflammatory cytokines (including IL-8, IL-1β, IL-
6), and activated immune cells (Olivier et al., 2014), each potentially capable of 
influencing the immune environment of the lower female genital tract during sexual 
intercourse (Denison et al., 1999, Robertson, 2005, Robertson et al., 2009, Sharkey et 
al., 2012a, Sharkey et al., 2007, Sharkey et al., 2012b).  
 
In Chapter 4, the presence of semen in CVL from HIV-1 negative women included in 
Chapter 3 was investigated, by detection of Y-chromosome (as evidence of sex within 
7-14 days) or PSA (as evidence of unprotected intercourse ≤48 hours of sampling). 
Concentrations of IL-12p70, IL-2 and IL-2Rα were lower in CVLs of women with Y-
chromosome and/or PSA present than women negative for these markers. Lower 
concentrations of cytokines detected in this study may be directly due to 
immunosuppressive effects of semen; or dilution of vaginal secretions and cytokines 
by the approximately 3ml volume of semen introduced during ejaculation (ranging 
from 0.1-10ml; Sharkey et al., 2007). In contrast, concentrations of TIMP-1 and 
MMP-9 were significantly higher in CVLs from women who tested negative for 
semen compared to those testing positive. MMPs and TIMPs are responsible for 
epithelial tissue degradation and remodeling (Birkedal-Hansen, 1995, Cawston, 1995, 
Lockwood and Schatz, 1996, Rodgers et al., 1994, Rodgers et al., 1993). Results in 
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Chapter 4 suggest that the presence of semen may influence the cytokine profile in the 
female genital tract and should be taken into consideration when investigating 
immunological factors in this compartment. 
 
The presence of semen products PSA and Y-chromosomes were assessed for their 
usefulness in objectively determining the accuracy of self-reported condom use in 
Chapter 4. About one fifth of the PSA positive and a third of Y-chromosome positive 
women, who reported that they had used a condom at their last sex act (Chapter 4), 
had detectable PSA and/or Y-chromosme in CVLs. This suggests either that condom 
use was over-reported (for PSA positive individuals) or that unprotected exposure to 
semen occurred days before the actual use of a condom [where Y chromosome 
remains stable in the female genital tract for 7-14 days, (Chomont et al., 2001b)]. 
Inconsistencies between reported condom use and detection of PSA/Y-chromosome 
in CVL may also be due to participants perceiving some topics as sensitive or the 
perceived fear of being non-compliant with barrier method use recommended during 
counselling sessions with study staff. 
 
Semen markers were detected more frequently in women not using injectable HCs 
compared to those using injectable contraception, although this difference was not 
statistically significant (Chapter 4). This trend agrees with suggestions that injectable 
HC users may be behaviourally distinct compared to women not using any HC (Gray, 
2012). For example, the presence of semen markers may be due to the fact that 
women who were not using injectable contraception were more likely to be married, 
have a stable partner, or were trying to conceive. 
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7.3 Impact of injectable HCs on innate cell activation and function 
Injectable HC may contribute to HIV-1 risk by directly influencing chemotaxis, 
maturation or activation of mucosal HIV-1 target cells, including genital tract DCs 
(Huijbregts et al., 2013, Huijbregts et al., 2014, Kleynhans et al., 2013, Kleynhans et 
al., 2011).  DCs are crucial in the early innate response because they recognize viral 
and bacterial infections through TLR-7/8 and TLR-9, respectively (Kawai and Akira, 
2010, Schlaepfer et al., 2006). DMPA has been shown to inhibit TLR-9-induced IFN-
α and TNF-α production in pDCs in vitro in mice (Hughes et al., 2008) and humans 
(Huijbregts et al., 2013). Furthermore, in vitro studies have also shown that higher 
concentrations of TNF-α inhibited entry of HIV-1 into primary target cells, CD4 T 
cells and macrophages and replication in productively infected cells (Herbein et al., 
1996, Lane et al., 1999). In Chapter 5, in vitro treatment of PBMCs with DMPA 
impaired the production of TNF-α by mDCs in response to the TLR-4 agonist LPS 
and the TLR-9 agonist CpG, while exogenously added progesterone and cortisol did 
not. In addition, DMPA also reduced the production of IL-6 by mDCs in response to 
LPS (Chapter 5), while cortisol and progesterone did not. IL-6 and TNF-α are 
responsible for maturation and migration of DCs to the lymph nodes; thereby 
potentially influencing the development of adaptive immunity more broadly 
(Banchereau and Steinman, 1998). The suppressive effect of DMPA on TNF-α and 
IL-6 production by mDCs, in response to LPS and CpG stimulation, may result in a 
blunted inflammatory response during early stage of HIV-1 infection, thereby 
favoring the propagation of a founder viral population over immune control. In 
addition, since DCs are the main antigen-presenting cell and produce cytokines that 
direct the maturation and differentiation of other parts of the acquired immune 
response (including B and T cells), this specific impact of DMPA on DC subsets is 
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likely to have a wide reaching impact on acquired immunity. Due to these non-
specific and broad immunosuppressive effects of DMPA, it is plausible that inhibition 
of TNF-α production by DCs indirectly supports HIV-1 replication. Together, these 
findings also suggest that cortisol and progesterone do not exert similar immune 
suppressive effects of innate dendritic cells like DMPA does.  
 
7.4 Effect of injectable HC use on HIV-1 disease progression  
In a randomized control trial in HIV-1 infected women in Zambia, faster rates of 
progression were reported among those using injectable HCs compared to those using 
IUDs (Stringer et al., 2009). In contrast, several observational studies found that HC 
use in women did not influence their rate of HIV-1 disease progression in those who 
become infected (Baeten et al., 2007b, Phillips et al., 2013, Lavreys et al., 2004, 
Heffron et al., 2013, Polis et al., 2010, Richardson et al., 2007). In the final Chapter of 
this dissertation (Chapter 6), HIV-1 infected women who were using injectable HCs 
had a similar disease course as women not using HCs, with similar CD4 counts at 12 
months post-infection and similar viral load trajectories during the first year of 
infection. Although this is a secondary analysis of data from the CAPRISA002 Acute 
Infection study (van Loggerenberg et al., 2008), no adverse effects of injectable HC 
use were noted in terms of HIV-1 disease progression. However, the CAPRISA002 
cohort as a whole was characterized by high numbers of rapid progressors (Mlisana et 





7.5 Injectable HC use and vaginal squamous epithelial thickness 
Several non-human primate and human studies have reported that DMPA use reduces 
the thickness of the vaginal epithelial lining, and influences the density of intracellular 
junction proteins between epithelial cells, which has been proposed to facilitate more 
efficient contact between HIV-1 and potential mucosal HIV-1 target cells (Ildgruben 
et al., 2003, Miller et al., 2000, Wieser et al., 2001, Wira et al., 2011). In women, 
however, several studies found no difference in thickness of the vaginal epithelium in 
those using DMPA compared to those who were not (Chandra et al., 2013, Mitchell et 
al., 2014, Bahamondes et al., 2000, Mauck et al., 1999). Previous clinical studies 
reported vaginal epithelial thicknesses ranging from 175-1020 µm, approximately 25-
31 epithelial cells layers in thickness (Bahamondes et al., 2000; Chandra et al., 2013; 
Mauck et al., 1999; Miller et al., 2000; Mitchell et al., 2014). In comparison, DMPA-
treated macaques, given higher doses of DMPA per kg than humans (30mg/kg 
compared to stat dose of 150mg in humans), had only two to three vaginal epithelial 
cell layers separating lamina propria from the vaginal lumen compared to more than 
25 cell layers in non-DMPA treated animals (Marx et al., 1996). In addition, dramatic 
atrophy of the vaginal epithelium following high-dose DMPA administrations was 
observed (Marx et al., 1996; Smith et al., 2000; Veazey et al., 2003). In Chapter 6, 
vaginal epithelial thickness from acutely HIV-1 infected women ranged from 279-413 
µm, with a median of 356 µm, and this did not differ between women using injectable 
HCs and those who were not using injectable HCs.  
 
Two different methods for measuring vaginal epithelial thickness were used in this 
study (manual and automated), which showed significant variability of the 
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measurements (Chapter 6). The manual counting method is outdated, subjective and 
does not take into account unevenness and variability in distances from the basal layer 
to the luminal surface (including epithelial rete pegs). In contrast, the automated 
method using IDL software includes measurements from the whole stratified 
squamous epithelium, including sinuous patterning of the epithelial rete pegs that 
extend into the dermal papillae, and does a multitude of serial and repeated 
measurements that scan the entire section (Carias et al., 2013; Tjernlund et al., 2015). 
This method is more objective and eliminates some bias inherent to manual counting. 
In addition to methodology used for measurements, other factors may contribute to 
variation in estimations of epithelial thickness, including timing in the menstrual 
cycle of tissue sampling (luteal versus follicular phase; which was not taken into 
account in this study), the pharmacokinetics of endogenous hormones, and biological 
heterogeneity among individuals in response to DMPA (Chandra et al., 2013). The 
different methods of measurement also make direct comparison between published 
studies challenging. Tjernlund et al. (2015) suggested measuring only from the non-
viable stratum corneum to the viable stratum malpighii, instead of the whole stratified 
squamous epithelium, to exclude variance that may occur from the epithelial rete 
pegs. While Chapter 6 focused on tissue from women after HIV-1 infection, it would 
be interesting in future studies to include non-infected women.  
 
7.5 Injectable HC use and vaginal HIV-1 target cell density and depth  
In Chapter 6, higher numbers of CD4+ T cells were found in the stratified epithelium 
from vaginal biopsies of acutely HIV-1 infected women using injectable HCs had 
than in women using no or non-hormonal contraceptive methods (including IUDs). In 
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HIV-1 negative women, others found no difference in the numbers of CD4+ T cells in 
the genital stratified epithelium following DMPA treatment (Chandra et al., 2013, 
Mitchell et al., 2014). If these increased mucosal CD4+ T cell numbers within and just 
below the surface of the vaginal stratified epithelium that was seen in acute HIV-1 
infection reflect pre-infection CD4 T cell density, it is plausible that this may have 
influenced their risk for HIV-1 acquisition. The median distance of CD4+ cells in the 
squamous epithelia from the vaginal lumen was 136 µm, ranging from 59 – 297 µm. 
According to Carias et al. (2013), HIV-1 virions migrate to depths of 50 μm or more 
within the epithelium to reach the underlying target cells, with 50 μm being the 
physical limit of depth measured using the field microscope (Carias et al., 2013). 
Importantly, increased HIV-1 target cell density during acute infection may increase 
the probability that these women transmit HIV-1 to their sexual partners, since there 
would be more target cells at the mucosa capable of releasing HIV-1 particles. 
However, only a few women in this study had detectable HIV-1 RNA in genital 
secretions, so this could not confirmed. 
 
Previously, pro-inflammatory cytokines in CVL during acute HIV-1 infection were 
associated with worse disease status and clinical course, including decreased CD4+ T 
cell counts and increased viral loads during both acute infection (Bebell et al., 2009) 
and 12 months post-infection (Roberts et al., 2012). In this study, CD4+ T cells in the 
stratified squamous epithelium of the vagina from acute infection were negatively 
associated with several pro-inflammatory cytokines (including IL-12p70, IL-1β, IL-6, 
TNF-α, IL-12p40, IL-18, IL-1α, MIF, TNF- β and TRAIL), although not significantly 
after adjusting for multiple comparisons. In addition, the depth (proximity of these 
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cells to the lumen) of CD4+ T cells in vaginal tissues was significantly associated 
with elevated concentrations of pro-inflammatory cytokine IL-1β and IL-6; and the 
chemokine MIP-1α. Pro-inflammatory cytokines (IL-1β and IL-6) and chemokines 
(MIP-1α) play a central role in initiating and sustaining the inflammatory response by 
recruiting immune cells from circulation and stimulating their differentiation and 
activation (Charo and Ransohoff, 2006). This suggests that these cytokines have the 
potential to enhance viral replication by promoting activation and recruitment of 
CD4+ T cells to the genital mucosa. 
 
Although CD68+ macrophage density was not influenced by HC use, acutely HIV-1 
infected women in this study who had the higher concentrations of pro-inflammatory 
cytokines RANTES, MCP-1, IP-10, and IL-17; and adaptive/hematopoetic cytokines 
IL-9 and IL-7 in CVLs also had the highest numbers of CD68+ macrophages in the 
vaginal stratified epithelium (Chapter 6). RANTES is part of the β-chemokine family, 
up-regulated during inflammation, and responsible for the recruitment of lymphocytes 
to the site of infection, including basophils, eosinophils, natural killer cells and 
monocytes (Baggiolini et al., 1997). RANTES and MCP-1 have varying affinities for 
their cognate receptors, including CCR1, CCR2, CCR3, CCR4 and CCR5, which are 
expressed on the surface of mature macrophages (Baggiolini et al., 1997; Decrion et 
al., 2005; Kaufmann et al., 2001). In addition, MCP-1 promotes immune cell 
activation and recruitment (Decrion et al., 2005). IP-10 is a biomarker for antiviral 
immune responses (Luster et al., 1985), while IL-17 plays a vital role in pathogen 
clearance and mediates pro-inflammatory responses by increasing the production of 
several other cytokines (Freel et al., 2010). This suggests that these cytokines have the 
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potential to increase the risk of HIV-1 acquisition, through enhancing and stimulating 
activation and simultaneously recruiting various immune cells that become targets for 
HIV-1 infection in the genital mucosa. 
 
Although CD68+ macrophage density was positively associated with CVL cytokine 
concentrations, the depth of CD68+ cells (proximity to the vaginal lumen) was 
counterintuitively negatively associated with CVL concentrations of several growth 
factors (including β-NGF, SCGF-β, and LIF), the pro-inflammatory cytokine IL-18, 
and the chemokine IFN-α2. IFN-α is an important inflammatory cytokine in anti-viral 
activity during acute HIV-1 infection and during late stage disease. It is expressed by 
monocytes upon viral infection, however, as monocytes differentiate into 
macrophages, they selectively lose their ability to produce IFN-α (Francis et al., 
1996). IL-18 is an inflammatory cytokine that, in combination with IL-12, causes 
differentiation of monocytes into macrophages (Yoo et al., 2005). Furthermore, a 
group of hematopoietic growth factors also regulate differentiation and proliferation 
of monocytes into macrophages (Hassan et al., 1994). Therefore, it is possible that 
this association between lower CVL concentrations of inflammatory cytokines and 
growth factors with depth of CD68+ macrophages could reflect mucosal monocyte 
differentiation into macrophages, which then migrate out of the tissue towards local 
lymph nodes to present antigen.  
 
In Chapter 6, CD68+ macrophages were found to be closer to the vaginal lumen in 
women using injectable HC compared to non-injectable HC users (median depth 97 
µm, IQR 81 – 117 µm in injectable HC users; versus 158 µm, IQR 132 – 164 µm in 
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non-injectable HC users). CD68+ macrophage density in vaginal biopsies also 
decreased by 5 cell/mm2 of tissue with every 1-Log increase in plasma viral load, 
possibly indicative of the impact of high viremia on activation induced macrophage 
apoptosis. Like CD4+ T cell and DCs, macrophages are the first immune cells to fight 
the virus at mucosal surface and may also be infected (Cicala et al., 2011; 
Koppensteiner et al., 2012). Macrophages produce chemotactic cytokines that recruit 
CD4+ T cell to the site of infection and support viral pathogenesis by increasing the 
number of these primary target cells available for HIV-1 replication during acute 
HIV-1 infection (Cicala et al., 2011; Koppensteiner et al., 2012). In tissues, 
macrophages are long-lived reservoirs of HIV-1, remain as foci of infection that 
constantly fuel infection and contribute to the inability to achieve complete HIV-1 
clearance during acute infection (Galiwango et al., 2012; Wu, 2011).  
 
7.6 Conclusion 
In this dissertation, injectable HC use was associated with decreased concentrations of 
certain pro-inflammatory cytokines, chemokines, growth factors, adaptive cytokines 
and TIMP-2. In vitro evidence further confirmed that DMPA had immunosuppressive 
effects on DC function, in response to TLR-stimulation. During acute HIV-1 
infection, injectable HC use was not associated with thinning of the vaginal epithelial 
barrier. However, injectable HC was associated with increased numbers of CD4+ T 
cells in the vaginal epithelium but not with faster HIV-1 disease progression. Despite 
increased CD4+ T cells in the vagina during acute HIV-1 infection, this dissertation 
found no evidence that DMPA increased infectiousness of women to their sexual 




This dissertation provides insight into potential biological mechanisms by which 
injectable HC use impacts mucosal and systemic immune responses (Hel et al., 2010, 
Murphy et al., 2014). It is unclear whether the DMPA-mediated changes to systemic 
and mucosal immune mechanisms described in this dissertation would impact on the 
susceptibility to HIV-1 infection. However, in light of evidence that injectable HC 
may modulate HIV-1 risk, large-scale randomized clinical trials assessing the impact 
of progestin-derivatives (DMPA or NET-EN) on genital and systemic innate and 
adaptive immune environment, as well as STIs, are needed to further investigate the 
mechanism(s) by which DMPA or NET-EN might increase risk of HIV-1 infection in 
women.  
 
7.7 Recommendations for future research 
Although various biological mechanisms by which injectable HC modulate host 
immune responses were investigated in this dissertation, there is still an urgent need 
to expand this type of biological mechanistic research to inform on decisions around 
use of fertility control choices in women in high HIV disease burden countries. All 
observational and laboratory studies that showed DMPA might modulate risk to HIV-
1 were secondary analyses of other trials not specifically designed to assess this 
association. It is imperative to find safe and effective alternatives to DMPA, 
alternatives that do not suppress the protective capabilities of the immune system at 
physiological levels. Future studies need to assess in detail potential 
immunomodulatory effects of other HCs (such as NET-EN, implants, levonorgestrel 
intra-uterine devices and COCs) on both the systemic and mucosal immune 
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environment, including inhibition of antiviral activity, epithelial structural integrity 
and immune cell function. These studies should investigate whether the rate of HIV-1 
seroconversion, transmission and disease progression varies in women using these 
other HCs compared to women not using any HC while concurrently reducing 
confounding effects as HC choice is modified by age, marital status, and 
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